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Abstract
Pregnancy associated plasma protein A (PAPP-A) is produced in increasing amounts 
with advancing pregnancy, a major source being the placenta. It was originally 
described as a homotetramer with ~ 200,000 Mr subunits. An alternative structure has 
since been proposed of a disulphide bridged complex consisting of equimolar amounts 
of the PAPP-A subunit and the proform of eosinophil major basic protein (pro MBP).
The increasing levels of PAPP-A produced during pregnancy and reports of possible 
proteinase inhibitory activity and immunomodulatory activity suggested that it may be 
an antiarthritic agent, involved in the amelioration of rheumatoid arthritis (RA) 
observed during pregnancy.
PAPP-A has been purified from late pregnancy plasma using ammonium sulphate 
precipitation, gel filtration chromatography, ion exchange chromatography and 
affinity chromatography. The purity has been confirmed by SDS PAGE and western 
blot analysis. The purified PAPP-A has been used to investigate functions of PAPP-A 
which may support or refute a role in the amelioration of the symptoms of RA during 
pregnancy.
Potential immunomodulatory actions of PAPP-A may be mediated by the inhibition of 
cytokine production or action. The effects of PAPP-A on the production of 
proinflammatory cytokines and also on the production of prostaglandin E2 (PGE2), an 
inflammatory mediator, were studied using the THP 1 human monocytic cell line and 
the MG-63 human osteoblast- like cell line. PGE2 was measured by 
radioimmunoassay and the cytokines IL-1, IL-6 and TNF a  using commercial ELISA 
kits from Biosource International. IL-1 a  stimulated the production of PGE2 and IL-6 
in the MG-63 cells, whereas PAPP-A had no significant effect on basal or IL-1 a  
stimulated IL-6 and PGE2 production. In THP 1 cells, LPS, as expected, stimulated 
the production of PGE2 , IL-lp, IL-6 and TNFa. PAPP-A alone also significantly 
stimulated their production at higher concentrations, having a much greater effect at 
higher concentrations than LPS alone. PAPP-A, when incubated with LPS, produced a 
greater than additive effect on the production of PGE2 , but in combination with LPS 
had no significant effect on the levels of IL-6 obtained with LPS alone.
Binding of PAPP-A to IL-1 a  and TGFp was studied using 125I-cytokines. Formation 
of PAPP-A cytokine complexes was determined using either native SDS PAGE or gel 
filtration chromatography. No evidence of cytokine binding was obtained. The binding 
of PAPP-A to human cartilage was also investigated, since this may facilitate any 
protective effects of PAPP-A, such as proteinase inhibition, on cartilage. Cartilage 
binding was studied using immunohistochemical methods. The results indicated that 
PAPP-A does bind to cartilage, suggesting a possible protective role.
The effect of PAPP-A on retinoic acid stimulated resorption of bovine nasal cartilage 
was studied and cartilage proteoglycan release measured as glycosaminoglycans using 
the dimethylemethylene blue assay. PAPP-A appeared to stimulate the resorption of 
cartilage.
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A key issue was whether PAPP-A functions as a proteinase inhibitor thus preventing 
connective tissue breakdown. Inhibition of elastase, cathepsin B, plasmin and trypsin 
was studied using colorimetric and fluorescent peptide substrates. PAPP-A was shown 
to competitively inhibit elastase, possibly due to the electrostatic interactions between 
the negatively charged PAPP-A and positively charged elastase.. It did not inhibit the 
other enzymes studied,
A monoclonal antibody to PAPP-A was produced by immunization of mice with the 
purified PAPP-A. This is currently been evaluated as to its potential use in a screening 
ELISA assay for monitoring PAPP-A levels.
Overall the effects of PAPP-A on monocytic cell cytokine and PGE2 production and 
its stimulation of cartilage proteoglycan breakdown suggest it does not have a major 
role in the remission of RA during pregnancy. However this work has demonstrated 
functions of PAPP-A not previously reported and confirmed earlier observations of 
inhibitory activity towards elastase. Further work is required to determine the key 
functions of PAPP-A during pregnancy.
II
Acknowledgements
My sincere thanks go to my supervisor Dr Rowena Bunning for her continued help 
and advice throughout, particularly her patience and guidance in the written part of 
this thesis.
Many thanks to Dr Jenny Shelton for her support and encouragement.
I would also like to thank Professor Kim Rainsford for his critical appraisal and 
helpful advice during the preparation of this thesis.
I am extremely grateful to the staff in Biomedical Sciences who have supported my 
work and given me a great deal of their time and encouragement, in particular to Terry 
Gaunt for his unfailing consideration and support.
I am very grateful to the Blood Transfusion Service for their kind generosity in 
supplying the serum samples and also to Dr Astrid Frazer for the kind donation of the 
tissue sections.
I would like to acknowledge the financial assistance of the Arthritis Research 
Campaign and the Biomedical Research Centre.
Special thanks go to my family and friends for their continuous love and patience over 
the last few years, in particular to my mum for helping me in the typing up of this 
thesis.
Finally, I would like to thank my dear husband Carl who has continually supported 
and encouraged me and has never lost faith in me despite the many trying times I 
encountered.
Ill
I would like to dedicate this thesis to my mum, dad, sister Nira, husband 
Carl and my very special nephew Ben.
1.1 Pregnancy in humans
Human pregnancy is a sequence of events that normally includes fertilization, 
implantation, embryonic and fetal growth and finally terminates in birth.
1.1.1 The early stages
The fertilisation of the female oocyte by the male spermatozoon is followed by a series 
of mitotic divisions. Each cell or blastomere undergoes a series of divisions, during 
which the total size of the conceptus remains the same. At around the 8 -16 cell stage 
the dividing conceptus changes morphology to a compact form called a morula. At the 
32-64 cell stage the blastocyst is formed which comprises of 2 cell types, the inner cell 
mass and the trophectoderm cells. The trophectoderm cells give rise to part of an 
accessory fetal membrane, the trophoblast of the chorion, which is involved in the 
nutrition and support of the fetus (Johnson and Everitt, 1995).
The conceptus, throughout its development from the fertilization stage to the blastocyst, 
is enclosed within the zona pellucida. The zona has two functions, firstly it prevents the 
blastomeres falling apart during cleavage and secondly it prevents two genetically 
distinct conceptuses from sticking together to make a single chimaeric conceptus 
composed of two sets of cells each of distinct genotype (Johnson and Everitt, 1995).
1.1.2 The implantation stage
The free living blastocyst can grow and survive for a short time in the uterine secretions 
from which it draws oxygen and metabolic substrates. However a stage is reached when 
the blastocyst cannot obtain adequate support. Then a few trophectodermal cells of the 
conceptus release enzymes that digest and liquify the endometrial cells and contact is 
made between the maternal epithelium and the conceptus. Within a few hours an 
increased vascular permeability in the area of stromal tissue underlying the conceptus is 
seen. The primary decidualization reaction then occurs which encompasses changes in 
intercellular matrix composition, stromal cell morphology and a progressive sprouting 
and in growth of capillaries. Some trophectodermal cells fuse together and form 
syncytiotrophoblast cells while others retain their cellularity as cytotrophoblast cells. A 
larger secondary decidua forms after 2-3 days as the major endometrium component of 
the placenta is prepared. The surface epithelium under the conceptus and some 
localized decidual tissue is destroyed and this functions as the “yolk reservoir” and
releases large quantities of primary metabolic substrates, lipids, carbohydrates, nucleic 
acids and protein, which are taken up by the growing embryo (Johnson and Everitt, 
1995). Implantation is complete at this stage, with the formation and invasion of the 
decidua, physical clamping of the conceptus to the uterus, establishment of a nutritional 
source (decidual “yolk”) and the inauguration of placental development.
The implantation of the conceptus can only take place when the endometrial epithelial 
surface in the uterus is receptive. The endometrium prior to this time has a high surface 
charge, long microvilli and a thick glycocalyx coat and is referred to as being in the 
pre-receptive stage. A loss of charge, shortening of the microvilli and thinning of the 
mucin coat results in the endometrium becoming responsive to the conceptus. These 
changes in the endometrium are controlled by hormones. Both oestrogen and 
progesterone are critical for effective implantation of the blastocyst in the uterus. 
Oestrogen stimulates the growth of the endometrium during the proliferative phase 
while progesterone stimulates the release of glandular secretions which include specific 
macromolecules and growth factors, which in turn stimulate the activation of the 
blastocyst. The epithelial cells are stimulated by steroids to make them responsive to a 
signal from the blastocyst to transmit signals to the underlying stromal cells to initiate 
decidualization. (Johnson and Everitt, 1995).
1.1.3 Factors involved in the signalling between the conceptus and uterus
The signalling between the conceptus and uterus involves both cytokines and 
prostaglandins, see table 1.1. The exact sequence of interactions between the various 
factors, however is yet to be established.
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Table 1.1 A summary of the factors involved in the signalling processes between the 
conceptus and the uterus (adapted from Johnson and Everitt, 1995)
Factor/s Role in the signalling Process
Oestrogen / Leukaemia inhibitory 
factor (LIF)
Induction of endometrium to produce 
Heparin binding EGF- like growth factor 
(HB - EGF)
HB-EGF Initiates the conceptus to shed its zona, 
attach to the endometrium and invade
Proteolytic Enzymes Digestion of epithelial layer, basement 
membrane and the stromal extracellular 
matrix to assist the invasion of the 
blastocyst
Granulocyte/ macrophage colony 
stimulating factor ( GM-CSF)
Assists in attachment of the blastocyst to 
the endometrium
Histamine and Prostaglandins Involved in the stromal'response
Transforming Growth Factor P 
(TGF P)
Promotes the implantation process, 
vascular permeability and growth of new 
capillaries
1.1.4 Embryonic development
Following implantation, the inner cell mass of the conceptus begins to differentiate into 
three primary germ layers, ectoderm, endoderm and mesoderm. They are the embryonic 
tissues from which all the tissues and organs of the body develop. As the embryo
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develops the endoderm becomes the epithelial lining of the digestive tract, respiratory 
tract and a number of other organs. The mesoderm forms the peritoneum, muscle, bone 
and other connective tissue and the ectoderm develops into the skin and nervous 
system.
During the early stages of growth of the implanted conceptus, nutrients and waste 
products are in the surrounding endometrial fluids. These materials diffuse through the 
thin “shell” of trophoblast cavities and tissues of the conceptus itself. Further 
development leads to the formation of embryonic membranes that lie outside the 
conceptus and protect and nourish it, these membranes are the yolk sac, amnion, 
chorion and allantois. The yolk sac is never functional in humans, whereas in some 
animals it functions all through pregnancy and in others it functions until the chorio­
allantoic placenta take over. In humans it becomes a nonfunctional part of the umbilical 
cord.
1.1.5 The placenta
The placenta provides buoyancy and freedom of movement and growth for the fetus, as 
well as acting as an anchoring device for the fetus in the uterus, but most important, it 
allows for exchange of nutrients and respiratory gases between mother and fetus.
The chorio-allantoic placenta is formed as a result of the outgrowth of an endodermal 
diverticulum (the allantois) from the hindgut region of the developing embryo. 
Fingerlike projections of the chorion, called chorionic villi grow into the decidua basilis 
of the endometrium. These will contain fetal blood vessels of the allantois which will 
serve as connections in the placenta between mother (chorio-allantoic placenta) and 
fetus (embryo), and this connection is the umbilical cord (Johnson and Everitt, 1995).
The placenta is generally functional by 3-4 weeks of pregnancy, however a full mature 
maternal blood flow may not develop until 10-12 weeks thus for the first few weeks of 
pregnancy the embryo has low oxygen levels in comparison to the later weeks. The 
placenta increases in size slowly and steadily until birth and then the fetus has a rapid 
growth phase just prior to birth resulting in a significant lowering of the ratio of 
placental weight to fetal weight. As the placenta starts to function it gradually takes 
over responsibility for production of a range of hormones, including progesterone and 
oestrogen.
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The placenta is an organ grown especially to nourish the fetus and to excrete waste 
products. Maternal and fetal blood streams are in very close proximity but do not mix. 
The maternal blood circulates across the fine terminal villi which also contain the fetal 
capillaries, see figure 1.1a. At these sites only a very thin layer of chorionic 
syncytiotrophoblasts separates fetal vessels from the maternal vessels, see figure 1.1b. 
Chemical substances diffuse from one bloodstream to the other, nourishment is taken 
from the maternal blood in the same way and waste products pass back through the 
placenta into the maternal blood stream to be excreted by the maternal kidneys. 
Infective agents such as viruses and bacteria, plasma proteins and complex molecules 
such as cholesterol will not gain access to the fetal circulation unless special transport 
mechanisms exist, as for example, in the transport of immunoglobulin G (IgG) 
antibodies across to the fetus.
Figure 1.1a and 1.1b Schematic view of the human placental interface. (Adapted from 
Johnson and Everitt, 1995).
Figure 1.1a
Chorionic plate
Maternal blood spaces
Stem villi (cut)
Terminal villi 
Basal plate of cytotrophoblast 
Basal decidua 
Maternal spiral arteries
Maternal veins drainingvenous lake ■ ■  maternal blood
fetal blood
Basement membrane of fetal capillary
Basement membrane of trophoblast
Cytotrophoblast
Syncytiotrophoblast
Maternal blood space
Figure 1.1b
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1.2 Pregnancy associated plasma proteins
1.2.1 Pregnancy associated plasma proteins - A, B, C and D
It has been known for many years that during pregnancy several proteins appear in the 
plasma that are not present in the non pregnant state. Lin et al. (1974a) investigated 
these proteins in the early 1960s. Hyperimmune antiserum was obtained from rabbits 
by repeated immunizations with plasma from the third trimester of pregnancy and then 
absorbing the antisera with non-pregnant female and/or male plasma. Gel diffusion 
tests were carried out using antisera to pregnancy plasma and four pregnancy proteins 
were detected. These were designated pregnancy associated plasma proteins (PAPP), - 
A, -B, -C, and -D (Gall and Halbert, 1972 ; Lin et al., 1973,1974b, 1974c). These 
proteins were not detected in cord sera, non pregnancy plasma or in male plasma using 
crossed immunoelectrophoresis, which at that time was the most satisfactory detection 
method. PAPP-A and PAPP-B did not show any relationship to other plasma proteins 
that are known to be increased in concentration during gestation, whereas PAPP-C was 
identical to the pregnancy specific p-glycoprotein (PSfG or SP-1) that had been 
characterised by Bohn (1971), and PAPP-D was the same as the hormone, human 
placental lactogen (hPL). Using monospecific antisera or by comparison with purified 
proteins, PAPP-A and PAPP-B were shown to be unrelated to many other pregnancy 
associated proteins including human chorionic gonadotrophin (hCG), a-fetoprotein, 
placental proteins (PP1, PP2, PP3, PP4, PP5) and pregnancy zone protein (PZP).
Heating pregnancy plasma to 60°C for 30 minutes did not inactivate any of the 4 
pregnancy associated plasma proteins. PAPP-A however was destroyed at 70°C, PAPP- 
C at 85°C and PAPP-D at 100°C after 30 minutes incubation (Lin et al., 1974b). It was 
also found that all of the proteins were stable between pH 4-10 at 0°C for two hours, 
whereas at pH 2 and 12 PAPP-A was completely destroyed. PAPP-C was also 
destroyed at pH 2 but not pH 12 and PAPP-D was stable at all the extremes. It was also 
reported that alternate freezing (-70°C) and thawing (room temperature) for at least 10 
cycles did not have any obvious effect on the reactivities of these antigens (Lin et al., 
1974b).
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The isoelectric points of the pregnancy associated plasma proteins were determined by 
polyacrylamide disc electrofocusing in a pH 3 to 10 gradient using whole plasma, see 
table 1.2. The four proteins were easily separated from each other by gel filtration on 
Sephadex G-200.
Table 1.2 The isoelectric points and Mr of the pregnancy associated plasma proteins 
(Lin et al., 1974b).
PREGNANCY ASSOCIATED PROTEIN PI VALUE M r
PAPP-A 4.4 +/- 0.1 750,000
PAPP-B *n.s 1,000,000
PAPP-C 3.8 +/- 0.2 110,000
PAPP-D 5.7 20,000
*n.s. not stated
On immunoelectrophoresis PAPP-A and PAPP-D migrated as ct2 and PAPP-B and 
PAPP-C as P2 globulins (Lin et al., 1974b).
On comparison of PAPPs with other pregnancy proteins with respect to electrophoretic 
mobilities and the pi values, it was suggested that PAPP-D or PAPP-A could represent 
the P2 pregnancy associated protein. However it was difficult to confirm that the PAPPs 
were pregnancy specific because of the poor sensitivity of methods available for their 
detection. (Lin et al., 1974b). There is still some uncertainty as to whether these 
proteins are present in the non pregnant state and their exact role in pregnancy has not 
been fully elucidated.
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1.2.2 Other pregnancy proteins
Other pregnancy associated proteins have been detected in gestational sera (Home and 
Nisbet, 1979). Some of these are described in more detail, table 1.3.
Table 1.3 Pregnancy proteins their sources and the levels detected during pregnancy 
(Adapted from Persellin, 1981).
Protein Mr Source Levels 
(maternal serum)
a  Fetoprotein 64,000 initially, the yolk 
sac and then the 
fetal liver
300ng/ml at term
ct2 Pregnancy 
associated globulin
(a PAG)
364,000 possibly leucocytes 
although also may 
be the liver
> 40mg/dl at term
Pregnancy specific 
glycoprotein (SP 1)
(possibly PAPP-C)
90,000 syncytiotrophoblasts 0.1-0.3mg/ml
throughout
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1.3 Pregnancy Associated Plasma Protein A (PAPP-A)
1.3.1 Levels of PAPP-A detected in pregnancy samples
PAPP-A levels in maternal serum have been shown to rise steadily through the second 
trimester and then more rapidly during the third trimester (Lin et al., 1974c; Lin et al., 
1978). The levels of PAPP-A in maternal serum/plasma have been reported at term by 
several workers, see table 1.4.and appear to vary between these workers. This may 
reflect the methods used, and/or the source of PAPP-A.
Table 1.4 Levels of PAPP-A present in serum/plasma samples using a variety of 
techniques and antibodies.
TECHNIQUE USED 
IN THE 
DETERMINATION
ANTIBODY
USED
CONCENTRATION 
OF PAPP-A AT 
TERM
Davey et al 
(1983)
Radioimmunoassay
(Serum)
Polyclonal
(DAKO)
109.6+/-80.1 mg/1
Sinosich et al 
(1984)
Radioimmunoassay
(serum)
Polyclonal
(DAKO)
48.7 mg/1
Duberg et al 
(1982)
Radioimmunoassay
(plasma)
Polyclonal
(Bischof)
238 +/- 75.6 mg/1
Oxvig et al 
(1994)
Immunoelectrophoresis
(Plasma)
Polyclonal
(DAKO)
15mg/l
10
It was also reported that the concentration of PAPP-A, detected in plasma, may depend 
to some extent on which anticoagulant is used, as shown in table 1.5 (Bischof et al., 
1983; Davey et al., 1983).
Table 1.5 The effect of different anti-coagulants on the apparent PAPP-A 
concentration measured by radioimmunoassay in the maternal blood collected in the 
third trimester (Davey et al., 1983).
Anticoagulant PAPP-A mg/1 +/- SD
Heparin 122.6 +/- 67.0
Citrate 119.1 +/- 62.5
Oxalate 118.6 +/- 95.5
Acid Citrate Dextrose 88.8 +/- 43.7
EDTA 136.9 +/- 66.2
Though PAPP-A concentrations tend to be expressed as mg/1, many workers have used 
the World Health Organisation (WHO) standard to quantify PAPP-A levels in samples. 
The WHO78/610 standard is derived from pooled late term pregnancy plasma which 
has been assigned an arbitrary value of 100IU/1 (lOOmlU/ml).
Early studies on PAPP-A showed that the concentration rose steadily in the maternal 
circulation up to 36/37 weeks and then more rapidly to term. In early pregnancy (6 
weeks) PAPP-A levels are significantly higher than in the non pregnant state which 
may indicate that the production or metabolism of PAPP-A is hormone dependent and 
that within the first few days after implantation some event, possibly hormonal, triggers 
the production of PAPP-A. Bischof et al.(l 984) has proposed that progesterone may 
trigger PAPP-A production by the endometrium. More recent reports indicate that a 
PAPP-A stimulatory factor can be precipitated by ammonium sulphate, suggesting that 
it is a protein (Bischof, 1986) and that progesterone is only indirectly linked to the 
production of PAPP-A.
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1.3.2 PAPP-A production and localisation in pregnant females.
PAPP-A levels were found to be three orders of magnitude higher in maternal than the 
fetal blood, 86,000 mIU/1 and 22.5 mIU/1 respectively, as determined by 
radioimmunoassay (Grundzinskas et al., 1985). These results strongly suggest that 
PAPP-A is produced by the mother and is present in the maternal circulation and not in 
the fetal circulation.
A study was carried out to compare the distribution of PAPP-A with other proteins of 
known origin, including human placental lactogen (hPL), AFP and Prolactin (PRL) 
using fetal and maternal tissues (Duberg et al., 1982). The results obtained for PAPP-A 
suggested that the decidua could be a possible source as the concentration found (57.0 
+/- 2.0ug/g)(15%) was more that three times higher than that in the trophoblast (16.9 
+/- 5.4ug/g)(4.5%). The highest concentration was found in maternal plasma at term 
(238.8 +/- 75.6ug/ml)(62.8%), see table 1.6 for results expressed as percentages.
Table 1.6 The percentage distribution of PAPP-A in maternal and fetal compartments 
as determined by radioimmunoassay (adapted from Duberg et al., 1982).
COMPARTMENTS PAPP-A (%)
Maternal Tissues
Maternal blood 62.8
Decidua 15.0
Fetal Tissues
Chorion 9.8
Amnion 7.4
Amniotic fluid 0.5
Cord blood 0.0(3)
Trophoblast 4.5
PAPP-A would appear to be predominantly maternally derived. However investigations 
on the localisation of PAPP-A using immunohistochemical techniques, see table 1.7 
detected PAPP-A in maternal and fetal cells.
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Table 1.7 A summary of the localisation of PAPP-A (refer to figure 1.1).
Cytotrophoblast Imaizumi 1983 
Dobashi et al 1984
Syncytiotrophoblast 
(as an apical rim)
Lin and Halbert 1976 
Wahlstrom et al 1981
Syncytiotrophoblast 
(within cytoplasm)
Imaizumi 1983 
Tornehave et al 1986
Corpus Luteum Sjoberg et al 1984
Endometrium
(Stroma)
Bischof et al 1984 
Wahlstrom et al 1985 
Sjoberg et al 1984
Doubt was expressed about some of the localisation (Chemnitz et ah, 1986) as it was 
demonstrated immunoelectrophoretically that the PAPP-A antiserum produced by 
Bischof et al. (1979), which had been used by other workers (Duberg et al.,1982; 
Bischof 1984; Schindler et al., 1984), was oligospecific and may therefore be detecting 
other proteins in addition to PAPP-A. The antiserum of Bischof et al. (1979) was then 
purified by absorbing with serum from non pregnant women followed by absorption 
with minced fetal connective tissue and precipitation with ammonium sulphate and ion 
exchange chromatography. The purified antibody produced was found to be 
monospecific. This monospecific antibody was then used in immunohistochemical 
experiments and PAPP-A was found to be exclusively in the cytoplasm of the 
syncytiotrophoblast (Chemnitz et al., 1986). More recently workers have confirmed the 
synthesis of PAPP- A by syncytiotrophoblasts by in situ hybridisation (Bonna et al., 
1994). It would appear that PAPP-A is produced by fetal cells such as 
syncytiotrophoblasts and maternal decidua during pregnancy.
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1.3.3 PAPP-A levels and distribution in non pregnant subjects
In some studies measurable levels of PAPP-A have been detected in the blood of non 
pregnant women (Bischof et al., 1981; Bersinger and Klopper, 1984), whereas other 
studies have failed to do so (Anthony et al., 1983; Sinosich, 1984). One possible 
explanation may be whether measurements were made in serum or plasma, as it was 
observed that coagulation of the blood changed the immunological properties of PAPP- 
A (Davey et al., 1983). It was found that the levels of PAPP-A, as determined by RIA, 
in a given sample were significantly different depending on whether the PAPP-A tracer 
or standard was derived from plasma or serum, see tablel.8. (Bischof and Meisser, 
1988).
PAPP-A has also been detected at low concentrations in seminal plasma (Martin-Du- 
Pan et al., 1983; Bolton et al., 1986). One could speculate that PAPP-A may have a role 
in the maintenance of sperm motility during transport to the site of fertilisation
Table 1.8 The effects of immunological heterogeneity of PAPP-A on the measured 
levels of PAPP-A in non pregnant females (adapted from Bischof and Meisser, 1988).
Origin of 
tracer
Type of 
standard
Antibody PAPP-A levels ng/ml 
+/-SD
serum plasma
Plasma Plasma Dako 45.4 +/- 7.6 46.0 +/- 16.4
Plasma Serum Dako 24.3 +/- 5.7 19.7 +/- 6.7
Plasma Plasma
In house 
Bischof and 
Meisser, (1988) 60.8 +/- 14.7 48.6 +/- 3.9
Serum Plasma
In house
Bischof and 
Meisser, (1988)
42.9 +/- 8.3 3.7 +/- 5.5
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1.3.4 Structure of PAPP-A
Various reports of PAPP-A separation, isolation and characterisation have lead to 
confusing and conflicting reports on it structure. The following section reviews the 
literature avaliable.
Bischof et al.(1980) isolated PAPP-A and concluded that the protein was a 
homotetramer glycoprotein of Mr between 750,000-820,00. Using PAGE gels, at 
neutral pH, in the presence of 4M urea PAPP-A had an Mro f450,000, whereas under 
reducing conditions an Mr o f218,000 was obtained. These results supported the 
hypothesis that PAPP-A is a dimer with the monomers being held together by 
electrostatic van der Waals forces and the monomer itself comprising of two chains 
linked together by disulphide bonds (Bischof et al., 1980).
PAPP-A was found to be deglycosylated by incubation with chondroitinase AC, 
neuraminidase, a- glucosidase and P- glucuronidase but not p- glucosidase (Sinosich, 
1988). This data confirmed the presence of glucuronic acid, as chondroitin sulphate 
moieties, in the carbohydrate component of PAPP-A, and suggested that PAPP-A is a 
proteoglycan (Sinosich, 1988). Chondroitin sulphate moieties are highly negatively 
charged glycans that, like heparin have many potent biological actions including 
protease inhibition, binding of metal ions and binding to components of the 
extracellular matrix (Sinosich, 1988). A model was proposed by Sinosich (1988), 
shown in figure 1 . 2  with two relatively stable disulphide linked dimeric complexes 
which ultimately link to form the complete PAPP-A molecule.
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Figure 1.2 Schematic representation of PAPP-A molecular conformation obtained 
from pooled pregnancy serum (Sinosich, 1988).
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Elucidation of the structure of this complex protein has been further complicated by the 
co purification of PAPP-A with pro major basic protein (proMBP) subunits. An 
alternative model described for PAPP-A is based on two heterodimers with proMBP as 
an intergral part of the ‘active’ protein (Oxvig et al., 1993), see figure 1.3.0 (PAPP-A \  Mr 200,00 subunits
pro MBP pro MBP Mr 50-90,000 subunits
Figure 1.3 Schematic representation of an alternative structure of PAPP-A.
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MBP has been characterised from the eosinophil and is derived from the 222 residue 
prepro MBP (Barker et al., 1988; Wasmoen et al., 1988). MBP isolated from the 
eosinophil granule is cytotoxic to mammalian cells and has been implicated in tissue 
damage associated with eosinophil infiltrates (Gleich et al., 1979; Frigas et al., 1980; 
Hamann et al.,1991).
PAPP-A, isolated from pregnancy serum, and subjected to trypsin and CNBr/trypsin 
digestion to produce peptides was found to contain several peptides that were derived 
not from PAPP-A, but from pro MBP. It was suggested that circulating PAPP-A was 
complexed with pro MBP through disulphide bridges, with one subunit of PAPP-A 
being bound to one molecule of pro MBP. The pro MBP subunit migrated on SDS- 
PAGE as a protein of Mr between 50-90,000 rather than the expected 23,400 and it was 
suggested pro MBP may form very stable oligomers even after denaturation. (Oxvig et 
al., 1993).
In pregnancy the plasma levels of immunoreactive MBP are greatly increased and it has 
been located immunohistochemically in the X cells and giant cells of the placenta 
(Maddox et al., 1983; Maddox et al.,1984; Wasmoen et al., 1987). MBP has been 
purified from placental tissue and seems to be tightly associated with unknown large 
proteins (Wasmoen et al.,1989). The actual site(s) of formation of the PAPP- 
A/proMBP complex is unknown, but probably involves specific interactions between 
the two proteins. The serum levels of MBP (0.28uM) (Wasmoen et al., 1987) and 
PAPP-A subunit (0.23uM) (Folkersen et al., 1981; Westergaard et al., 1983a) present in 
late term suggest that essentially all MBP antigen present is bound to PAPP-A.
The amino acid sequence of PAPP-A derived from pregnancy serum, was determined 
from partial protein sequencing and from the sequence of cloned cDNA. The PAPP-A 
monomer was found to contain 1547 amino acid residues, but derived from a larger 
precursor of placental origin. PAPP-A contains 82 cys residues, which are bridged, 14 
putative sites for N- glycosylation and 7 putative sites for attachment of 
glycosaminoglycan groups.
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Results from the sequence analysis show that PAPP-A is not related to ot2m as reported 
by Sutcliffe et al (1980). The major part of the PAPP-A sequence is unrelated to any 
known protein sequence to date (Kristensen et al.,1994).
The carbohydrate composition of the isolated reduced and carboxymethylated PAPP-A 
and the proMBP subunits and of the intact PAPP-A/proMBP were found to be 13.4% 
(w/w), 38.6% (w/w) and 17.4% (w/w) respectively (Oxvig et al., 1994).
The amino acid compositions of the subunits agreed with those expected from their 
cDNA sequences (Barker et al., 1988; McGrogan et al., 1988; Kristensen et al., 1994) 
and also the amino acid composition of the complex is compatible, with PAPP-A and 
proMBP being present in equimolar amounts (Oxvig et al., 1993).
1.3.5 Similarities between PAPP-A and (X2 in
PAPP-A is similar in a number of respects to 0 C2m, as indicated in table 1.9. Both have 
similar Mr, identical pis and similar electrophoretic mobilities and were thought to 
have similar subunit structures. Because of their similar physicochemical properties 
they co-elute on gel filtration chromatography and are generally difficult to separate. It 
was suggested that PAPP-A may be a modified form of oc2m (Sutcliffe et al., 1980), 
however subsequently this was found not to be the case (Oxvig et al., 1993).
Table 1.9 Comparison of (X2m and PAPP-A (Sinosich, 1988; Sinosich et al., 1983).
PAPP-A a 2m
Mr 820,000 725,000
Molecular conformation Homotetrameric Homotetrameric
Carbohydrate (%) 19.4 8.6
Carbohydrate (Mr) 159,080 62,350
Protide (Mr) 660,920 662,650
pi 4.42 4.42
Zinc atoms per molecule 15.8 4.2
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PAPP-A and oc2m differ in their carbohydrate content indicating that 012m is a 
glycoprotein and PAPP-A is a proteoglycan containing glucuronic acid in chondroitin 
sulphate moieties (Sinosich et al., 1982). They also have different amino acid 
sequences (Sinosich et al., 1990).
1.3.6 Possible roles for PAPP-A
There have been reports of many possible roles for PAPP-A and the following section 
summarises the current data and literature available to date.
1.3.6.1 The role of PAPP-A as a protease inhibitor
Initial findings indicated that PAPP-A inhibited the caseinolytic and fibrinolytic 
activity of plasmin (Bischof, 1979). These results prompted workers to suggest that 
PAPP-A may play a role in the regulation of the fibrinolytic system during pregnancy.
PAPP-A has been shown to inhibit complement induced haemolysis. It specifically 
inhibits C3 by binding to this complement component and not by inhibiting C3 
convertase as demonstrated for C3 inactivator (Bischof et al., 1982; Bischof et al.,
1984). It was suggested that heparin contaminating PAPP-A preparations caused this 
inhibition (Sinosich, 1982).
Thrombin activity was inhibited by PAPP-A in a dose-dependent manner. Its effects on 
thrombin were similar to those of heparin and it was suggested that it resulted from 
similarities between the carbohydrate composition of heparin and that of PAPP-A 
(Meisser et al., 1985). Heparin is an inhibitor of coagulation, of complement, of 
lymphoblastogenesis, and of elastase (Currie, 1967; Rosenberg and Damus, 1973; 
Novitskaya et al., 1975; Marossy, 1981; Chang and Boackle, 1986). It was later 
suggested by Meisser et al. (1988) that the inhibitory effects on thrombin activity 
originally attributed to PAPP-A (Bischof, 1981) were due to contaminating traces of 
heparin that had leached from the heparin Sepharose column used in PAPP-A 
purification and not PAPP-A.
There have been reports that PAPP-A inhibits granulocyte elastase activity and this 
inhibition was shown to be non competitive (Sinosich et al., 1982). Inhibition of
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elastase by PAPP-A (K j 1.7  x 10'7M) was approximately ten fold greater than that of 
a 2m (K j 1.6 x 10' 6 M) (Marossy, 1981; Sinosich et al., 1982 ). Other workers however 
(Bischof et al., 1990) suggested that the inhibition of elastase was due to contaminating 
heparin. More recently Oxvig et al. (1994) have reported competitive inhibition of 
human leukocyte elastase (HLE) by PAPP-A by a colorimetric assay with synthetic 
substrates (K j 5-10 x 10 ‘9 M), however significant inhibition was seen only at low ionic 
strengths. At ionic strengths greater than 150mM inhibition of HLE was negligible.
Fluorometric methods were used to study the effect of PAPP-A on human plasmin and 
colorimetric methods for bovine pancreatic chymotrypsin, bovine pancreatic trypsin 
and human leukocyte elastase. The results observed indicated that PAPP-A did not 
inhibit plasmin, trypsin or chymotrypsin, it did however inhibit elastase as previously 
described. a 2m was used as a control inhibitor and was shown to inhibit all four 
proteases (Sinosich et al., 1982). Oxvig et al. (1994) also reported no inhibition of 
trypsin or chymotrypsin by PAPP-A
It has been well documented that a 2m binds and inhibits trypsin, chymotrypsin, 
cathepsin B, papain and plasmin (Starkey and Barratt, 1977). PAPP-A samples that 
contained a 2m as a internal positive binding control were used to study the effect of 
PAPP-A on trypsin. A sample containing a 2m and PAPP-A was incubated with 
iodinated trypsin. The majority of the counts in these samples were precipitable with 
anti a 2m antibody, less than 10% were precipitable with anti-PAPP-A antibody 
suggesting that a 2m -trypsin complexes are formed but not PAPP-A-trypsin complexes, 
indicating little or no binding of PAPP-A to trypsin. The experiment was repeated 
using iodinated plasmin, and as previously described, there was no evidence to suggest 
that PAPP-A could bind to plasmin (Gore and Sutcliffe, 1984).
Subsequent studies however, have suggested that PAPP-A is capable of binding 
proteinases with a conformational change that causes the enzyme to be trapped in the 
same way as in a 2m -  proteinase complexes, as described in section 6.1. Colorimetric 
assays were carried out to measure residual activity of trypsin and plasmin after 
incubation with PAPP-A. Several substrates of differing molecular weights were used.
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The access of the substrates to the enzyme’s active site was found to be sterically 
hindered as inhibition was much more pronounced with large substrates than with 
smaller ones, although inhibition was still seen with the smaller substrates. The trypsin 
inhibitory curve was found to be much steeper than plasmin and reached complete 
inhibition at a molar ratio of 1.0. These observations provide further support that 
PAPP-A and ot2m are structurally and functionally related proteins despite the different 
amino acid sequences (Zorin et al., 1995).
The effects of PAPP-A on proteinase inhibition are very conflicting, see table 1.10. 
Further investigation is required. A key element in this confusion is the differences in 
purification procedures employed by different workers.
Sinosich et al. (1985) suggested a possible role for PAPP-A as a proteinase inhibitor 
that may contribute to the follicular protease inhibitor pool which helps maintain 
proteolytic homeostasis in the pre and post ovulatory phase. It may also contribute to 
survival of spermatozoa and embryo in the reproductive tract by preventing damage 
from maternal leukocyte derived proteinases.
1.3.6.2 Modulation of the immune system by PAPP-A
There have been many theories proposed to explain the non rejection of the fetus. One 
is the suppression of the maternal cell mediated immune response, possibly by 
inhibition of lymphoblastogenesis of T lymphocytes by plasma proteins. PAPP-A was 
shown to inhibit lymphocyte responsiveness to phytohemagglutinin stimulation in vitro 
(Lin et al., 1974b; Bischof et al., 1982), other workers however refute this (McIntyre et 
al., 1981). Since it is well documented that heparin inhibits lymphocyte transformation 
(Currie, 1967; Novitskaya et al., 1975) it was suggested that heparin contaminating the 
PAPP-A preparation used, was responsible for this effect (Meisser et al., 1988).
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Table 1.10 A summary of reports of PAPP-A’s inhibitory activities
CHYMOTRYPSIN
irid*
C/3d*
No inhibition
(N-benz-L-tyr-pNA ) 
(BTN)
No Inhibition 
(Vs)
TRYPSIN
c/3d*
Inhibition
(Remazol hide powder/  
NaBz-D-L-arg- 
pNA(BAPNA))
No Inhibition
(N-tert-biit-car-L-ala-
pNA)
(BAN)
No Inhibition 
(Vs)
PLASMIN
c/id*
Inhibition
{Remazol hide powder/ D- 
val-leu-lys-pNA )
No inhibition
(Boc-L-glu-L-lys-L-lys-
MCA)
C/3d*
ELASTASE
No inhibition
( MeSuc-L-ala-L-alci-L- 
pro-L-val-pNA) 
(AAPV-pNA)
t/3d*
Non competitive 
Inhibition
(N-suc-L-anl-L-ala-L-val-
pNA)
(SAAVN)
Competitive Inhibition
(MeSuc-L-ala-L-ala-L- 
pro-L-val-pNA) 
(AAPVpNA)
Bischof et al. 
(1990)
Zorin et al. 
(1995)
Sinosich et al. 
(1982)
Oxvig et al. 
(1994)
1.3.6.3 PAPP-A as a carrier for placental steroids
The binding of steroids to purified PAPP-A was investigated to determine whether 
PAPP-A could be a carrier protein for placental steroids. No binding was seen between 
PAPP-A and 3H-progesterone, 3H-oestradiol, 3H-oestrone, 3H-oestriol, 3H- testosterone 
or 3H-corticosterone (Bischof, 1979).
1.4 Studies into the potential use of PAPP-A as a screening and diagnostic tool 
during pregnancy.
In studies measuring PAPP-A levels by Laurell immunodiffusion it was found that 
PAPP-A levels increased as pregnancy advanced, as mentioned earlier in section 1.3.1. 
The maximal concentration of PAPP-A at term was given as 137+/- 74 arbitrary units 
(giving a value of 100 units to a late term pregnancy pool) (Smith et al., 1979).
As mentioned previously (1.3.1) in a normal pregnancy PAPP-A levels increase as 
pregnancy advances (Lin and Halbert, 1978). However a number of studies reported 
low first trimester levels of PAPP-A in pregnancies with an abnormal karyotype 
(Muller et al., 1993; Wald et al., 1992; Brambati et al., 1994). This suggested that the 
PAPP-A measurements may have a clinical value in screening for chromosomal 
abnormalities, in particular, Downs syndrome (DS) in the first trimester. DS is a 
congenital disorder with mental retardation and physical abnormalities, with an 
incidence at birth of ~ 1.3 in 1000. Individuals with this disorder usually have 47 
chromosomes instead of the normal 46 (an extra chromosome 21).
Maternal serum human chorionic gonadotrophic (hCG) and a  fetoprotein (AFP), with 
or without unconjugated estriol (UE3), double or triple test, are routinely measured in 
the second trimester of pregnancy as a screen for DS as these levels differ for a 
abnormal fetus compared to a normal fetus (Wald et al., 1994). First trimester screening 
and early diagnosis would be beneficial with respect to early termination of the 
pregnancy.
Brambati et al. (1994) reported for the first time that a combination of serum PAPP-A, 
maternal age and free P-hCG measurements in the first trimester could lead to 
enhanced detection rates for pregnancies affected by DS and other fetal aneuploidies.
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Krantz et al. (1995) also carried out a study using PAPP-A levels with maternal age and 
free p-hCG. An efficiency of 6 8 % at a 5% false positive rate was achieved. This level 
of first trimester detection equals or exceeds results reported in the second trimester 
with either the two or three marker protocol. Wald et al. (1996) concluded that 
screening using maternal age and serum PAPP-A at 10 weeks of pregnancy was better 
than the double test (a fetoprotein and hCG with maternal age) and similar to the triple 
test (a fetoprotein, unconjugated oestriol and hCG with maternal age) at 15-22 weeks.
Sinosich et al., 1982 also suggested that biochemical screening in the first trimester for 
maternal serum PAPP-A was a useful tool for the detection of fetal chromosomal 
abnormalities since the serum PAPP-A levels in pregnancies with a DS fetus at 10 
weeks were 0.15 multiples of mean (MoM) and at 11 weeks, 0.29MoM. Thus detection 
of PAPP-A levels of less than 0.3 MOM in singelton pregnancies at 10 weeks followed 
by confirmatory tests, such as Chorionic villus sampling (CVS), would be useful for 
DS detection and offer termination possibilities early. It was estimated that all of 
affected fetuses would be detected at 10 weeks in this way and 50% at 11 weeks 
(Hurley et al., 1993).
PAPP-A levels were measured using radioimmunoassay (Sinosich et al., 1980) at 9-14 
weeks gestation and the study confirmed and expanded on the existing data by 
confirming the association between depressed levels of PAPP-A in early pregnancy 
serum and DS (Muller et al., 1993). Further confirmation was provided by Bersinger et 
al. (1994) who showed that at 10-11 weeks 40% of pregnancies with trisomy 21 have
i Lmaternal serum PAPP-A levels below the 5 centile of the normal range. This is also 
the case for 70% of pregnancies with trisomies 18 and 13. The sensitivity of detection 
using PAPP-A measurement may provide an earlier diagnosis which has some 
advantages.
In addition to the differences in PAPP-A levels in the serum of mothers of DS babies, 
levels are altered in other obstetric disorders (Lin et al., 1976).
The development of a radioimmunoassay (Bischof et al., 1981) has made the 
measurement of maternal circulating PAPP-A during the early stages of pregnancy 
possible and indicated it to be of potential use as a marker of fetal well being. Maternal
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PAPP-A measurements were taken from 51 pregnant women and the results compared 
favorably with other biochemical tests of placental function.
PAPP-A measurements may be a valuable tool in the management of threatened 
abortion, particularly in patients who appear normal in ultrasonic examination 
(Westergaard et al., 1983).
Sjoberg et al.(1987) measuring PAPP-A by radioimmunoassay, (Sjoberg et al. 1984) 
reported subnormal levels in many cases of ectopic pregnancy and intrauterine 
abortion, however no distinction could be made between the two disorders.
1.5 Pregnancy and rheumatoid arthritis
Hench, (1938) was quoted as saying that rheumatoid arthritis (RA) in the presence of 
pregnancy “finds it difficult to progress or indeed to do otherwise than beat a rather 
precipitous retreat” since he found a marked or complete remission of the symptoms of 
‘chronic arthritis’ during 30 of 34 pregnancies in 20 of 22 patients. The majority of 
pregnant patients experience symptomatic improvement of RA, however there are 
approximately 25% who do not improve and in actual fact pregnancy may aggravate 
the disease (Neely and Persellin, 1977).
During pregnancy an improvement in RA may occur at any time but it is most 
commonly seen near the end of the first trimester. Amelioration of symptoms in the 1st 
trimester can be detected by slightly over 50% of patients, with an additional 14% at 
the end of the second trimester and a further 6 % in the third trimester, see figure 1 .1 1 .
In the vast majority of cases the improvement will continue throughout the whole of the 
pregnancy.
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Figure 1.11 The effect of pregnancy on rheumatoid arthritis disease activity : analysis 
of 308 pregnancies. Improvement, once experienced, usually persisted throughout the 
course of gestation (adapted from Cecere and Persellin, 1981).
The amelioration of the symptoms can be easily monitored by changes in the patients 
stiffness, pain and swelling of joints and their general well being. There seems to be no 
relationship between the age of patient, the duration of disease activity, or the stage of 
RA, with the degree of improvement of RA during pregnancy. Some patients may have 
complete amelioration whereas others may be subject to minor flare ups. Patients’ who 
have a remission of their symptoms during their first pregnancy will also experience 
remission of RA in any subsequent pregnancies and those not benefiting from any 
remission will not benefit in any further pregnancies. This may suggest an inherent 
regulation of the mechanism responsible for the amelioration. The reoccurrence of the 
symptoms of disease develops post partum, with the majority of patients relapsing 
within 6 weeks (Cecere and Persellin, 1981).
Nicholas and Panayi (1988) believed that the improvement of the symptoms of RA may 
be due to the induction of an immunosuppressive state that may involve many factors. 
Immunosuppression has been reported with many factors, including, hCG, AFP, 
progesterone, SP 1, PAPP-A, prostaglandins and sex steroids.
Generally corticosteroid levels increase progressively throughout pregnancy and they 
were found to exert multiple effects on the inflammatory and immune responses. It was
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suggested that these hormones play a role in the amelioration of inflammatory disorders 
during pregnancy (Rocklin et al., 1979).
The immunosupressive activities of hCG are somewhat controversial. There have been 
reports of inhibition of phytohaemagglutinin induced T cell proliferation by hCG 
(Teasdale et al., 1973), but these effects may be due to contaminants (Patillo et al., 
1976).
Davies and Browne (1985) discovered two immunosuppressive activities, so called 
immunosuppressive factor I and II (ISFI and ISFII) on fractionation of pregnancy 
serum by gel filtration column chromatography. It was reported that these two factors 
were present in the non pregnant state as inactive proforms and they are activated
^  I ^  iduring pregnancy by Ca and Mg and a protein called pregnancy depleted 
immunoregulatory factor (pd IRF) (Mr 100,000). However, Nicholas et al. (1988) 
concluded that it would be too simplistic a view that one serum factor alone, such as 
IRF, produced in excess during pregnancy, could account for disease remission of RA. 
More than likely there is a multifactorial etiology which will be very difficult to 
elucidate.
1.6 Rheumatoid arthritis
RA is a common systemic autoimmune inflammatory disorder affecting approximately 
1% of the population worldwide (Harris, 1990; Scutellari and Orzincolo, 1998). It most 
commonly affects women (75%) between the ages of 20-60.
The actual cause of RA is unknown, although several different factors are thought to be 
involved in triggering the disease, including environmental and genetic factors. Current 
research is focusing on exogenous infectious agents as well as endogenous substances 
such as connective tissue proteins (e.g. collagen and proteoglycans) and altered 
immunoglobulins. Rubella virus, mycoplasma and Epstein- Barr virus have all been 
implicated as possible causative agents of RA along with other infectious agents. 
Epstein- Barr virus is well established as a polyclonal activator in the overproduction of 
immunoglobulins including rheumatoid factor (Slaughter et al., 1978; Djavad et al. 
1996).
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The majority of RA sufferers produce “rheumatoid factor”, an autoantibody (IgM) 
which binds to the Fc portion of human IgG. Rheumatoid factor is thought to promote 
inflammation and tissue damage by activating the complement cascade (Pope et al., 
1974; Brown et al. 1982).
In its least severe form, RA usually only causes mild pain to certain joints resulting in 
troublesome hindrance more than disability. However in the most severe form of RA it 
can cause extreme inflammation of the joints, cartilage, muscles, tendons, bone 
ligaments and/or internal ligaments resulting in permanent severe joint disfigurement 
and damage and severe pain.
1.6.1 Joint pathology of RA
The synovium or synovial lining is a thin cellular layer which lines the joint. It 
produces nutrients such as glucose which diffuse to the cartilage via the synovial fluid 
(Firestein and Zvaifler, 1992). The synovial lining consists of two cell types, one 
mucosal and the other phagocytic. Normally it acts as a barrier to serum proteins and as 
a means of disposal of unwanted materials.
In RA the synovium is intimately involved in the disease process. The earliest change 
in the joint is vasculitis, inflammation of small blood vessels resulting in increased 
capillary permeability and oedema (swelling) of the synovium and cellular infiltration 
(Chapel and Haeney, 1995). This is followed by the infiltration by blood-derived cells, 
chiefly memory T cells, macrophages and plasma cells into the inflamed synovial joints 
(Feldmann et al., 1996). The macrophages display surface class II major 
histocompatibility (MHC) antigens, this expression may be important as class II 
antigens form complexes with peptides for recognition by T helper cells thereby 
helping in the induction and maintenance of inflammatory lesions (Ridderstad et al.,
1991). The presentation of a relevant antigen to CD4+ T helper cells of an 
immunogenetically susceptible host may trigger the events in RA. Antigen presenting 
cells (macrophages or dendritic cells in the synovial membrane) may ingest, process 
and present foreign protein antigens to T-lymphocytes, which initiate a cellular immune 
response and stimulates the differentiation of B lymphocytes into plasma cells that 
secrete antibody (Harris, 1990).
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Large numbers of neutrophils are present in the synovial fluid of patients with RA, but 
very few in the synovial membrane itself. Neutrophils are reported to gain access to the 
joints by the presence of chemoattractants and cytokines (including IL-1 and TNF), 
acting directly on endothelial cells to induce the expression of endothelial- leukocyte 
adhesion molecules that render the endothelial surface hyperadhesive (Bevilacqua et 
al., 1989). Once inside the joints the neutrophils are rapidly activated by the 
phagocytosis of cellular debris and aggregates of immune complexes, which then 
results in degranulation and the release of proteinases (Hibbs et al., 1984; Korchak et 
al., 1984; Henson et al., 1987). It is estimated that more than one billion neutrophils 
enter a moderately inflamed knee joint each day (Hollingsworth et al., 1967). The 
amount of synovial fluid increases with inflammation, causing joints to be swollen, see 
figure 1.4.
Activation of fibrinolysis via production of plasmin may also lead to plasmin mediated 
activation of collagenase and stromelysin produced by the rheumatoid synovium (Werb 
et al., 1977; Okada et al., 1988). Clotting cascades are also activated leading to the 
production of fibrin that coats the synovial membrane (Van De Platt et al.,1977).
As the disease progresses and becomes established the overgrowth of cellular elements 
of the synovium causes even more thickening and a marked increase in the surface 
area, producing an inflammatory granulation tissue called “pannus”.
The macrophages in this pannus, which are resident or derived from infiltrating 
monocytes, and synovial cells, produce destructive proteinases which erode cartilage 
and bone, starting at the junction between cartilage and subchondrial bone at the joint 
margin and gradually working inwards until the cartilage is totally destroyed (Dieppe et 
al., 1989; Bresnihan, 1999). They also produce cytokines which stimulate chondrocytes 
to self destruct their matrix (Arend and Dayer, 1990).
It is thought that the rheumatoid factor is capable of precipitating out with IgG in 
superficial layers of cartilage forming complexes that may be attractants for the 
invasive and destructive pannus (Shiozawa et al., 1980; Jasin, 1985).
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Figure 1.4 A normal joint in comparision to a RA joint (adapted from Chapel and 
Haeney, 1993).
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1.6.2 The main cytokines that play a major role in RA
Cytokines are protein mediators that play a part in inflammation, the immune response, 
cell growth and repair, see table 1 .1 2 .
Studies have been carried out to investigate the effects of human TNFa, IL- 6  and IL-1 p 
on human articular cartilage chondrocytes in culture. IL-1 p and TNFa stimulated the 
chondrocytes to release IL-6 . IL- 6  did not affect proteoglycan synthesis or quality. 
(Malfait et al. 1994). IL-1, IL-6 , and TNF a  are produced by macrophages and have all 
been detected in the synovial membranes of patients with RA (Feldmann et al., 1990; 
Tetta et al., 1990; Firestein and Zvaifler, 1992). These cytokines are involved in the 
initiation of immune responses and have broad effects on many cells leading to cell 
proliferation, increased prostaglandin production, matrix degrading protease activity, 
fever and resorption of bone (Harris, 1990).
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IL-1, IL- 6  and TNFa have many biological properties which qualify them as 
potentially important in the pathology of RA such as stimulation of B lymphocytes to 
produce antibodies, T lymphocytes to produce cytokines, induction of MHC class II 
expression by macrophages, increased production of PGE2 and eicosanoids, and 
stimulation of the production of stromelysin and collagenase by synovial cells and 
chondrocytes. All are endogenous pyrogens and potent inducers of acute phase proteins 
(Dayer et al., 1985; Bendzen, 1988; Akira et al.,1990).
These cytokines have been shown to regulate each other, TNFa can stimulate IL-1 
which in turn can stimulate the production of TNFa. These two cytokines in concert 
can stimulate IL- 6  expression which via a feedback mechanism can reduce IL-1 and 
TNFa secretion. Each of the cytokines can stimulate their own production (Akira et 
al.,1990).
IL -1 and TNFa production has been shown to be inhibited by PGE2 production in cell 
systems (Kunkel and Chensue, 1985; Larrick and Kunkel, 1986) and even though PGE2  
is coproduced with IL- 6  its production by chondrocytes is not mediated by IL- 6  
(Bunning et al., 1990).
Transforming growth factor p (TGF P) appears to counteract many of the inflammatory 
effects of IL-1, IL- 6  and TNFa while acting synergistically to enhance the effects of 
other cytokines (Edwards et al., 1987). The latent form is activated by the rheumatoid 
factor (Ridderstad et al., 1991). It is chemotactic for monocytes and induces IL-1 
production in these cells (Arend and Dayer, 1990). In cultured chondrocytes the 
production of type II collagen has been shown, by immunocytochemical techniques, to 
be enhanced by TGFp (Frazer et al., 1994).
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Table 1.12 A key to the cytokines and their properties
CYTOKINE M r SOURCE BIOLOGICAL
ACTIVITIES
Interleukin la  
Interleukin 1 p 17,000 human monocytes/ 
macrophages
Involved in the activation 
of T and B cells. 
Stimulation of non 
immune cells to produce 
proteinases (Arend and 
Dayer, 1990)
Interleukin 6 26,000 monocytes, 
lymphocytes and 
fibroblasts
Stimulates the production 
of acute phase proteins. 
Key role in stimulating 
antibody production by B 
cells (Wong, 1988)
Tumour Necrosis 
Factor a  ( TNFa)
17,000 monocytes and 
macrophages
Shares many biological 
activities with IL-1 
(Arend and Dayer, 1990) 
osteoclast activating 
factor, stimulates synovial 
cells to release PGE2 and 
collagenase (Dayer et al., 
1985).
Transforming 
Growth Factor p 
(TGF P)
25,000
variety of cells 
including platelets, 
osteoblasts, synovial 
fibroblasts and 
macrophages
Stimulation of matrix 
synthesis and inhibition of 
degradation (Arend and 
Dayer, 1990) 
Stimulation of production 
of TIMP and proteinase 
inhibitors by connective 
tissue cells (Edwards et 
al, 1987).
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1.6.3 Possible treatments for RA
There is no actual cure for RA to date but there are a number of treatments available 
which all eleviate the symptoms to varying degrees depending on the severity of the 
disease.
Non Steroidal Anti-inflammatory Drugs (NSAIDS) can help to control the pain and 
inflammation in the initial stages of RA. They act by reducing prostaglandin production 
by the inhibition of the cyclo-oxygenases (COX) enzyme in the RA joint. They can 
however, lead to complications such as increased gastro-intestinal toxic effects and 
even death because of the requirement of prostaglandin synthesis in normal physiology 
(Daoud et al., 1999; Shah et al., 1999).
The use of synthetic inhibitors of matrix metalloproteinases (MMPs) may be useful for 
the prevention of connective tissue breakdown and it is of great interest whether the 
blocking of one MMP would be sufficient to halt the progressive and chronic 
destruction of connective tissue seen in RA (Cawston, 1998). Highly specific MMP 
inhibitors have been made which remain biologically active after oral ingestion. These 
have been shown to be active in animal models (Karran et al., 1995).
Therapeutic efforts are now being directed towards disrupting (modifying, blocking, 
switching off) the cascade of biochemical events considered to be responsible for tissue 
destruction. Studies have suggested that blocking the TNFa pathway may be of 
important therapeutic use as results^have indicated that blocking TNFa also blocked 
IL-1 production. This makes TNFa an interesting target for possible treatments of RA 
(Hauselmann, 1997; Camussi and Lupia, 1998). It has been very recently reported that 
treatment of arthritic mice with anti IL-12 and anti-TNFa antibodies synergistically 
suppressed the progression of the collagen induced arthritis (Butler et al., 1999). It has 
also be reported that treatment with a chimeric monoclonal antibody to TNF a  has been 
shown to suppress inflammation and improve patient well being in RA, the 
mechanisms of actions however have not been fully explored (Charles et al., 1999).
A new promising drug treatment that has not yet been approved by the FDA is the use 
of the antibiotic minocycline (a form of tetracycline) as it was found to help reduce
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joint inflammation in patients with mild to moderate RA. Researchers do not know 
exactly why the antibiotic has this effect at present. The antibiotic tetracycline has been 
shown to be an inhibitor of collagenase either through direct inhibition or by allowing 
the enzymes to autodegrade (Cawston, 1998).
1.6.4 Cartilage
Human articular cartilage covers the long bones in synovial joints and protects the bone 
against pressure and acts like a ‘shock absorber’. When cartilage is compressed, water 
is forced out of the system resulting in the proteoglycan being concentrated which in 
turn increases their osmotic pressure. When the force is released the water flows back 
into the proteoglycan gel (Lohmander, 1988).
Cartilage is a connective tissue composed of chondrocytes and an extensive complex 
extracellular matrix of fibrous collagen immersed in a proteoglycan gel which is 
synthesised by the chondrocytes and can also be degraded by them. The total cell 
volume is 2% of the total tissue volume, with 75% of the extracellular matrix being 
water. Of the dry substance, 70% represents collagens (mainly type II), 20% 
proteoglycans (mainly aggrecan) and the remaining 1 0 % cartilage matrix proteins 
(Lohmander, 1988; Poole, 1997). Careful regulation of matrix synthesis and 
degradation is an integral requirement for the maintenance of a healthy functional 
cartilage.
The metabolism of chondrocytes, particularly proteoglycan synthesis may be 
modulated by a number of factors, including extracellular macromolecules, mechanical 
stress and the levels of circulating growth hormones. Insulin like growth factor (IGF) is 
a known stimulator of proteoglycan synthesis (Handley et al., 1985). Under normal 
conditions the cartilage does not have its own blood supply and the synovial lining 
layer is responsible for providing nutrients. Intimal cells produce hyaluronic acid, 
which along with proteoglycan serve as lubricants for the joint (Firestein and Zvaifler,
1992).
1.6.4.1 Type II Collagen
Collagen is the major protein of connective tissue. Five different types of collagen have 
been identified in hyaline articular cartilage, (types II,VI, IX, X and XI) with type II
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collagen being the most predominant (Van der Rest and Garrone, 1991). This fibre- 
forming or interstitial collagen is composed of triple helical polypeptide chains, with 
each chain comprising just over 1000 amino acids. There are three amino acids per turn 
of the helix and every third amino acid is glycine. The amino acid sequence of the 
individual collagen chains is Gly-X-Y and there is an abundance of proline and 
hydroxyproline. The mature type II collagen molecule is incorporated into collagen 
fibrils and contains non helical telopeptides at its amino and carboxy termini, 18 and 27 
amino acids in length respectively. The telopeptides are critical for the formation of 
stable collagen as they provide some of the cross- links important to the tensile strength 
of collagen fibrils (Buttle et al., 1994). The structure of the collagen triple helix renders 
it resistant to the action of most proteases (Van der Rest and Garrone, 1991).
1.6.4.2 Aggrecan
Aggrecan is a large aggregating proteoglycan, the major proteoglycan in cartilage. It 
binds and retains water in the matrix and plays a fundamental role in the mechanical 
function of cartilage. Aggrecan is the largest and most complicated of the 
proteoglycans. It consists of a core protein with three globular domains (G1-G3) and a 
region of Mr > 200,000 to which are attached 200 chains of different types of 
glycosaminoglycans and oligosaccharides, see figure 1.5. The total Mr is in the range 1- 
3 million. The first globular domain (Gl) is known to associate with hyaluronic acid 
and the link protein and this property enables proteoglycan (PG) monomers to form 
highly charged aggregates in the Mr range 100-200 million via non covalent attachment 
(Lohmander, 1988; Cawston, 1995). The link protein stabilises the interaction between 
PG and hyluronate by binding to both a section of the aminoterminal domain of the PG 
core of the protein and to a hyaluronate decasaccharide sequence (Lohmander, 1988). 
These highly charged aggregates are immobilised in the matrix and are responsible for 
pulling water into the tissue creating a swelling pressure and therefore permitting the 
cartilage to resist compression (Cawston, 1995).
Carbohydrates represent about 90% of the large cartilage PG. The core protein carries 
two types of GAG chain, chondroitin sulphate and keratan sulphate. Typically there are 
1 0 0  chondroitin sulphate chains per molecule that are attached through a glycosidic 
bond between a serine in the peptide and a xylose residue at the reducing end of the 
GAG chain (Muir, 1958). The content of keratan sulphate increases with age, with a
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large proportion located in an intermediate region of the core protein. There are about 
40 chains per molecule (Lohmander, 1988).
Figure 1.5 The structure of the major proteoglycan found in cartilage aggrecan 
(Cawston, 1995).
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1.6.5 Degradation of the cartilage components
Degradation of cartilage involves both damage to the collagen fibrillar network and 
loss of the large proteoglycan aggrecan. Proteinase cascade reactions are the simplest 
way to interpret data regarding aggrecan and collagen breakdown.
The actual degradation of the cartilage components themselves has been investigated 
by looking at cartilage breakdown in culture using cartilage explant culture systems 
(Tyler 1991; Van den Berg, 1998; Uebelhart and Williams, 1999). It was found that a 
limited cleavage of the core protein occurs to produce monomers with a slightly smaller 
average hydrodynamic size which are unable to bind to hyaluronic acid and therefore 
rapidly diffuse out of the matrix. The majority of monomers of proteoglycans are 
cleaved adjacent to the binding region between G1 and G2 regions of the core proteins,
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these fragments diffuse out of the cartilage. Initially most of the link protein and 
binding region remains as a fragmented complex devoid of glycosaminoglycan within 
the explant, presumably still bound to hyaluronic acid. With time these components 
gradually diffuse out into the matrix leading to total breakdown of the proteoglycan 
structure.
In vitro collagen breakdown requires much longer incubations of cartilage explants and 
higher levels of IL-1 (150-350pM) than aggrecan (Tyler 1988; Kozaci et ah, 1997). In 
vivo aggrecan is lost before collagen. The only mammalian proteinases known to be 
capable of type II collagen helical cleavage are the specific collagenases, interstitial 
collagenase, matrix metalloproteinase 1 (MMP 1), collagenase 3 (MMP 13) and 
neutrophil collagenase (MMP 8 ) (see section 1.6.6.4.1), which hydrolyse a single Gly- 
Leu bond three quarters of the way from the amino terminus of each a  chain (Gross et 
al., 1965; Gross et al., 1980). The larger components are released and readily degraded 
into smaller pieces by proteinases such as gelatinase A and B (Roughley, 1978; 
Campbell et al., 1986; Tyler, 1985;). The proteinases involved can be synthesised by 
chondrocytes under appropriate stimulation or they may be produced by the cells 
(macrophages, neutrophils) that have infiltrated the inflamed synovium or synovial 
cells themselves. It is most likely that a series of proteinases act together in a cascade of 
proteolytic activation (Buttle et al., 1995).
The loss of aggrecan from human cartilage occurs after a specific proteolytic cleavage 
within the interglobular domain between G1 and G2. Studies on the fragments of 
aggrecan have shown by N-terminal sequencing that there is only one cleavage site. It 
was suggested that aggrecan breakdown is catalysed in vivo by a single glutamyl 
aggrecanase. However, this proteinase may not be the only enzyme directly involved in 
aggrecan degradation as collagenase cleaves aggrecan at the Asn-Phe and Glu-Ala 
cleavage sites but with a much higher preference for the Asn-Phe site (Fosang et al., 
1994). Two aggrecanases, aggrecanase 1 and 2 have only recently been identified 
(Abbaszade et al., 1999; Tortorella et al., 1999) (see section 1.6.6.4.2).
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1.6.6 Proteinases
Proteinases may be involved in several aspects of joint disease. Their are four main 
classes of proteinases, aspartic, cysteine, serine, and metalloproteinases which have 
been classed on the basis of the chemical groups responsible for catalytic activity. The 
majority of proteolytic enzymes are synthesised as inactive zymogens or 
proproteinases. Proteolytic activation of the proteinases involved in the breakdown of 
cartilage by the proteinases themselves is an important factor in cartilage breakdown, 
which probably occurs through a ‘cascade’ system (Buttle et al., 1995).
1.6.6.1 Aspartic proteinases
Cathepsin D is the only aspartic proteinase likely to be involved in the pathogenesis of 
RA. It has been shown to degrade cartilage proteoglycan most rapidly at pH 5.0. 
Cathepsin D cleaves the hyaluronic binding region from the molecule and splits the 
polysaccharide attachment region into fragments (Barrett and Saklatvala, 1985). 
Cathepsin D is secreted by cartilage cultures stimulated with retinoic acid (Ret) (Fell 
and Dingle, 1963).
1.6.6.2 Cysteine proteinases
Cathepsin B and Cathepsin L both cleave the N- terminal peptides of collagen that 
contain the cross links within and between collagen molecules. Cathepsin B cleaves the 
hyaluronic binding region from cartilage proteoglycan and degrades the 
glycosaminoglycan attachment region to small fragments. (Morrison et al., 1973; 
Roughley and Barrett, 1977; Roughley, 1977).
1.6.6.3 Serine proteinases
Serine proteinases include many of the proteins of the “cascade” of coagulation, 
fibrinolysis, complement and kinins. They include enzymes such as thrombin, 
plasminogen activators, plasmin, Cls, Clr, and elastase.
Plasminogen activators (PAs) catalyse the cleavage of plasminogen to yield the serine 
proteinase plasmin. The activities of PAs are increased by the addition of IL-1 
(Bunning et al., 1987; Leizer et al., 1987), TNFa, TGFp (Campbell et al., 1990) and 
Ret (Meats et al., 1985) in chondrocytes. Plasmin has the capacity to degrade cartilage
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proteoglycan (Lack and Roger, 1958) but has little effect on collagen although it does 
activate latent collagenase. Plasmin may activate latent metalloproteinases involved in 
cartilage breakdown (Buttle et al., 1995).
Leukocyte elastase attacks elastin which is a crossed linked structural protein that is 
important for the elastic strength of the joint capsule and is highly resistant to 
proteolytic attack (Barrett and Saklatvala, 1985). It also acts on cartilage proteoglycan 
to remove the hyaluronic acid binding region and then fragment the glycosaminoglycan 
attachment region (Keiser et al., 1976; Roughley and Barrett, 1977; Roughley, 1977). 
Leukocyte elastase also degrades collagen fibers, initially by degrading the N-terminal 
peptides which breaks the crosslinking that plays a crucial part in the stabilization of 
collagen fibers. The individual molecules are then degraded to small peptides and 
amino acids by further proteolytic attack (Davies et al., 1978; Mainardi et al., 1980).
1.6.6.4 Metalloproteinases
1.6.6.4.1 Matrix metalloproteinases (MMPs)
MMPs are a large group of proteinases that are synthesised by mesenchymal cells and 
are either secreted directly into the extracellular matrix (as inactive proproteinases) or 
retained at the cell surface (Buttle et al., 1995). MMPs are enzymes that are dependent 
on metal ions for activity and are divided into four main groups, stromelysins, 
collagenases, gelatinases and membrane type MMPs (Nagase, 1997), see table 1.13. A 
large number of studies indicate that MMPs are involved in the pathological destruction 
of joint tissue (Vincenti et al., 1994) as this large group of proteases are capable of 
hydrolysing extracellular matrix components (Murphy, 1993). They are secreted as 
inactive proenzymes that are activated proteolytically by the removal of a 10 kMr 
polypetide chain from the protein. This process removes the cysteine residue that 
previously blocked the active site of the zinc atom (Andrews et al.,1990). MMPs are 
controlled by various cytokines, growth factors and other agents that stimulate the 
production of proMMPs (Goldring et al., 1993). Prostromelysin is activated by plasmin 
to produce the active stromelysin (MMP 3) which has been found, along with 
collagenase in rheumatoid synovial fluid (Brinckerhoff, 1991).
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Table 1.13 Summary of MMPs and proteins degraded (modification from Nagase, 
1997).
Enzyme Matrix Substance
Collagenases
Interstitial collagenase MMP 1 Collagen types, I, II, III, VII, X, gelatins,
entactin, aggrecan, link protein.
Neutrophil collagenase MMP 8 Collagen types, I, II, III, aggrecan, link protein
Collagenase 3 MMP 13 Collagens I, II, III
Collagenase 4 MMP 18 Collagen I
Gelatinases
72k Mr gelatinase A MMP 2 Gelatin types, I, II, III, elastin, collagen types, I,
IV, V, VII, X,XI fibronectin, aggrecan, elastin.
92k Mr gelatinase B MMP 9 Gelatin types I, V, collagen types IV, V, XIV,
aggrecan, elastin, entactin.
Stromelysins
Stromelysin -1 MMP 3 Proteoglycan, fibronectin, laminin, gelatin types
I, III, IV, V, collagen types, III, IV, V, IX
Stromelysin-2 MMP 10 Gelatin types I, III, IV, V, weak on collagen
types, III, IV, V, Fibronectin.
Membrane-Type MMPs
MT1-MMP MMP 14 Collagens I, II, III, fibronectin, laminin-1,
dermatan sulfate proteoglycan.
MT3-MMP MMP 15 Not known
MT4-MMP MMP 16 Activated proMMP-2
MT4-MMP MMP 17 Not known
Others
Matrilysin MMP 7 Gelatin types I, III, IV, V, fibronectin, laminin,
collagen IV, aggrecan, entactin, proteoglycan.
Stromelysin 3 MMP 11 Weak activity on fibronectin, laminin, collagen
IV, aggrecan, gelatins.
Metalloelastase MMP 12 Elastin
Unnamed MMP 19 Not known
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The synthesis and secretion of the collagenases and stromelysins is also stimulated by 
proinflammatory cytokines such as IL-1 and TNFa  (Goldring et al, 1993).
Their involvement in the normal turnover of connective tissue matrix is well 
established (Case et al., 1989). Collagenase is the only proteinase that can cleave the 
triple helix of type II collagen in cartilage. This leads to an unwinding of the triple helix 
which is then readily cleaved by the 72 or 92k Mr gelatinases and also by collagenases 
and stromelysin 1.
1.6.6.4.2 A disintegrin and metalloproteinase (ADAM) family of proteins
The ADAM family of proteinases contains more than twenty members having 
homology to the snake venom metalloproteinases (Jia et al., 1996; Black and White, 
1998). These proteins, as their name suggests, contain a disintegrin and a 
metalloproteinase domain so may be involved in cellular interactions and/ or 
proteolysis, though not all ADAMs are known to have a functional metalloproteinase 
domain. They are mainly membrane bound proteins. Human chondrocytes have been 
shown to express ADAMs 10,12 and 15 which may be involved in cartilage breakdown 
(McKie et al., 1997).
More recently aggrecanase, the key enzyme(s) thought to be involved in aggrecan 
breakdown in osteoarthritis and inflammatory joint disease, has been purified and 
cloned and shown to be a member of the ADAMTS family of proteins (Abbaszade et 
al., 1999; Tortorella et al., 1999). ADAMTS proteins hav„e,multithrombospondin (TS) 
motifs and no transmembrane domain as in ADAMs. These proteins are therefore 
secreted proteins which may bind to extracellular matrix via their TS motifs.
Aggrecanase brings about the cleavage of aggrecan core protein at Glu373-Ala374 
which occurs in arthritic disease (Lohmander et al., 1993). Two aggrecanases have 
been characterised to date, aggrecanase 1 and 2 (ADAMTS 4 and 11 respectively) 
(Abbaszade et al., 1999; Tortorella et al., 1999). Aggrecanase is ineffective at cleaving 
several substrates cleaved by MMPs, including extracellular matrix components, type II 
collagen and gelatin (Tortorella et al., 1999).
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1.6.7 Proteinase inhibitors
The activities of proteinases are modulated by naturally occurring inhibitors. In the RA 
synovial fluid it is thought that these inhibitors become saturated by the proteinases 
released into the synovial fluid or even destroyed allowing the free enzymes to degrade 
connective tissue (Harris, 1990).
1.6.7.1 Alpha 2 macroglobulin (a2 in)
ct2m is a tetrameric plasma glycoprotein of Mr 725,000, composed of identical subunits 
linked in pairs by disulphide bonds containing 8-11% carbohydrate. It is synthesised by 
the liver and distributed mainly intravascularly, plasma concentrations ~ 2.5mg/ml, 
although it can be detected in most serous fluids. In early pregnancy ct2m reaches a new 
steady state level 20% higher than in the non pregnant state (Ganrot and Bjerre 1967). 
No changes in turnover of ot2m are observed in patients with rheumatoid arthritis 
(Norberg et al., 1970) and no disease has been recognised where the determination of 
ct2in is of diagnostic interest.
(X2m has the unique property of binding and inhibiting the great majority of 
endopeptidases regardless of their specificity or catalytic mechanism (Barrett and 
Starkey, 1973; Werb et al., 1974; Starkey and Barrett, 1977). On binding proteinases it 
undergoes a conformational change which can be detected using native, gradient gel 
electrophoresis, the oc2m-proteinase complex migrating faster in gradient gels than the 
native protein. This “fast” form was attributed to a more compact form of the complex 
(Barrett et al.,1979). The irreversible transition from the “slow” or S form into the 
“fast” or F form is associated with the binding of a proteinase (Barrett et al., 1979).
Only the fast form can interact with the ot2in receptor, termed o^m receptor-low density 
lipoprotein receptor related protein (LRP) which is present on a variety of cells 
including macrophages, hepatocytes and fibroblasts (Van Leuven et al., 1979; Dickson 
et al., 1981; Pizzo and Gonias, 1984; Moessrupt and Giliemann, 1991).
Similar conformational changes of ct2m can also be achieved by treatment with primary 
amines such as methylamine. The structure of o^m-methylamine is nearly identical to 
that of a 2m-proteinase complexes and are recognised equivalently by LRP (Pizzo and 
Gonias, 1984).
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The “trap hypothesis” was introduced (Barrett and Starkey, 1973) to explain how the 
oc2m rapidly undergoes a conformational change as the proteinase attacks a vulnerable 
“bait region” in the ot2m molecule which then physically encapsulates the proteinase 
within it. Access of substrates to the active site of the enzyme becomes sterically 
hindered causing inhibition that is most pronounced with large substrates. Further 
studies have supported this theory, however one such study suggested that the reaction 
of 012m with proteinases does not involve proteolytic cleavage (Harpel, 1973).
Some endopeptidases do not react with ct2m at an appreciable rate, indicating they are 
not “trapped”. This is probably due to their narrow specificity and/or large Mr 
(>80,000). Plasma kallikrein and plasmin (Mr 90,000) are the largest proteinases 
reported to be bound. Trypsin and chymotrypsin linked to Sepharose have been found 
to have little capacity to be “trapped” by ct2m (or bind in any way) or even cleave the 
bait region. This suggested that the bait region may be internal, so that any proteinases 
that cleave it must already be well within the “trap” (Barrett and Starkey, 1973). 
Proteinase molecules “trapped’ by 0 C2m are usually able to act on low molecular weight 
substrates with minor changes in Km and Vmax which can be attributable to the new 
environment of the proteinase molecule. Substrates of Mr above 10,000 will be totally 
excluded from the complex due to steric hindrance and therefore larger substrates will 
not be able to enter the complex, resulting in (X2m having an inhibitory effect on the 
enzyme. The antigenic activity of proteinase molecules trapped by 0 C2m being blocked 
is one of the clearest indications that the entire molecule is enclosed, since antigenic 
determinants are likely to cover the whole surface of the molecule and therefore would 
not be masked by an enzyme-a2m interaction that would be restricted to the active site 
of the proteinase (Geokas et al., 1977; Sayers and Barrett, 1980).
The high molecular weight of 0 C2m prevents it from escaping into the synovial fluid of 
the normal joint, in inflammation however it is able to pass through into the synovial 
fluid and is present in the same concentration as in plasma. ct2m complexes have a 
greater tendency to accumulate in synovial fluid than in plasma (Barrett and Saklatvala,
1985).
a.2m may also have a transport function for various hormones and metals. About a third 
of zinc in plasma is bound to a 2m (Iwamato and Abiko, 1970).
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It has been proposed that a 2m may play an important multifunctional role at sites of 
inflammation by scavenging both active peptides and proteases that are released by 
cells at the site of injury (O’Conner- McCourt et al., 1987).
1.6.7.2 Tissue inhibitors of matrix metalloproteinases (TIMP)
TIMPs play an important role in the control of connective tissue breakdown by 
blocking the action of activated MMPs and preventing activation of the proenzymes. 
There are four TIMPs all with approximate Mr of 21,000, that contain two domains 
held in a rigid conformation by six S-S bonds (Cawston, 1998). TIMPs are synthesised 
by connective tissue cells and bind tightly to all known active MMPs with a 1:1 
stoichiometry (Gomis-Ruth et al., 1997). TIMP 1 and TIMP 2 have been recently 
shown to prevent cartilage collagen breakdown in culture which suggests that MMPs 
are involved in the breakdown of cartilage collagen (Ellis et al., 1994).
1.6.8 Prostaglandins
Prostaglandins are chemical mediators which are continually synthesised by most cells 
from fatty acid chains cleaved from membrane phospholipids. Their production is 
increased in most cells when they are activated by a change in their environment.
The unsaturated fatty acid, arachidonic acid is the precursor for the synthesis of the 
major classes of both prostaglandins and leukotrienes (O’Banion. 1999; Dubois et al., 
1998). The action of phospholipase A2 causes the liberation of arachidonic acid and 
Lyso - platelet activating factor (PAF) from membrane phospholipids. “Free” 
arachidonic acid can then be converted to prostaglandin G2 (PGG2) and prostaglandin 
H2 (PGH2) by the enzyme cyclooxygenase COX. PGH2 is subsequently converted to a 
variety of eiconsanoids that include PGE2 , PGD2, PGD2 , PGF2a, PGI2 and 
thromboxane (TX) (Dubois et al., 1998; O’Banion. 1999).
Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and 
COX-2. Evidence provided by animal models of inflammatory arthritis strongly 
suggests that increased expression of COX-2 is responsible for increased PG 
production seen in inflamed joints (Anderson et al., 1996). Studies carried out on 
primary cells derived from human synovial tissue or cell types (e.g., monocytes) have
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shown that pro-inflammatory agents, IL-1, TNFa and LPS induce COX-2 expression 
(Crofford. 1997).
E series prostaglandins are important mediators of inflammation, fever and certain 
types of pain. PGE2 is the most abundant cyclooxygenase product in inflammatory 
lesions and along with PGEi can increase vascular permeability. However they are 
much less effective than other inflammatory mediators, such as histamine and 
bradykinin but can markedly potentiate the increase of vascular permeability produced 
by them (Roberts and Newton, 1982.). PGE2 has effects on the immune system 
suppressing the functions of T and B lymphocytes, natural killer (NK) cells. PGE2 also 
inhibits the proliferation of synovial fibroblast-like cells and is a known stimulant of 
osteoclast mediated bone resorption (Shiroky, 1989).
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1.7 Aims and Objectives
The aims of this study were to obtain the purest sample of active PAPP-A possible and 
to determine whether PAPP-A was a proteinase inhibitor and/or modulator of cytokine 
production or activity during pregnancy. In such a role, PAPP-A may act as a 
protective agent for inflamed rheumatoid joints and thus be involved in the 
amelioration of the symptoms of RA, observed during pregnancy.
This investigation had the following objectives :
1. to devise a purification protocol for PAPP-A from pregnancy plasma for the 
production of PAPP-A for functional studies;
2. to study the effects of PAPP-A on the production of cytokines IL-1, TNFa and IL- 
6 , which may be involved in the pathogenesis of RA, by monocytic and connective 
tissue cell lines;
3. to study the effects of PAPP-A on cytokine action via PAPP-A binding of 
cytokines;
4. to study the inflammomodulatory effects of PAPP-A via investigation of its effects 
on PGE production;
5. to study the binding of PAPP-A to cartilage and its effects on Ret-stimulated 
cartilage proteoglycan breakdown to determine whether it may have a 
chondroprotective role;
6 . to determine whether PAPP-A has proteinase inhibitory activities which may be 
important in the reduction of cartilage breakdown.
In view of the possible importance of PAPP-A during pregnancy it was important to 
review the current literature and confirm, or refute some of the findings described by 
other workers and also to expand the data currently available on the functions of 
PAPP-A.
These studies on PAPP-A were intended to increase our knowledge of this molecule, 
the functions of which are not clear cut. By studying the effects of PAPP-A on the
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inhibition of proteinases, cytokine production and binding and cytokine stimulated 
activities we can better evaluate its possible role, if any, in the remission of RA during 
pregnancy. Agents, which protect connective tissues from breakdown, may in the 
future provide models for developing therapeutic agents for the treatment of RA.
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Chapter Two 
Materials and Methods
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2.1 Protein purification techniques
2.1.1 Ammonium sulphate precipitation.
2.1.1.1 Principle
Salt fractionation is a technique that can be used in the early stages or in the bulk 
purification of proteins. Ammonium sulphate, when added to a protein solution will 
precipitate a number of these proteins by “salting out” and the remainder will stay in 
the supernatant. This method can be optimised for a particular protein to firstly remove 
the majority of the unwanted proteins present in the sample and secondly to concentrate 
the protein of interest.
2.1.1.2 Method
This method is based on a modification of that described by Lin et al. (1974).
Plasma taken from pregnant women in the final stages of pregnancy was adjusted to a 
final concentration of 30 % saturation with solid ammonium sulphate, this solution 
being gently rotated at 4°C for 18 hours. The amount of solid ammonium sulphate 
required was taken from a standard table. The solution was then centrifuged at 6000g 
for 30 minutes in a Sorvall RC 5 refrigerated centrifuge at 4°C. The supernatant was 
then transferred into a separate centrifuge bottle and further ammonium sulphate was 
added to give a final concentration of 60 % saturation. This sample was left for 18 
hours, again with gentle rotation, at 4°C. The preparation was centrifuged for 30 
minutes at 6000g and 4°C, the supernatant was discarded and the remaining precipitate 
was resuspended in the smallest volume of buffer (0.05M
Tris[hydroxymethyl]aminomethane/hydrochloric acid (Tris/HCl) containing 0.15M 
sodium chloride (NaCl), pH 7.8 with 0.02 % sodium azide) possible to ensure complete 
dissolution of the pellet. The solution was then dialysed overnight at 4°C in 3 changes 
of 30 volumes of the resuspension buffer used previously.
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2.1.2 Gel filtration chromatography
2.1.2.1 Principle
Gel filtration (exclusion) chromatography utilises polymeric gels of cross linked 
dextran, agar, agarose or polyacrylamide in beads to separate substances of different 
molecular size. The basic principle is that the sample passes down the column and the 
separation depends on the different abilities of the sample molecules to enter the pores 
of the gel matrix. Very large molecules cannot pass through the pores to enter the gel 
and therefore move through the chromatographic bed faster whereas smaller molecules 
which can enter the pores move more slowly through the column relative to their size 
since they spend a proportion of their time within the bead stationary phase. Molecules 
entering the pores are therefore eluted in order of decreasing molecular size, with the 
largest molecules being eluted first.
2.1.2.2 Method
The gel matrix employed was Ultrogel AcA 34 which is composed of an homogeneous 
network of polyacrylamide and agarose in bead form, with a fractionation range of 
20,000-350,000 packed into an XK 50/100 column (5 x 100 cm).
The critical stage was the packing of the column as a poorly packed column will give 
rise to uneven flow, zone broadening and loss of resolution. The homogeneity of the 
column was checked using a 2mg/ml dextran blue solution (Mr 2,000,000). The sample 
obtained from the ammonium sulphate stage, or, approximately 80ml, (if the volume 
after dialysis exceeded 80ml) was loaded onto the column at a flow rate of 40ml/hour. 
0.05M Tris/HCl containing 0.15M NaCl, pH 7.8 with 0.02% sodium azide was run 
through and 9ml fractions were collected. The column was then washed with at least 
three column volumes of 0.05M Tris/HCl containing 0.15M NaCl, pH 7.8 with 0.02% 
sodium azide to elute all the other smaller remaining proteins. Ideally the column 
should be kept flowing at a decreased speed constantly. The absorbance of the 
fractions was then measured in a Cecil 1020 UV-Visible spectrophotometer at a 
wavelength of280nm to determine the presence of protein in each fraction. The 
fractions shown to contain protein were also analysed for the presence of PAPP-A 
using rocket immunoelectrophoresis as described in section 22.2.2.
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The fractions that produced distinct rocket like immunoprecipitates contained PAPP-A 
and were pooled and dialysed against three changes of 25mM Tris/HCl containing 
50mM NaCl pH 7.6 ready for the next stage of purification.
2.1.3 Ion exchange chromatography (IEC)
2.1.3.1 Principle
The basic principle of ion exchange chromatography (IEC) is that separation of 
proteins is achieved on the basis of the charges carried by the solute molecules. Many 
biological molecules are polar and so ion exchange is often used as it is capable of 
separating molecules with very small differences in charge, and therefore is a technique 
with potentially high resolution. The presence of charged groups covalently bound to 
the insoluble matrix is a fundamental property of an ion exchanger. Most ion exchange 
experiments are performed in two stages, the first stage being sample application and 
adsorption. Unbound substances are washed from the column using column buffer, the 
bound substances being exchanged with the counter ions due to their greater affinity 
for the ion exchanger. The second stage is the elution of the bound substances from the 
column again by an exchange mechanism. The substances bound are exchanged for 
counter ions in the elution buffer which now possess a greater affinity than the bound 
substances and therefore elute from the ion exchanger. The affinities can be controlled 
by varying conditions such as ionic strength and pH.
2.1.3.2 Method
The ion exchange matrix used was DEAE Trisacryl gel, an anion exchanger, packed 
into a column (1.5cm x 35cm). The gel was initially washed with 8 M urea solution, 
followed by two column volumes of 25mM Tris/HCl pH 7.6. The column was then 
connected to a Fast Protein Liquid Chromatography System (F.P.L.C.), which works on 
the principle of two connecting pumps that can mix the different buffers in pump A and 
in pump B to produce varying salt gradients or pH gradients. A salt gradient was 
required for this method. Pump A reservoir contained 25mM Tris/HCl pH 7.6 and 
pumpB reservoir contained 25mM Tris/HCl containing 1M NaCl pH 7.6. Prior to the 
run the F.P.L.C. was programmed to wash the column with three alternate salt 
concentrations (ABA), each of 40ml. The dialysed sample previously pooled was then 
loaded onto the column at a flow rate of 1 ml/minute. The eluent was monitored, using a
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flow cell, at an absorbance of 280nm, for the presence of protein. A large peak was 
seen when the sample was loaded onto the column indicating that many of the proteins 
were not binding to the column.
Following the addition of the sample onto the column it was washed with 25mM 
Tris/HCl pH 7.6 until the base line on the chart recorder measuring absorbance 
reached zero, indicating that all the remaining proteins were bound to the column. The 
F.P.L.C. was then programmed to increase the salt concentration to 0.5M, keeping the 
flow rate at 1 ml/minute. A second protein peak was eluted from the column after a 
short time and this was collected and stored at 4°C. The salt concentration was then 
increased to 1M and any remaining proteins eluted were collected and stored at 4°C. 
The column was then washed again as described initially to regenerate it ready for a 
future run .
2.1.4 Negative affinity chromatography
2.1.4.1 Principle
Affinity chromatography is a technique which enables the purification of a biomolecule 
on the basis of its biological function or individual chemical structure. Affinity 
chromatography is a type of adsorption chromatography in which the molecule to be 
purified is specifically and reversibly adsorbed by a complementary binding substance 
(ligand) immobilised on an insoluble support (matrix). Negative affinity however, as 
the name suggests, adsorbs all the unwanted proteins onto the ligand and the protein of 
interest is eluted from the column in the wash stage. The bound unwanted proteins are 
then eluted from the column using an elution buffer. Recovery of purified proteins is 
very high although there is a dilution of the sample, requiring concentration by, for 
example, the Centripreps.
Sepharose 4B is the most widely used matrix to which affinity ligands are bound, due 
to its high binding capacity and low non-specific adsorption. Cyanogen-bromide 
activated Sepharose 4B (CN-Br act. Sep 4B) is the suggested matrix to couple proteins 
and nucleic acids under mild conditions. The activated groups react with the primary 
amino groups of protein ligands and multipoint attachment ensures that proteins do not 
hydrolyse from the matrix.
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2.1.4.2 Preparation of anti-total human serum affinity column
lOg of freeze dried CN-Br act. Sep 4B were washed with 2 litres of ImM hydrochloric 
acid (HC1) on a sintered glass filter (porosity G3) for at least 15 minutes. The ligand, 
anti-total human serum (5-10 mg/ ml of gel) was dissolved in coupling buffer, 0.1M 
sodium bicarbonate containing 0.5M NaCl pH 8.3 and the mixture rotated end over end 
overnight at 4°C. The excess ligand was then washed away with coupling buffer and 
any remaining active sites were blocked using 0.1M Tris/HCl containing 0.5M NaCl 
pH 8.0 for 2 hours at room temperature.
The gel was then packed into a column (1.5cm x 35cm) and washed using the F.P.L.C. 
system with three alternate cycles (ABA) using 0.1M Tris/HCl containing 0.5M NaCl 
pH 8,0 and 0.1M sodium acetate containing 0.5M NaCl pH 4.0 at a flow rate of 
1 ml/minute. The samples obtained at 0.5M and 1M salt concentrations from the IEC 
column were pooled, then loaded onto the negative affinity column at a flow rate of 
0.25ml/minute. The eluent should contain all the proteins not found normally in the 
serum i.e. the pregnancy proteins and these were monitored again through the flow cell 
at 280nm to determine at which point they were being eluted. The column was then 
regenerated using 0.1M glycine, pH 2.9 and all the proteins that were bound to the 
column were eluted. The samples collected throughout the run, including those in the 
regeneration step were analysed on Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS PAGE).
2.1.5 Anti PAPP-A affinity column
2.1.5.1 Principle
An affinity column which binds PAPP-A follows the same principle as any affinity 
column in that the antibody attached to the matrix will bind the protein specific to it, in 
this case PAPP-A. The other proteins will elute from the column leaving PAPP-A 
bound and then by altering the buffer conditions the bound proteins can be eluted.
2.1.5.2 Method
CN-Br act. Sep 4B was prepared as described in section 2.1.4.2. using rabbit -anti 
human polyclonal PAPP-A antibody (5-10 mg/ ml of gel).
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The gel was then packed into a column (1.5cm x 35cm) and washed using the F.P.L.C. 
system as described in 2.1.4.2. The ion exchange samples eluted using buffers 
containing 0.5M and 1M NaCl, previously concentrated, were loaded onto the column 
at a flow rate of 0.25ml/minute. The column was washed with 50mM Tris/HCl 
containing 0.3M NaCl pH 7.6 until all the unbound proteins had been eluted, by 
monitoring the eluent at 280 nm in the flow cell. The column was then washed with 
0.1M glycine pH 2.9 to elute any proteins still bound to the column. The samples from 
all stages were collected and analysed on SDS PAGE.
2.1.6 Anti (X2 macroglobulin (o^m) affinity column
2.1.6.1 Principle
The anti (X2m affinity column followed the same principle and method as the anti 
PAPP-A column, the only difference being that rabbit-anti human ot2m antibody was 
used as opposed to rabbit-anti human PAPP-A antibody as the coupling ligand.
2.1.6.2 Method
The samples obtained from the pooled 0.5M and 1M NaCl elution steps from the IEC 
were loaded onto the column at a flow rate of 0.25ml/minute. The unbound proteins 
were eluted from the column and the eluent monitored at an absorbance of 280nm until 
baseline absorbance was reached. The column was then washed and regenerated as 
described for the anti- PAPP-A column in section 2.1.5.2 to elute the bound a 2m. 
Samples were collected from both of stages and analysed on SDS PAGE.
2.1.7 Wheat germ lectin affinity column
2.1.7.1 Principle
Lectins are proteins which possess the ability to react reversibly with specific sugar 
residues which enables them to bind polysaccharides and glycoproteins. Immobilised 
lectins are very valuable tools for isolating and separating glycosylated proteins due to 
their specificities for commonly occurring sugars. The binding that takes place between 
the lectin and the sugar residue on the protein is analogous to the interaction between 
an antibody and antigen. Proteins that are bound to the column can be eluted by using
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buffers with higher ionic strengths or a competitive binding substance. Wheat germ 
lectin-Sepharose 6 MB consists of the lectin from wheat germ coupled to macrobeads of 
Sepharose 6 B by the cyanogen bromide method.
Wheat germ lectin binds N-acetyl-glycosaminyl residues and wheat germ lectin- 
Sepharose 6 MB is a group specific adsorbent for the purification of glycoproteins and 
polysaccharides. ct2m is known to bind with weak affinity to this matrix and PAPP-A 
has been reported to have a stronger affinity (Sinosich et al., 1987). It may therefore be 
a very useful step in the separation of ct2m from PAPP-A.
2.1.7.2 Method
Samples obtained from the pooled 0.5M and 1M NaCl elution steps from the IEC were 
loaded onto a wheat germ lectin column at a flow rate of 0.25ml/minute. The eluent 
was monitored at an absorbance of 280nm through a flow cell and the eluted proteins 
collected. The column was then washed with at least 10 column volumes of 0.1 M 
Tris/HCl, pH 7.4 to remove any unbound and weakly bound proteins, these fractions 
were also collected. The bound substances were then eluted using a competitive sugar,
0.1M methyl-a-D-mannoside. Fractions were monitored at 280nm and protein 
containing fractions collected. Samples collected were analysed by SDS PAGE.
2.1.8. Gel filtration using Trisacryl GF 2000 
2.1.8.1 Principle
The principle of gel filtration chromatography has been described in section 2.1.2.1. 
This matrix was investigated as an alternative to the AcA 34 Ultrogel because of its 
large pore size and large fractionation range (10,000-15,000,000).
2.1.8.2 Method
The method was essentially the same as that described in section 2.1.2.2.
The column was packed and the homogeneity of the column was checked using a 
2mg/ml dextran blue solution (Mr 200,000). The sample obtained from the ammonium 
sulphate stage, was loaded onto the column at a flow rate of 40ml/hour and then 50mM 
Tris/HCl containing 0.15M NaCl, pH 7.8 with 0.02% sodium azide was run through
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and 9ml fractions were collected. The column was then washed as described in section
2.1.2.2. The absorbance of the fractions was then determined in a Cecil 1020 UV- 
Visible spectrophotometer at a wavelength of 280nm to determine the presence of 
protein in each fraction. The fractions shown to contain proteins were also analysed for 
the presence of PAPP-A using rocket immunoelectrophoresis, as described in section
2 .2 2 .2 .
2.2 Protein detection and determination techniques
2.2.1 Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS PAGE).
2.2.1.1 Principle
The technique of SDS PAGE is a quick method for the determination of protein relative 
Mr and purity of a sample. The detergent SDS has long been recognised as a powerful 
protein denaturant and solubilising agent. It was reported by Weber and Osborn (1969) 
that proteins dissolved in high concentrations of SDS exhibit electrophoretic mobilities 
in polyacrylamide gels which are a direct function of their sub-unit Mr. When SDS is 
present in excess in the sample, all the proteins have the same charge density, and 
hence the same amount of SDS bound per unit weight of polypeptide. SDS binds to 
hydrophobic regions of proteins, causing them to unfold and gives them a net negative 
charge. The application of an electric current through the gel will result in the proteins 
being separated depending on their ratio of charge to mass, the higher the ratio of 
charge to mass the faster the molecule will migrate. The Mr of a protein is calculated by 
running a series of standard protein solutions also on the gel and comparing this 
protein’s electrophoretic mobility with the standard proteins. The percentage 
acrylamide added to the gel will determine the molecular range of proteins to be 
analysed on the gel, a high percentage gel separating low Mr proteins and a low 
percentage gel separating high Mr proteins.
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2.2.1.2 Reagents
1. Resolving Buffer :
2. Stacking Buffer:
3. Acrylamide/bisacrylamide:
4. Ammonium persulphate :
5. TEMED
6. Running Buffer (X10):
7. SDS :
8. Reducing sample buffer : 
(X2)
9. Non reducing sample buffer 
(X2)
10. Stain:
11. Destain:
12. Protein standards:
1.5M Tris/HCl pH 8 . 8
0.5M Tris/HCl pH 6 . 8
30% (w/v) acrylamide and 0.8% N,N- bis-
methylene acrylamide.
1 0 % (w/v) in distilled water
N,N,N’ ,N’ - Tetramethylethylenediamine
0.25M Tris/HCl containing 2M glycine and 1%
SDS (w/v) pH 8.3
1 0 % (w/v) in distilled water
0.06M Tris/HCl containing 2% (w/v) SDS, 10%
(v/v) glycerol, 0.05% (v/v) bromophenol blue
and 5% mercaptoethanol
As for reducing but without the mercaptoethanol
0.25% Coomassie brilliant blue R250 made up 
in destain
45% methanol and 5% acetic acid in distilled 
water
Biorad prestained high Mr markers containing 
Myosin, (200,000) a-Galactosidase (116,200) 
Phosphorylase b (97,400), Ovotransferrin 
(77,000) Glutamate dehydrogenase (55,500), 
Ovalbumin (42,700).
2.2.1.3 Method
This method is a modification of the method employed by Laemmli, (1970). The gel 
apparatus used was the Biometra mini gel twin G42 apparatus.
The plates were thoroughly cleaned with 70% ethanol to ensure they were grease and 
dust free to prevent uneven gel formation that would interfere with the movement of 
the proteins down the gel, and were then assembled with the spacer ready for use. The
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resolving gel mixture (5% acrylamide) was then made up as below:
Resolving buffer 3.0ml
Acrylamide/bis 1.3ml
Distilled water 3.5ml
SDS (10%) 80ul
APS (10%) lOOul
TEMED 40ul
Total Volume 8ml
The first four solutions were added, mixed gently and then the remaining two solutions 
were added. The mixture was carefully poured into the gel cast, followed by the 
addition of a layer of ethanol on top to prevent exposure to the air that would hinder the 
polymerisation.
Once the resolving gel had set, the ethanol was poured off the top and the surface 
washed several times with distilled water. The stacking gel (3.6 % acrylamide) was 
then prepared:
Stacking buffer 1.25ml
Acrylamide/bis 0 .6 ml
Distilled water 3.0ml
SDS (10%) 2 0 ul
APS (10%) lOOul
TEMED 40ul
Total Volume 5ml
As previously the first four solutions were mixed, the remaining two added and the 
mixture mixed gently again. The mixture was poured onto the top of the resolving gel 
and the 10 tooth comb carefully inserted, ensuring no air bubbles were present. The 
stacking gel was left for about thirty minutes to completely polymerise. During this 
time the samples were prepared, 15ul of reducing sample buffer was added to 15ul of
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sample in an Eppendorf tube and they were then incubated at 70°C for 10 minutes. The 
non-reduced samples were made up by the same procedure using non- reducing sample 
buffer and incubated at room temperature for 10 minutes. The clips were then removed 
from the gel cassette followed by the comb and spacer and the gel was then placed in 
the gel tank and clipped into place. The tank buffer was diluted 1 in 10 in distilled 
water and then poured into the upper and lower chambers of the tank. The samples and 
standard were carefully loaded into the numbered wells, 15ul in each and the lid placed 
on the tank. The gel was then run at 150V for approximately 45 minutes. Once the gel 
run had completed, as determined by the bromophenol blue band at the bottom of the 
gel, the lid was removed and the gel cassette removed. The plates were then 
disassembled and the gel placed in destain for 15 minutes to remove any SDS and then 
placed in stain overnight at room temperature. The following day the gel was washed 
several times in destain until clear protein bands could be seen and the appearance of 
these recorded photographically.
2.2.2 Rocket immunoelectrophoresis for PAPP-A detection
2.2.2.1 Principle
Rocket immunoelectrophoresis, first described by Laurell (1966) is a quantitative 
method by which the presence and/or concentration of a known protein can be 
determined in a simple, quick and reproducible way. Electrophoresis is performed in an 
agarose gel containing a monospecific antiserum. The sample proteins are pipetted into 
wells in the gel and when an electrical current is applied the antigen starts to migrate 
out of the well into the antibody containing gel, at this point the antigen concentration 
exceeds that of the antibody. The antigen continues to migrate towards the anode 
forming a “rocket” shaped precipitate at the point when antigen and antibody 
concentration are equal. The height of the rocket is directly proportional to the 
concentration of antigen.
2.2.2.2 Method
Agarose gels were prepared using Litex agarose type H.S.A in which the migration of 
human IgA and IgG was zero at pH 8 .6 .
A 1% agar solution was prepared by adding lg of the agar to 100ml of barbitone buffer 
(0.07M 5-5 diethylbarbituric acid containing 0.15M Tris, 0.35mM calcium lactate and
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2mM sodium azide pH 8 .6 ). The mixture was gently boiled for a few minutes, removed 
from the heat and then boiled again for a few minutes taking great care not to bum the 
agar. The initial volume was then restored and the agar was placed in a water bath at 56 
°C ready for pouring. The glass plates (10cm x 10cm) were cleaned with distilled 
water and 95% ethanol to ensure they were “squeaky” clean. 20ml of agar solution was 
then pipetted into a test tube and lOOul of rabbit anti-human PAPP-A polyclonal 
antibody (DAKO) was added to the tube (antibody concentration of lul/cm ), the tube 
was gently agitated and the agar then poured onto the flat even surface of the glass 
plate. The gels were then covered and allowed to set. Once the gels had set, 3mm wells 
were made along one side of the plate to allow for sample application. The 
electrophoresis tank consisted of two troughs on either side of the cooling plate and
0.07M barbitone buffer pH 8 . 6  was added to each of the troughs and 3 MM filter paper 
wicks were presoaked in them. The gels were then placed on top of the cooling bed and 
6 ul samples applied to the wells.
The wicks were then gently placed onto opposite edges of the glass plates, taking care 
not to cover the wells but ensuring sufficient contact with the plates to allow the current 
to travel through the gel. The condensation lid was put over the plates and the 
electrophoresis tank was run overnight, at room temperature, for 16 hours at 300 V.
The power was switched off and the plates removed from the tank. The plates were 
washed in distilled water, then three times in saline solution (0.6% NaCl), each wash 
for 15 minutes, followed by three washes in distilled water. The next stage was to dry 
the gels before staining, this was done in an oven at 90°C for at least one hour. The gels 
were then stained in nigrosin rapid stain solution (0 .0 0 2 % nigrosin in 2 0 % acetic acid) 
for 1 hour and then destained in 5% acetic acid until rocket like peaks were visible.
2.2.3 Bicinchoninic acid (BCA) protein assay
2.2.3.1 Principle
This protein assay is a highly sensitive assay for the spectrophotometric determination 
of protein concentration in dilute solutions. This system combines the well known
94* ireaction of protein with Cu in an alkaline medium (yielding Cu ) with a highly 
selective detection reagent for Cu+, BCA. The purple reaction product formed by the
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interaction of two molecules of BCA with one cuprous ion (Cu+) is water soluble and 
absorbs strongly at 570 nm, this being the wavelength employed in this assay.
2.2.3.2 Method
The bovine serum albumin was serially diluted over the range Oug/ml - 5000ug/ml in 
diluent buffer (0.1M Tris/HCl pH 7.6) and 20ul pipetted in triplicate into a 96 well 
plate. Each unknown protein sample was then pipetted in duplicate (20ul) into the 96 
well plate, followed by the addition of200ul of BCA working solution (49ml of 
Bicinchoninic acid solution with 1ml of 4% copper sulphate) to all the wells. The plate 
was then incubated at room temperature for 30 minutes and the absorbance read in a 
multiskan MS plate reader at 570nm. A protein standard curve was constructed, see 
figure 2 . 1  and the unknown protein concentrations calculated.
E 1co
u>
@  0 8
< DOc(0nL. 0.6O(/)
<  0 .4
0.2
1000  2 0 0 0  3 0 0 0  4 0 0 0  5 0 0 00
Protein Concentration ug/ml
Figure 2.1 A typical protein standard curve, protein concentration is expressed as mean 
+/- SE.
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2.2.4 Western blot analysis for PAPP-A
2.2.4.1 Principle
Western blotting is a powerful technique to identify unknown proteins in samples and 
also to evaluate the specificity of antibodies.
The antigen or antigens under investigation are first separated by gel SDS PAGE as 
described in section 2.2.1.3. The gel is then blotted onto a specific membrane to which 
the antigen (protein) binds. Antibody is then incubated with the membrane and will 
bind to its specific antigen. An enzyme labelled anti- immunoglobulin will then bind to 
the antibody and can be readily detected using a colorimetric substrate.
2.2.4.2 Reagents
1. Towbin Transfer buffer :
2. Tris buffered saline : 
(TBS)
3. TBS containing Tween 20 
(TBST)
4. Dilution buffer:
5. Blocking solution:
6 . Primary antibody:
7. Secondary antibody:
8 . Substrate :
25mM Tris, 192mM glycine in 20 % methanol 
and 80 % distilled water 
20mM Tris, 0.9% NaCl in 21 of distilled 
water pH 7.5
0.05% Tween 20 in 11 of TBS
0.2% marvel in 500ml of TBST
5% marvel in 100ml of TBS
Rabbit anti-human PAPP-A
1 in 2 0 0  in dilution buffer
Goat anti-rabbit IgG horse radish peroxidase
(HRP) 1 in 10,000 in dilution buffer
18mg of 4-chloronapthol in 6 ml of methanol
mixed immediately before use with 30ml of TBS
containing 300ul of 1 M imidazole and 30ul of
hydrogen peroxide (H2O2) (30%)
2.2.4.3 Method
An SDS polyacrylamide gel was run as described in section 2.2.1.3 and washed in 
Towbin transfer buffer to eliminate any SDS for 15 minutes. Polyvinylidene difluoride 
(PVDF) membrane was cut to the same size as the gel and prewet in methanol for 30 
seconds and then soaked in Towbin transfer buffer with 3MM filter paper and the gel
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for 15 minutes.
A “ sandwich” was made from the components as follows :
______________sponge +VE
______________filter paper
xxxxxxxxxxxxxxxx membrane
______________gel
______________filter paper
______________sponge -VE
This was then placed in the cassette and the cassette inserted into the tank, with the gel 
nearest the -ve electrode. The tank was filled to the mark with chilled Towbin buffer 
and the system set up for 1 hour at 150V. The cassette was then carefully disassembled 
and the gel put into Coomassie R250 blue stain to detect any proteins present that had 
not transferred. The membrane was washed three times in TBST for 10 minutes each 
wash. The membrane was then incubated in blocking solution overnight at 4°C with 
gentle rocking.
The following day the membrane was washed three times for 10 minutes each wash in 
TBST and then incubated with primary antibody for 2 hours at room temperature with 
gentle rocking. The membrane was washed as previously and then incubated with the 
secondary antibody for 1 hour with gentle rocking. The wash procedure was repeated 
followed by an additional three washes in TBS for 10 minutes. The substrate was then 
added to the membrane and after about 1 0  minutes purple bands could be seen, 
denoting the presence of PAPP-A on the membrane. The membrane was removed from 
the substrate, washed in distilled water and air dried. The results were recorded 
photographically.
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2.2.5 Native PAGE
2.2.5.1 Principle
Native, or non denaturing PAGE follows the same principle as the SDS PAGE apart 
from the fact that the proteins can be detected in their native state, i.e. as they are found 
in nature and not in their denatured monomer state. Native gels are particularly useful 
for antibody blotting or detection of biological activity, because the native 
conformation of proteins is maintained.
2.2.5.2 Method
The actual running method is essentially the same as that described for SDS PAGE, 
section 2.2.1.3 with some alterations to the actual composition of the gels.
The resolving and separating gel mixtures were the same as for SDS PAGE except for 
the substitution of distilled water for the SDS solution. The non- reducing sample 
buffer was the same as the reducing sample buffer without SDS or mercaptoethanol. 
The samples that were run on the gel were incubated with non- reducing sample buffer 
for 5 minutes at room temperature and NOT heated at 70°C as for SDS PAGE gels. The 
running buffer also contained no SDS.
2.2.6 Paragon serum protein electrophoresis
2.2.6.1 Principle
The Paragon Serum Protein electrophoresis (SPE) kit is intended for the electrophoretic 
separation of proteins into five generally distinct, well resolved zones, which are 
composed of many individual proteins. The five distinct fractions are, albumin, alpha 1, 
alpha 2, beta, gamma globulins. The principle of electrophoresis is that when proteins 
are placed in an electrical field they will migrate toward one of the electrical poles. The 
Paragon kit was used to determine the purity of the monoclonal antibodies produced, as 
described in section 2.16.4.2.
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2.2.6.2 Reagents
1. SPE Gel
2. Barbital Buffer
As supplied
0.05M Barbital buffer, pH 8 . 6  
20% Acetic acid- 30% Methanol 
5% Acetic acid
0.5% 8-Amino-7-(3-nitrophenylazo)-2-(phenylazo)- 
l-napthol-3,6-disulfonic acid disodium salt in 
5 % Acetic acid
Undiluted normal serum obtained from BTS.
3. Acid-Alcohol Solution
4. Acetic Acid Solution
5. Paragon Blue Stain
6 . Serum Sample
7. Monoclonal Antibody Undiluted
2.2.6.3 Method
Each compartment of the Paragon electrophoresis cell was filled with 45ml of barbital 
buffer. The containers of the wet processor system were filled with 300ml of the 
following solutions, in sequence :
Acid-Alcohol solution 
Paragon Blue Stain solution 
5% Acetic Acid solution 
Acid-Alcohol solution 
5% Acetic Acid solution
The SPE gel was removed from the foil package and blotted gently with the gel blotter. 
The template was then carefully aligned on the gel with position “A” dots located on 
the edges of the gel and then placed on the gel surface ensuring it was sealed. The 
serum samples and pure monoclonal antibody samples were loaded into each of the 
slots, 5ul into each slot and allowed to diffuse into the gel for 5 minutes. The template 
was gently blotted and then discarded to ensure no sample smearing on the gel. The gel 
was placed onto the gel bridge assembly, aligning positive and negative sides of the gel 
with corresponding positions marked on the gel bridge and placed into the paragon 
electrophoresis cell and the lid secured. The gel was allowed to run at 100 volts for 25 
minutes.
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Upon completion of the electrophoresis the gel was removed from the cell and placed 
in the gel frame. The gel was placed in Acid Alcohol solution I for 3 minutes and then 
dried in the Paragon Dryer. The dried gel was dipped in the following :
Paragon Blue Stain solution 3 minutes
5% Acetic Acid solution 2 minutes
Acid-Alcohol solution 2 minutes
5% Acetic Acid solution 2 minutes
The gel was then removed from the gel frame and blotted dry with the gel blotters or
tissue until completely dry. The gel was then visually evaluated for the presence of 
proteins.
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2.3 Cell culture techniques
2.3.1 Introduction
Cell culture is the growth of cells in vitro by providing them with nutrients to support 
growth. There are a wide range of cell culture media and tissue culture grade 
plasticware available, along with an ever expanding collection of cell lines available 
from the European Collection of Animal Cell Culture (ECACC) and also from the 
American Tissue Culture Collection (ACTCC).
2.3.2 Preparation of media
Foetal calf serum (FCS) was heat inactivated by placing it in a water bath at 56°C for 
30 minutes before use. Complete media were prepared by adding 55ml of FCS (final 
concentration 10%) and 5.5ml of L-glutamine (final concentration 2mM) to a 500ml 
bottle of Dulbecco’s Modified Eagle’s Medium- with Glutamax (DMEM) or to a 
500ml bottle of Roswell Park Memorial Institute (RPMI)1640 media.
2.3.3 Subculturing of cell lines growing in suspension
Cell suspensions were allowed to grow to maximal density. The suspension was then 
poured into a 50ml centrifuge tube and centrifuged at 200g for 5 minutes. The 
supernatant was gently poured off and the pellet resuspended in 1 0 ml of complete 
media. The resuspension was split into a number (obtained from data sheet supplied 
with the cell line) of tissue culture flasks (75 cm2) and complete media was added to all 
of the flasks to give a total volume of approximately 30ml in each flask. They were 
then incubated at 37°C in a humidified atmosphere of 95% air / 5 %CC>2 until they 
reached maximal density and required further subculturing.
2.3.4 Subculturing of cells growing in monolayer
Cells growing in monolayer are physically attached to their substratum and have to be 
detached before being subcultured. The cells in a 75 cm2 flask were washed three times 
with 30ml of phosphate buffered saline (PBS) followed by the addition of 5ml of a 
trypsin/EDTA (0.05% trypsin, 0.02% EDTA) solution to dislodge the cells from the 
flask. Cells were incubated at 37°C until they detached from the flask, the time varying 
with the cell line. The reaction of the trypsin was stopped by the addition of complete 
media (DMEM) as the FCS present in the medium inhibits trypsin. The suspension was
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then centrifuged for 5 minutes at 200g. The supernatant was discarded and the pellet 
resuspended in 5 ml of complete media and the cells counted using a haemocytometer. 
The cell suspension was then split into tissue culture flasks (75 cm2) according to the 
split ratios (details supplied with cell line) and then incubated at 37°C in a humidified 
atmosphere of 95% air / 5 %C0 2  until they reached maximal density and required 
further subculturing.
2.3.5 Trypan blue exclusion method
This method is used for viable cell counting as live cells do not take up the trypan blue 
dye whereas dead cells do. Trypan blue solution (0.4% in PBS) was mixed 1:1, with a 
cell suspension, the cells were then counted using a haemocytometer and the number of 
viable and non-viable cells /ml were calculated.
2.3.6 Cryopreservation of the cell lines
Suspension and monolayer cells were subcultured, the pellets were resuspended in heat 
inactivated FCS and the cells counted. The cell suspension was placed on ice and 
adjusted to a final concentration of 1-10 X 106 cells per ml with FCS. The precooled 
“Mr Frosty” was then filled with the appropriate number of cryovials. Dimethyl 
sulfoxide (DMSO) was then added dropwise, with swirling, to the cell suspension to 
obtain a final concentration of 10%. The mixture was aliquoted into the precooled 
cryovials, 1ml in each and the “Mr Frosty” placed in the -70°C freezer overnight. The 
cryovials were then placed in liquid nitrogen vessels for long term storage.
2.4. Culture of the MG-63 human osteosarcoma cell line
MG-63 cells were grown in 75cm2 flasks with DMEM containing 10% heat inactivated 
FCS and 2mM glutamine at 37°C in a humidified atmosphere of 95% air / 5 %CC>2 . The 
cells were allowed to grow to confluency and were then passaged into either 24 well 
plates (7 x 104 cells per well) for experimental purposes or into 75cm2 flasks (1 x 106  
cells per flask) to maintain the culture. The MG-63 cells were passaged as described 
for cells growing in monolayer.
2.5 Culture of the human monocytic THP 1 cell line
THP-1 cells were grown in 75cm2 flasks with RPMI 1640 containing 10% heat 
inactivated FCS and 2mM glutamine at 37°C in a humidified atmosphere of 95% air /
68
5 %C0 2 - The cells grow in suspension and were maintained at 2-9 x 105 cells per ml. 
For experimental purposes the cells were plated out into 96 well plates (6x105 cells per 
well) as described in the subculture of cells growing in suspension.
2.6 Cartilage resorption assay
2.6.1 Culturing of bovine cartilage explants
2.6.1.1 Principle
This method was described by Dingle et al. (1975).
2.6.1.2 Method
Nasal septa were dissected from bovine noses and mucus membranes removed 
aseptically in a flow hood, followed by washing thoroughly with three changes of PBS 
to remove the blood and debris. The cartilage was then cut into strips of uniform 
thickness (2 mm) using a sterile scalpel and discs of cartilage were then punched out of 
the strips using a sterile leather punch, discarding any damaged cartilage. The explants 
in a petri dish were then washed a further three times in PBS and incubated for 24 
hours in a humidified atmosphere at 37°C in an atmosphere of 95% air / 5 %C0 2  , in 
culture medium (DMEM) with 2mM glutamine and lOOU/ml penicillin and lOOug/ml 
streptomycin. The following day the explants were plated out into 96 well plates, 1 disc 
per well for the cartilage resorption assay. The outer wells of the plate contained PBS 
only to prevent any “edge” effect.
Retinoic acid was used as the resorbing agent (Meats et al., 1985). A stock solution of 
retinoic acid was made up in DMSO to a concentration of 10 '2 M, this was further 
diluted in ethanol to give a concentration of 10'3 M. The solution was further diluted in 
DMEM to a final working solution of 1 x 10 ' 6 M. The cartilage discs were incubated 
with and without retinoic acid and test substances, 2 0 0 ul in each well, for a total of 7  
days with a change of medium containing test substances at day 3. Media from day 3 
and day 7 were stored at -20°C prior to dimethylmethylene blue assay. The cartilage 
discs were stored at -20°C prior to being digested.
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2.6.2 Digestion of cartilage explants
2.6.2.1 Reagents
1 . 0 .1 M phosphate buffer
2. 50mM EDTA:
3. 50mM cysteine/HCl
4. 25mg/ml papain
0.1M sodium phosphate buffer, pH 6.5 
465mg of ethylenediaminetetraacetic acid 
disodium salt (EDTA) in 25ml of phosphate 
buffer
197mg of cysteine/HCl in 25ml of phosphate 
buffer
625mg of papain in 25ml of phosphate buffer
2.6.2.2 Method
Each cartilage piece was put in a labelled LP4 tube followed by the addition of 0.49ml 
of phosphate buffer and 70ul of each of the other reagents to a total volume of 700ul. 
The tubes were capped and placed in a water bath at 65°C for at least two hours or until 
the pieces had digested.
2.6.3 Dimethylmethylene blue assay for sulphated glycosaminoglycans
2.6.3.1 Principle
The concentration of proteoglycan released, measured as glycosaminoglycan, 
chondroitin sulphate, was determined using the dye 1,9 dimethylmethylene blue as 
described by Famdale et al. (1982). The sample is mixed with the dye and the 
absorbance change due to the binding of the dye with glycosaminoglycans measured.
2.6.3.2 Reagents
1. Formate buffer:
2. DMB working solution
3. Stock chondroitin sulphate 
(porcine rib)
0.1M sodium formate, adjusted to pH 3.5 with 
formic acid
16mg of dimethylmethylene blue dissolved in 
5ml of ethanol and then made up to 11 with 
formate buffer
4mg/ml chondroitin sulphate in 
DMEM or digest buffer
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2.6.3.3 Method
Two standard curves were prepared, one for the samples in DMEM and the other for 
the digest samples. The stock chondroitin sulphate solution was further diluted to give a 
top standard of 40ug/ml either in DMEM or digest buffer and a range of standard 
concentrations were then made ranging from 0 - 40ug/ml. Aliquots of 40ul of each 
standard in triplicate were then added to wells in a 96 well plate followed by 40 ul of 
each sample in duplicate to the other wells. It was necessary to dilute some of the 
samples 20 fold for day 3 and day 7 and some of the digest samples had to be diluted 
10 fold. DMB working solution, 250ul, was then added to all of the wells and after 2 
minutes the absorbances were measured in a multiskan MS platereader at 570 nm. The 
results were expressed as % cumulative glycosaminoglycan release at days 3 and 7.
This was determined from proteoglycan release into the media at days 3 and 7 and 
proteoglycan remaining in the cartilage discs as determined from the cartilage digests.
2.7 Prostaglandin E radioimmunoassay.
2.7.1 Principle
The amount of prostaglandin E2 (PGE2) was measured using a modification of the 
radioimmunoassay (RIA) technique as described by Andrews (1988). The antiserum 
does not distinguish between PGEi and PGE2 , see table 2 .1 , the amount of PGE2 is 
more correctly the amount of PGE present in the samples.
Cross Reactant % Cross Reactivity
PGEi
PGE2
PGAi
PGA2
PGBi
PGB2
PGFicc
PGF2p
240
100
10
8
0.7
0.9
3.2
4.2
Table 2.1 Specificity of PGE 2 antisera
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Radioimmunoassays work on the principle that a limiting and constant amount of 
antibody is incubated with a fixed concentration of labelled antigen to produce a known 
% bound constant. In RIA, the sample to be assayed is mixed with the antibody (Ab) 
and a small amount of labelled antigen (Ag*) and the following reactions takes place:
Ag +Ab <=> Ag.Ab 
Ag* +Ab o  Ag*.Ab
The radiolabelled antigen competes with the antigen in the sample for the available 
binding sites on the antibody, so the higher the concentration of antigen in the sample 
the less radioactive antigen will be able to bind to the antibody, resulting in a greater 
radioactive content in the free antigen (unbound). The reaction is completed after a 
fixed time period that has been optimised for the individual assay. In a number of 
systems reaction mixtures are left overnight at 4°C. The concentration of the unlabelled 
antigen in the sample can thus be calculated by setting up a standard curve using known 
amounts of unlabelled antigen. In the PGE2 RIA, free PGE2 (antigen) is removed using 
adsorption techniques with dextran-coated charcoal, leaving the bound PGE2 
antigen/antibody and labelled antigen/antibody complexes in the supernatant. 
Radioactive counts obtained from the supernatant (“bound counts”) can then be used 
as a measure of unlabelled PGE concentration.
The amounts of labelled antigen and antibody are kept constant, and have been chosen 
to give optimal conditions i.e. when a maximum of about 50% of labelled antigen is 
bound to antibody.
72
3. PGE2 standard
2.7.2 Reagents
1. Stock Buffer : 0.1M Tris/HCl containing 1.4M NaCl pH 7.4
2. Working Buffer : 0.5g of gelatin (0.1%) and 0.1 g of sodium azide
(0.02%) were dissolved in 100ml of distilled water, 50ml 
of stock buffer was added and the volume made up to 
500ml with distilled water. The pH was checked and 
adjusted to pH 7.4 with 1M HC1 
lmg of PGE 2 was dissolved in 1ml of absolute 
ethanol
lOul of this solution was then diluted to 1 ml with ethanol, 
a further ten fold dilution was made to give a stock of 
lug/ml. lOOul aliquots were made and stored at -20°C for 
a maximum of 6  months.
[ 5,6,8,ll,12,14,15(n)-3H]-prostaglandin E2 (specific 
activity 181Ci/mmol, 6.70T Bq/mmol) was diluted 
1 in 1500 in working buffer to give an approximate 
count of ~ 2500cpm/100ul of tracer.
One vial of rabbit anti-PGE antiserum was made up to 
5ml in working buffer and stored in 1.25ml aliquots at 
-20°C. For use an aliquot was made up to 10ml with 
working buffer.
6 . Dextran coated charcoal: 300mg of activated charcoal and 62.5mg of dextran T70
were suspended in 50ml of working buffer and left 
stirring on ice for at least 30 minutes before use.
4. Tracer
5. Antibody:
2.7.3 Method
The PGE2 standard was diluted in DMEM to construct a standard curve in the range
0.039 -lOng/ml and the samples were diluted, if necessary in DMEM. All tubes were 
kept on ice throughout the assay and were set up according to table 2 .2 , with the 
standards being assayed in triplicate and the samples in duplicate, antibody being added 
last.
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NON
SPECIFIC
BINDING
(NSB)
TOTAL
COUNTS
(TC)
MAXIMUM
BINDING
STANDARD TESTS
Sample lOOul
Standard lOOul
Buffer lOOul 300ul
DMEM lOOul lOOul lOOul
Tracer lOOul lOOul lOOul lOOul lOOul
Antibody lOOul lOOul lOOul
Table 2.2 Protocol for the PGE2 radioimmunoassay
The tubes were incubated at 4°C for 24 hours. The following day 200ul of the ice cold 
dextran coated charcoal was added to all of the tubes except the TC. The tubes were 
vortexed and then left at 4°C for exactly 5 minutes, they were then centrifuged at 1400g 
for 15 minutes in the MSE mistral 2L at 4°C to separate the free from the bound. 
Aliquots of 200ul of the supernatant was then carefully removed and pipetted into 
labelled scintillation vials and 2ml of optiphase Hisafe scintillation fluid was then 
added to each vial. The vials were then capped and the radioactivity determined in 
each sample in a Wallac 1212 Rackbeta liquid scintillation counter.
A standard curve was constructed of % bound counts vs PGE2 concentration, see figure
2 . 2  and used to determine unknown amounts of PGE2 in samples of culture media. 
Results were expressed as ng per ml culture media.
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Figure 2.2 Typical standard curve for PGE 2 radioimmunoassay
2 . 8  Cytokine assays
The cytokine assays carried out were all commercial ELISA kits from Biosource, with 
the following range sensitivities :
Human 1L-1 j3 0 - 250 pg/ml
Human IL- 6  0 - 250 pg/ml
TNF a  0 - lOOOpg/ml
2.9 Immunohistochemistry using human cartilage sections
2.9.1 Principle
Immunohistochemistry is a technique for identifying and localising antigens in cells 
and tissue sections using specific antibodies. PAPP-A binding to cartilage was 
determined by incubation of PAPP-A with unfixed cryostat sections of human articular 
cartilage. After washing of the sections, any bound PAPP-A was detected using anti
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PAPP-A antibody and a peroxidase labelled secondary antibody. Antibody to type II 
collagen was used as a positive control in this system and rabbit immunoglobulin 
fraction as the negative control.
2.9.2 Reagents
1. PBS
2. Block
3. PBS/BSA
4. Primary antibody
5. Positive control
7. Negative control
8 . Secondary antibody
9. DAB
10. PBS/Glycerol 1:1
11. PAPP-A
2.9.3 Method
Cryostat sections from macroscopically normal femoral head cartilage were incubated 
overnight at 4°C in a moisture chamber with either PAPP-A (500ug/ml) or PBS under 
the same conditions. All of the slides were then washed three times in PBS for 3 
minutes each wash. The primary antibody, positive and negative control, were then 
added to the slides (lOOul to each) and the slides incubated at room temperature for 1 
hour in a moisture chamber. The slides were then washed in PBS as previously 
described and secondary antibody or PBS were added. The slides were incubated for a 
further hour followed by the wash step to remove any traces of the unbound antibody. 
The substrate was then incubated with the slides for about ten minutes for colour to 
develop and then rinsed in distilled water. The sections were mounted in PBS/glycerol 
and examined under the Olympus light microscope and photographs taken.
lx as supplied
1% BSAinPBS
0.1% BSA in PBS
Rabbit anti human - PAPP-A
1: 200 dilution in PBS/BSA
Rabbit anti-human type II collagen antibody
1: 200 dilution in PBS/BSA
Rabbit immunoglobulin fraction
1 :1200 dilution in PBS/BSA
Goat anti-rabbit HRP labelled
1: 3000 dilution in PBS/BSA
lmg/ml 3,3’- Diaminobenzidine tetrahydrochloride
10ml of PBS+ 10ml of glycerol
500ug/ml
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2.10 Elastase assay.
2.10.1 Principle
The assay used was a colorimetric assay and was a modification of that described by 
Sinosich et al. (1982) and Oxvig et al. (1994). Elastase enzyme cleaves the p- 
nitroanilide (pNA) substrate releasing the chromphore p- nitroaniline which can be 
monitored by the change in absorbance at 405nm.
2.10.2 Reagents
1. Assay buffer
2. Substrate
3. Enzyme
4. PAPP-A
2.10.3 Method
The assay was optimised using a range of substrate and enzyme concentrations and 
varying amounts of enzyme. To a cuvette, 1.925ml of substrate (O.l-l.OmM) was 
added followed by the addition of 25ul of the elastase enzyme. At each substrate 
concentration 50ul of PAPP-A or 50ul of buffer was added to the cuvette and the rate 
of reaction was monitored over 5 minutes at a wavelength of 405nm in a Cecil 5000 
scanning UV- visible spectrophotometer at 25°C. The effect of PAPP-A at varying 
concentrations was also determined, 0.625 - 62.5nM using fixed enzyme (12.5nM) and 
substrate concentrations (0.5mM). Aliquots of PAPP-A, 50ul, were also incubated with 
25ul of enzyme for 30 minute at room temperature prior to addition to the enzyme
50mM Tris-HCl containing 50mM NaCl pH 8.0 
lOmg of MeO-Suc-Ala-Ala-Pro- Val-pNA in 
lml of DMSO and then further diluted in assay 
buffer to give a final working concentration of 
ImM
Human leukocyte elastase, specific activity 20- 
22U/mg protein) made to a concentration 
of luM in assay buffer, to give a final 
concentration in the cuvette of 12.5nM.
PAPP-A was diluted in assay buffer to a 
concentration of 2.5uM to obtain a final 
concentration in the cuvette of 62.5nM, which 
is the normal level at term.
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assay system to determine whether any inhibitory activity was destroyed by enzymic 
degradation. A control containing 50ul of buffer and 25ul of enzyme was also tested 
under the same conditions.
2.11 Plasmin assay
2.11.1 Principle
Plasmin was assayed using a colorimetric assay with a peptide p- nitroanilide substrate, 
(pNA). Plasmin releasing the chromphore p- nitroaniline which can be monitored by 
the change in absorbance at 405nm.
2.11.2 Reagents
1. Assay buffer
2. Substrate
3. Enzyme
4. PAPP-A
50mM Tris-HCl containing 50 mM NaCl pH 8.0 
H-D -Ile-Phe-Lys-pNA dissolved in DMSO to a 
final concentration of lOOmM 
Human plasmin (specific activity 7 U/ mg of protein) 
made up to 20uM in assay buffer, to give a final 
concentration in the cuvette of 0.4uM 
PAPP-A was diluted in assay buffer to a 
concentration of 2.5uM
2.11.3 Method
The assay conditions were optimised using a range of enzyme and substrate 
concentrations. To a cuvette containing 930 ul of assay buffer and 25 ul of substrate 
(0.01-1.0 mM), 25ul of either PAPP-A or buffer was added followed by the addition of 
20ul of enzyme. The colorimetric reaction was monitored by the change in absorbance 
at 405nm in the Cecil 5000 scanning spectrophotometer at 25°C.
Aliquots of PAPP-A, 25ul, were also incubated with 20ul of enzyme for 2 hours at 
room temperature prior to addition to the enzyme assay system to determine whether 
any inhibitory activity was destroyed by enzymic degradation. A control containing 
25ul of buffer and 20ul of enzyme was also tested under the same conditions.
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2.12 Trypsin assay
2.12.1 Principle
Trypsin was assayed using a colorimetric assay with a peptide nitroanilide substrate, 
Bz-DL-Arg-PNA-HCl (DL-BAPNA).
2.12.2 Reagents
1. Assay buffer
2. Substrate
3. Enzyme
4. PAPP-A
2.12.3 Method
The assay conditions were optimised using a range of enzyme and substrate 
concentrations. To a cuvette containing 965 ul of buffer and 25ul of substrate ( 0.1-2.5 
mM) lOul of enzyme was added. The colorimetric reaction was monitored by the 
change in absorbance at 405nm in the cecil 5000 scanning spectrophotometer at 25°C. 
At each substrate concentration 25ul of PAPP-A or 25ul of buffer was added to the 
cuvette and the rate of reaction was monitored over 5 minutes. Aliquots of PAPP-A, 
25ul, were also incubated with lOul of enzyme for 2 hours at room temperature prior to 
addition to the enzyme assay system to determine whether any inhibitory activity was 
destroyed by enzymic degradation. A control tube was also set up as described for the 
previous enzyme assays.
lOOmM Tris-HCl containing 20mM CaCL pH 8.0 
DL-BAPNA dissolved in DMSO to a 
final concentration of lOOmM 
Human trypsin (specific activity 2.5 U/ mg of protein) 
made up to 45uM in assay buffer, to give a final 
concentration in the cuvette of 0.45uM 
PAPP-A was diluted in assay buffer to a 
concentration of 2.5uM
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2.13 Cathepsin B assay
2.13.1 Principle
Cathepsin B was assayed using a fluorescent assay with a peptide napthylamide 
substrate, Z-Arg-Arg-pNA.
2.13.2 Reagents
1. Assay buffer 50mM potassium phosphate buffer pH 6.0
2. Activating Buffer 20.5mg of dithiothreitol (DTT) and lOOul of Brij 35
detergent were made up in 100ml of the 50mM phosphate 
buffer pH 6.0.
3. Substrate 50mg of the substrate, Z-Arg-Arg-pNA was dissolved
in 425ul of distilled water and 425ul of assay buffer 
was then added to give a concentration of lOOmM
4. Enzyme Human cathepsin B (specific activity 588.7U/ mg of
protein) diluted to 98nM in assay buffer, to give 
a final concentration in the cuvette of 9.8nM
5. PAPP-A PAPP-A was diluted in assay buffer to a
concentration of 2.5uM
2.13.3 Method.
The assay conditions were optimised using a range of enzyme and substrate 
concentrations. The enzyme was activated for 5 minutes at 40°C by the addition of 
180ul of activating buffer to 20ul of enzyme in a 96 well plate followed by the addition 
of 5ul of the substrate (0.1-2.5mM). The reaction was monitored in the Wallac 
fluorescent plate reader at Xex355- Zem460 nm for 3 minutes. The effect of PAPP-A on 
the enzyme was determined by the addition of either 4ul of PAPP-A or 4ul of buffer to 
the wells just before the addition of the substrate.
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2.14 Calculations of Km and Ki
The value for Km was obtained from the enzfitter programme and the value for Ki was 
determined by the following equation (Dawes, 1972):
Km(I) =  Km (  1 + JTj_)
K,
Rearranging
k , = h j k ™
K m(i) - K m
Km is the Michaelis constant, defined as the substrate concentration at half maximum 
velocity of reaction and is characteristic for a given enzyme.
Km(i) is the substrate concentration at half maximum velocity of reaction in the presence 
of the inhibitor.
Ki is the dissociation constant of the enzyme inhibitor complex.
[I] is the inhibitor concentration.
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2.15 Methods for determining cytokine binding to PAPP-A
The role of PAPP-A as a cytokine binding plasma protein was investigated using a 
number of techniques. Binding of TGFp and IL-ip were chosen since it has been 
previously observed that 0C2m, which has similarities with PAPP-A, binds both these 
cytokines (Borth and Luger, 1989; O’Conner-McCourt and Wakefield, 1987).
2.15.1 Gel filtration Chromatography
2.15.1.1 Principle
The method described is a modification of the method described by O’ Conner- 
McCourt (O’Conner-McCourt and Wakefield, 1987). The cytokines used were 
radiolabelled IL -ip  (l25I IL-ip) and TGF p (l25I TFGp). The PAPP-A sample, after 
mixing with the labelled cytokine, could be separated into PAPP-A - cytokine 
complexes, free PAPP-A and free cytokine on a pre-equilibrated Sephadex G200 
column. The complexes and free cytokine could then be determined by the radioactive 
counts associated with the fractions collected.
2.15.1.2 Method
Sephadex G200 powder was preswollen overnight in column buffer (0.1M Tris/HCl 
containing 50mM NaCl, pH 7.4) at 4°C. The gel slurry was then carefully poured into a 
1 0 ml plastic pipette (glass wool at the bottom acted as the filter) and packed under 
gravity. The column was washed with 3 column volumes of column buffer and the 
column was calibrated with a 2 mg/ml dextran 2 0 0 0  solution to determine the void 
volume.
Aliquots of 200ul of PAPP-A (lOOug/ml) (1.25uM) were then applied to the column 
and 1ml fractions were collected. The protein content of each was determined using the 
BCA method, (section 2.2.3.2) to monitor the exact point of elution of PAPP-A from 
the column. Various PAPP-A concentrations (62.5ug/ml-1000ug/ml) (0.078uM -  
1.25uM) were preincubated with different concentrations of the labelled cytokines 
(0.05nM-50nM) for different times, 30 minutes to 24 hours. Aliquots of 25ul of the 
incubation mixtures were then carefully loaded onto the gel surface and allowed to 
enter the gel. Column buffer was then carefully added, dropwise, to the column
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avoiding any disruption on the surface of the gel.
Fractions of 1ml were collected in glass tubes until the PAPP-A and the labelled 
cytokine had been eluted. Elution of labelled cytokine could be monitored with a 
Geiger counter. The fractions were then counted for y radioactivity in a Wallac 1261 
multigamma gamma counter and results expressed as counts per minute.
2.15.2. PAGE analysis using autoradiography
2.15.2.1 Principle
The method employed was a modification of that described by Huang et al. (1988). 
PAPP-A and labelled cytokines 125I IL-ip and 125I TFGp were incubated and then 
subjected to native PAGE to determine if they were bound by PAPP-A. Radioactive 
PAPP-A -cytokine complexes and free labelled cytokines were determined by 
autoradiography of the gels. The relative position of the radioactive bands seen on the 
film would determine whether the labelled cytokine was free or bound to the PAPP-A.
2.15.2.2 Reagents
1. PAGE gels:
2. Tank buffer:
3. Markers :
4. Diluent buffer:
5. PAPP-A:
6. 125I IL-ip :
7. 125I TGFp :
8 . Crosslinker:
9. Glycine:
10. Fixer:
11. Developer :
12. Silanising fluid
Ready made 4 % acrylamide gels 
0.25M Tris/HCl containing 2M glycine, pH 8.3 
Prestained high Mr markers, Myosin 205,000, 
P-Galactosidase 118,000, BSA 85,000 and 
Ovalbumin 47,000.
0.1% BSA in PBS
62.5ug/ml-1000ug/ml in diluent buffer
0.5nM-50nM in diluent buffer
0.5nM-50nM in diluent buffer
5mM suberic acid bis (N -hydroxy-succinimide ester)
in DMSO
2.5M in distilled water
1:4 dilution in distilled water of concentrate
1:5 dilution in distilled water of concentrate
Silane A174 ( y methacryloxypropyl- trimethoxysilane)
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2.15.2.3 Method
125Aliquots of 25ul of PAPP-A at varying concentrations were incubated with 25ul of I 
IL-1 p at varying concentrations in small covered glass vials for 2 hours at room 
temperature. 5ul of glycerol were then added to 25ul of this sample and it was then 
loaded onto a native PAGE gel. The gel was run at 150V for approximately 3 hours or 
until the bromophenol blue, present in the markers, ran off the bottom of the gel. The 
gel was then very carefully taken off the plates and dried onto filter paper. The dried 
gel was then placed onto developing film in a cassette, the comer marked to determine 
the orientation and autoradiographed at -70°C for 48 hours. The film was then fixed and 
developed in the dark room. This procedure was repeated with different incubation 
times for PAPP-A and cytokines, from 30 minutes to 24 hours and also on extended 
autoradiography incubation time of 7 days at -70°C.
Crosslinking the samples was also carried out by incubating the incubation mixture 
with 0.20 volume of 5mM suberic acid bis (N -hydroxy-succinimide ester) for 2 
minutes at 4°C and stopping the reaction with 0.05 volume of 2.5M glycine.
PAGE analysis with autoradiography was carried out in the same way for TGFp, the 
only difference being that 125I TGFp, bound very strongly and quickly to plastic and 
glass, therefore all steps had to be carried out in silanised tubes and transfers with
|< ^Csilanised pipettes to prevent any loss of I TGFp. Silanisation was carried out by 
soaking all glassware and pipettes in distilled water, followed by 1 0 0 % ethanol, and 
then finally in silanising fluid before leaving them to dry in an oven before use.
2.15.3 PAGE analysis using gel dissection
A minor modification of the PAGE gel analysis was performed using gel dissection as 
opposed to autoradiography.
2.15.3.1 Method
The PAGE gel was run as previously described in section 2.15.2.3 and then the gel very 
carefully removed from the plates and placed onto filter paper that had been premarked 
with the lane distances. The gel was then carefully sectioned, using a scalpel blade, into 
lanes and then each lane was cut into 5mm sections. Each section was placed in a
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labelled LP4 tube along with the filter paper underneath and then counted in the Wallac 
1261 multigamma gamma counter .
2.16 The preparation of a monoclonal antibody to PAPP-A
An overall scheme for the production of monoclonal antibodies is shown in figure 2.3.
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Figure 2.3 A schematic diagram to show the stages in the production of a monoclonal 
antibody (Newell et al., 1988).
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2.16.1 Immunization of the mice
This work was carried out by the Sheffield Hybridoma centre, University of Sheffield.
2.16.1.1 Principle
The primary aim of immunization was to stimulate the production of clones of antigen- 
committed B lymphocytes, to a point of differentiation which was suitable for fusion. 
BALB/c mice were used for immunization as they are readily available and easy to 
handle.
It has been found that antigens are much more immunogenic when presented to the host 
suspended in an adjuvant. Freund’s complete adjuvant is the most commonly used and 
consists of a mixture of oil (Bayol F) and detergent (mannide monooleate) containing 
Mycobacterium tuberculosis. The timing and the number of immunizing boosts may 
make a considerable difference to the immune response, a reasonable response may be 
seen with some antigens after just one injection whereas others may require several 
injections.
2.16.1.2 Method
A sample of pure PAPP-A (50ug made up in 50 ul of sterile PBS) was mixed with an 
equal volume of complete Freunds adjuvant. The solution was mixed on a vortex 
followed by several passes through a syringe and needle until an emulsion formed 
which did not separate on standing. The mixture was then injected into five 6-10 week 
old BALB/C mice subcutaneously. After 14 days the injections (intraperitoneal) were 
repeated using the same amount of antigen but mixing it 1:1 with incomplete Freunds 
adjuvant. The mice were injected at day 35 as previously. At day 45 tail bleeds were 
taken from all the mice by excising the tip with sterile scissors and then collecting the 
blood into a capillary tube. The circulating antibody level was determined using the 
assay described in section 2.16.3. The best responder, as determined from the assay, 
was further injected with lOOug of antigen (PAPP-A) in PBS on day 56 to give a final 
boost and 3 days later the mouse was sacrificed for fusion.
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2.16.2 The fusion and hybridoma selection procedure
This work was carried out by the Sheffield Hybridoma centre, University of Sheffield.
2.16.2.1 Principle
Polyethylene glycol (PEG) is used for the fusion of spleen cells with myeloma cells to 
produce hybridomas. The PEG causes aggregation of the integral proteins in the cell 
membrane, resulting in areas of lipid bilayer stripped of protein which would merge 
with stripped membrane from adjacent cells allowing the fusion to occur. On fusion of 
plasma membranes a multinucleated cell is formed. Subsequently nuclei fuse and 
contain the chromosomes from each parent cell. The hybridoma is unstable at this stage 
and tends to lose chromosomes from either parent until stability is attained (Kuby, 
1997).
Medium containing aminopterin is used for the hybridoma growth to ensure the main 
DNA synthesis pathway is blocked, by addition of an inhibitor of the enzyme 
dihydrofolate reductase, aminopterin. Only the fused hybrid cells that have a functional 
hypoxanthine- guanine phosphoribosyl transferase (HGPRT) inherited from the parent 
spleen cells survive and grow as this is required to circumvent the aminopterin block. 
Unfused myeloma cells do not survive due to the deficiency of this enzyme as they 
cannot synthesise DNA via the salvage pathway using HGPRT and de novo synthesis is 
blocked by aminopterin (unfused spleen cells only survive a few days in culture).
2.16.2.2 Method
The myeloma SP2/0 cells were grown in RPMI containing 10% FCS and 24 hours prior 
to fusion the cells were split to between 3.0-5.0 x 105 cells/ml so they were in the 
logarithmic phase of growth required for optimal fusion efficiency.
The source of B lymphocytes used in the fusion experiments was the spleen of the 
immunised mouse which was aseptically removed. The cells were perfused out of the 
spleen by gently pricking and forcing medium through the tissue. This procedure 
usually removes between 0.5-2.0 x 108 lymphocytes per spleen. The fusion ratio of 
spleen : myeloma was 1:5. The pre-determined number of myeloma cells, were then 
centrifuged in a universal together with the spleen cells at approximately 400g for 5 
minutes at 30°C. The cell pellet was then resuspended in 10ml of RPMI (containing no 
FCS) and then centrifuged again for 7 minutes as previously.
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The cell pellet was gently warmed in the hand and 1ml of prewarmed (37°C) PEG Mr 
1500 was added with constant swirling to ensure adequate mixing. RPMI, 1ml 
(prewarmed to 37°C, no FCS), was then added over 1 minute, followed by a further 
9ml over 2 minutes. The cell suspension was then centrifuged for 15 minutes at 300g at 
30°C. The pellet was resuspended in warm RPMI / HAT media (containing 
Hypoxanthine, Aminopterin, and Thymidine). The cells were then plated at a density of 
approximately 1 . 0  x 1 0 6 total cells/ml in multiwell plates and incubated in a humidified 
atmosphere at 37°C in an atmosphere of 95% air / 5 %C0 2 . The fused hybridoma cells 
shared the properties of both cell types. They could survive and divide in culture 
indefinitely, a property of immortal myeloma cells, and they produced antibody, a 
property of differentiated B lymphocytes.
The cells were fed every 2-3 days with lOOul of complete HAT medium. There were 
only a few hybrids in each well. Within 7-10 days each hybrid was showing clonal 
growth (clumps of > 100 cells appeared and the medium began to turn yellow). The 
supernatants were tested for antibody using the screening assay described in section
2.15.3. The cells from the wells of positive supernatants were removed and cloned to 
ensure only strongly growing and antibody producing cells were present. This cloning 
procedure was repeated several times.
2.16.3 The screening procedure
The screening procedure was carried out “in house”.
2.16.3.1 Principle
The screening procedure should preferably be of the same type as that proposed for a 
diagnostic kit, i.e. it should be rapid and applicable to large numbers of samples. The 
initial screening may involve several hundred samples and may have to be repeated 
several times before all the positive clones have been selected. It is also important to 
note that a monoclonal antibody that is detected using one detection system, for 
example ELISA, may not function in another, such as western blotting. The ELISA is 
probably the most useful assay for the screening of hybridoma supernatants and was 
therefore the method chosen.
2.16.3.2 Reagents
1. PBS
2. PAPP-A
3. Blocking Solution
4. Negative Control
5. Positive Control
6 . Secondary Antibody
7. TBS
8 . Substrate
0.1MPBS pH 7.6 
lug/ml of PAPP-A in PBS 
1% Gelatin in PBS 
RPMI media
Mouse Serum (Tail bleed) diluted 1: 1000 in PBS. 
Rabbit-anti-mouse alkaline phosphatase 
conjugate diluted 1:15,000 in PBS 
0.1M Tris buffered saline (TBS) pH 7.6 
0.0742g of 4-nitrophenyl disodium phosphate in 
0.1M Tris/HCl containing 20mM magnesium chloride
2.16.3.3 Method
The assay was optimised in the first instance using different concentrations of PAPP-A 
and different concentrations of positive and negative controls, see reagents section 
2.16.3.2, to ensure the correct antigen concentration was used in the screening 
procedure. The correct antigen concentration is the lowest dilution which gives the 
highest antibody titre for the positive serum, without giving high backgrounds with the 
negative serum.
Specialist “Pro bind” 96 wells plates were coated overnight with PAPP-A diluted in 
PBS, 100 ul per well and the plate left overnight at 4°C or 3 hours at 37°C. The 
unbound PAPP-A was then removed by inverting the plate and tapping it gently on 
absorbent paper. The wells were then washed six times with 300ul of PBS. 200ul of 
blocking solution was added to each well to block any section of the plate that did not 
have PAPP-A bound to it and hence reduce non-specific binding of the following 
antibodies. The plates were left for 90 minutes at 37°C and then washed as previously 
described.
50 pi of supernatant sample was carefully pipetted into each well, or 50 pi of negative 
or positive control. The plates were then left at room temperature with shaking for 90 
minutes and then transferred to 37°C for 30 minutes to ensure optimal binding. The 
wells were washed again as previously, followed by the addition of lOOul of the
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secondary antibody. The plates were left for another 2 hours with shaking and then 
washed six times with TBS (phosphate inhibits the final stage). The final stage was the 
addition of 100 pi of the substrate. The plates were left to develop for approximately 
50 minutes and then read in a multiskan MS platereader at 405 nm.
The wells with an absorbance reading close to that of the positive control were 
identified and the cells cloned. These cells were then retested to confirm that the 
antibody was still being produced and then recloned several times to ensure single 
clone growth. The positive single clones were then grown up in cell culture to enable a 
sufficient amount of cell culture supernatant to be produced to carry out the next stage 
which was the antibody purification procedure.
2.16.4. The purification of the monoclonal antibody
2.16.4.1 Principle
After the cloning procedure the cells must be bulk cultured to obtain sufficient antibody 
containing supernatant. This supernatant can then be used to obtain a purified antibody 
sample. The hybridoma cells can be stored in 90% FCS and 10% DMSO in liquid 
nitrogen for further use. A few litres of end culture supernatant is sufficient if less than 
lOOmg of antibody is required. End culture supernatant is that obtained after the cells 
have reached maximal density.
The main task of the purification procedure was to separate the monoclonal antibody 
from the other contaminants in the culture media. Several different techniques can be 
used at this stage to purify the antibody, the one used in this procedure was affinity 
chromatography using Protein G matrix. The principle behind this technique is that the 
Fc portion of IgG binds to Protein G (cell surface protein of Group G streptococci that 
has a type III Fc receptor) over a wide pH range (Guss et al., 1986). To elute the IgG it 
is necessary to lower the pH to approximately 2.5-3.0 depending on the sample.
2.16.4.2 Method
The monoclonal culture supernatant was centrifuged at 10,000g for 10 minutes to 
remove cells and debris, the sample was then filtered through a 0.45um sterile filter.
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The Hi Trap column (containing pre packed Protein G) was then equilibrated with 
20mM sodium phosphate buffer, pH 7.0 (start buffer), and washed with at least 3 times 
the column volume using a 10ml syringe connected to the top of the column. The 
sample was then applied through the 1 0 ml syringe and all of the flow through collected 
into a beaker. The column was then washed with 5 column volumes of start buffer and 
the eluent collected and monitored at 280nm until no more protein could be detected. 
This stage was crucial as excessive washing had to be avoided as the interaction 
between the protein of interest and the ligand may be weak. The bound protein of 
interest was then eluted from the column by the addition of 3 column volumes of
0.1M glycine/ HC1 pH 2.7, as previously, the fractions from the column were 
monitored at 280nm. The 1ml fractions were collected in tubes containing lOOul of 
neutralizing buffer, (1.0M Tris/HCl pH 9.0) to bring the pH to around 7.0. The 
fractions were then analysed for protein content by the BCA method (as described in 
section 2.2.3.2) and for purity by SDS PAGE gel electrophoresis (as described in 
section 2.2.1.3). The antibody was stored at -20°C in lOOul aliquots.
2.17. Current ELISAs for PAPP-A
At present there are several ELISAs for PAPP-A, however the question as to their 
specificity required clarification and the vast majority of published data has been using 
polyclonal antibodies. The use of polyclonal antibodies may give rise to some 
polyspecific binding of other proteins. Also the sensitivity of the assay is of the utmost 
importance if PAPP-A determination is to be used for screening and/or diagnostic 
purposes in the first trimester of pregnancy. In this project several ELISAs have been 
used, both commercial and in house using our monoclonal antibody.
2.17.1 ELISA using a commercial polyclonal PAPP-A antibody (DAKO)
2.17.1.1 Principle
Dako have produced a commercial protocol for the detection of PAPP-A in samples 
using their polyclonal PAPP-A antibody and a polyclonal PAPP-A peroxidase 
conjugated antibody. This assay has many shortcomings, the main one being the use of 
the same polyclonal in both stages, differing only in that one is conjugated.
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2.17.1.2 Reagents
1. Coating buffer:
2. Washing buffer:
3. Dilution buffer:
4. Standard:
5. Primary antibody:
5. Secondary antibody:
6 . Substrate buffer:
7. Substrate:
8 . Stop solution:
0.1M sodium carbonate- bicarbonate buffer, pH 9.6 
0.01M phosphate buffer, 0.5M NaCl, 0.1% Tween 20, 
pH 7.2
as above for wash buffer 
Pregnancy serum ~ 45mg/l PAPP-A 
Rabbit anti-human PAPP-A (polyclonal)
Diluted 1:1390 in dilution buffer
Rabbit anti-human PAPP-A HRP labelled
(polyclonal) Diluted 1: 500 in dilution buffer
0.05M phosphate citrate buffer, pH 5.0
0.4mg/ml o-phenylenediamine (OPD) dihydrochloride
in substrate buffer. Immediately before use 40ul/100ml of
30% H2 O2 was added
0.5M sulphuric acid
2.17.1.3 Method
A 96 well “pro bind” plate was coated overnight at 4°C, lOOul of primary antibody 
being added to each well. The plate was then washed 4 times manually. Test samples 
and standards were then diluted to appropriate concentrations and lOOul was added per 
well. The plate was then incubated at room temperature for 2 hours, followed by the 
wash procedure as previously. Secondary antibody, lOOul, was then added to all the 
wells and the plate incubated for 1 hour at room temperature. The plate was then 
washed 6  times to remove unbound secondary antibody. The colorimetric substrate, 
OPD, was then added to all the wells, lOOul per well and the plate placed in the dark 
for 15 minutes to develop. When colour development was complete the reaction was 
stopped with the stop solution, lOOul to each well. The absorbance reading for each 
well was then determined by using the multiskan MS platereader at 492nm absorbance.
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2.17.2 Dr Christiansen’s ELISA for PAPP-A
2.17.2.1 Principle
A monoclonal antibody was very generously donated by Dr M Christiansen to enable 
an ELISA system to be optimised for the measurement of PAPP-A in the different 
stages of the purification procedure. The assay protocol was also very kindly supplied.
2.17.2.2 Reagents
1. Coating buffer :
2. Dilution buffer:
3. Wash buffer:
4. Standard:
5. Primary antibody:
6 . Secondary antibody:
6 . Conjugated antibody:
7. Substrate buffer:
8 . Substrate:
8 . Stop solution:
2.17.2.3 Method
A 96 well plate was coated overnight at 4°C with 1 OOul of polyclonal antibody and left. 
The plate was then washed once with wash buffer and lOOul of standard, serum or 
controls were added to each well. The plate was incubated at room temperature for 2 
hours with slow shaking. The plate was then washed 4 times in wash buffer and lOOul 
of monoclonal antibody was added to each well and the plate incubated for 1 hour at
0.1M sodium carbonate- bicarbonate buffer, pH .9.6 
0.01M phosphate buffer containing 0.5M NaCl, 1%
Triton X-100 and 1% bovine serum albumin (BSA), 
pH 7.2
0.01M phosphate buffered saline, pH 7.2,
0.05% Tween 20.
WHO IRP 78/610 assuming 100 IU/1 (45mg/l) of 
PAPP-A
Polyclonal anti-PAPP-A pool diluted 1:1000 in 
carbonate buffer.
Monoclonal antibody 234-3, 75ul in 12ml of dilution 
buffer.
Rabbit anti mouse HRP labelled (DAKO P260)
Diluted 1: 2000 in dilution buffer.
0.05M phosphate citrate buffer, pH 5.0 
0.4mg/ml o-phenylenediamine (OPD) dihydrochloride 
in substrate buffer. Immediately before use 40ul/100ml of 
30%. H2O2 was added 
0.5M sulphuric acid.
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room temperature with slow shaking. The plate was then washed 6  times in wash buffer 
followed by the addition of lOOul of conjugated antibody, for 1 hour at room 
temperature. The plate was washed 6  times as previously described, and then lOOul of 
OPD substrate was added and the plate left in the dark for 30 minutes to allow the 
colour to develop. The reaction was stopped after 30 minutes with 150ul of stop 
solution and the absorbance read on the multiskan MS platereader at 492nm
2.17.3 The in house monoclonal ELISA method
2.17.3.1 Principle
The monoclonal antibody produced in house as described in section 2.16 was initially 
tested in the ELISA system as described in section 2.16.2.3. The monoclonal antibody 
was simply substituted for the monoclonal antibody provided by Dr Christiansen.
2.17.3.2 Method
The in house monoclonal antibody was diluted 1:100 in carbonate buffer and 
substituted into the assay in section 2.17.2.3.
2.18 Statistical analysis
All of the experiments were repeated at least three times to ensure the results were 
reproducible and for a given experiment, means and standard errors were calculated. 
Analysis of significance was by analysis of variance (ANOVA) followed by a multiple 
range analysis test to determine least significant difference (Zar, 1998).
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2.18 Reagents and Suppliers
Acetic acid
30% Acrylamide/ bisacrylamide
4% acrylamide PAGE gels
Ammonium persulphate
Ammonium sulphate
Bichinchoninic acid solution
Na-Benzoyl-DL-arginine-p-nitroanilide (BAPNA)
Bovine nasal septa
Bovine serum albumin
Brij 35
Bromophenol Blue
Calcium chloride
Calcium lactate
Charcoal, activated
Chondroitin sulphate (porcine rib)
4- Chloronapthol 
Coomassie brilliant blue R250 
Copper sulphate
Cyanogen bromide activated Sepharose 4B
Cysteine/HCl
Cytokine kits
DEAE Trisacryl
Dextran Blue
Dextran T70
3,3’ Diaminobenzidine tetrahydrochloride 
5,5’- Diethylbarbituric acid (Barbitone)
Di- sodium hydrogen phosphate
1,9 Dimethylmethylene blue 
Dimethyl sulphoxide 
Di-potassium hydrogen phosphate 
Dithiothreitol
Dulbecco’s Modified Eagle’s Medium (DMEM)
Fischer
Biorad
Biorad
Sigma
Sigma
Sigma
Bachem
Abbatoir
Sigma
Sigma
Sigma
Merck
Fischer
Sigma
Sigma
Sigma
Sigma
Fischer
Pharmacia
Sigma
Biosource
Pharmacia
Sigma
Sigma
Dako
Fischer
Merck
Sigma
Sigma
Fischer
Sigma
Gibco Life Technologies
95
Ethanol Fischer
Ethylenediaminetetraacetic acid Sigma
Femoral head sections Gift from Dr A Frazer
Foetal calf serum Gibco Life Technologies
Gelatin Sigma
Glycerol Sigma
Glycine Sigma
Goat anti-rabbit IgG -HRP Sigma
Rabbit anti-human polyclonal ot2m Dako
Rabbit anti-human polyclonal PAPP-A Dako
Goat anti-rabbit-IgG peroxidase Sigma
Hitrap protein G Pharmacia
30% Hydrogen peroxide Sigma
Human cathepsin B Calbiochem
Human leukocyte elastase Bachem
Human plasmin Calbiochem
Human trypsin Calbiochem
Hydrochloric acid Fischer
Imidazole Sigma
1251 Interleukin 1 (IL-1) p Amersham
Interleukin 1 a National Institute for 
Biological Standards and 
control (NIBSC)
Kodak film fixer Sigma
Kodax film developer Sigma
Late term pregnancy plasma Blood Tranfusion Service
L-Glutamine Gibco Life Technologies
Litex Agarose type HSA Park Scientific
Magnesium chloride Merck
Mercaptoethanol Sigma
Methanol Fischer
y methacryloxypropyl-trimethoxysilane (Silane A174) Sigma
Methyl a-D- mannoside Sigma
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MG-63 cell line
Molecular weight markers
N ,N,N ’N ’ - T etramethylethylenediamine
Nigrosin
4-nitrophenyl disodium phosphate 
o-phenylenediamine dihydrochloride 
Optiphase Hisafe scintillation fluid 
Papain
PAPP-A monoclonal antibody 234-3
PAPP-A standard- WHO IRP 78/610
Paragon blue stain
Paragon SPE gels
Penicllin/Streptomycin
PGE Standard
Phosphate buffered saline
Potassium dihydrogen phosphate
Prestained molecular weight markers
[ 5,6,8,1 l,12,14,15(n)-3H]- Prostaglandin E2
Rabbit anti PGE antiserum
Rabbit anti-human PAPP-A antiserum
Rabbit anti-human PAPP-A -HRP
Rabbit anti-human serum
Rabbit anti-human type II collagen antibody
Rabbit anti-mouse phosphatase conjugate
Rabbit immunoglobulin fraction
Retinoic acid (all trans)
RPMI 1640 media 
Sephadex G200 
Sodium acetate 
Sodium azide 
Sodium bicarbonate 
Sodium chloride 
Sodium citrate
Sodium dihydrogen phosphate
ATCC
Merck
Sigma
Merck
Merck
Sigma
Fischer
Sigma
Gift from Dr Christiansen 
Gift from Dr Christiansen 
Beckmann 
Beckmann
Gibco life technologies 
Sigma
Gibco life technologies
Fischer
Biorad
Amersham
Sigma
Dako
Dako
Dako
Monosan
Sigma
Dako
Sigma
Gibco Life Technologies
Pharmacia
Merck
Sigma
Merck
Sigma
Fischer
Merck
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Sodium dodecyl sulphate 
Sodium formate
Suberic acid bis (N-hydroxy-succinimide ester) 
Sulphuric acid 
THP 1 cell line
Tris [hydroxymethyl] aminomethane 
Trisacryl GF 2000
1251 Transforming growth factor (TGF) p 
Trypan Blue 
Trypsin EDTA 
Tween 20 
Ultrogel Ac A 34 
Urea
Wheat germ lectin Sepharose 6MB
Sigma
Sigma
Sigma
Fischer
ECACC
Sigma
Pharmacia
Amersham
Gibco Life Technologies 
Gibco Life Technologies 
Sigma
IBF Biotechniques
Merck
Pharmacia
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2.19 Addresses of Suppliers
ATCC
Manassas
United States of America
Amicon Ltd 
Stonehouse 
Gloucester 
GL10 2BJ
Amersham International PLC 
Little Chalfont 
Bucks 
HP7 9NA
Becton Dickinson (UK) Ltd
Cowley
Oxford
0X4 3LY
Bachem
Budendorf
Switzerland
Biometra Ltd 
Whatman House 
Maidstone 
ME16 OLS
Beckmann Coulter Ltd 
High Wycombe 
Buckinghamshire 
HP 12 4JL
CB4 6 AZ 
DAKO Ltd 
High Wycombe 
Buckinghamshire 
HP13 5 RE
ECACC 
Porton Down 
Salisbury
Fahrenheit Lab Supplies 
Rotherham 
South. Yorks 
S60 1RR
Fischer Chemicals 
Loughborough 
Leicestershire 
LE11 5RG
Gibco Life Technologies
Paisley
Scotland
PA3 4EF
Gelman Sciences Ltd 
Northampton 
NN4 7EZ
IBF Biotechnics
Villeneuve-La-Garenne
France
Biorad Laboratories Ltd 
Bio-Rad House 
Hertfordshire 
HP2 7TD
Life Sciences International 
Basingstoke 
Hampshire 
RG 21 6 YH
Calbiochem- Novabiochem (UK) Ltd
Beeston
Nottingham
NG9 2JR
Cecil Instruments Ltd 
Cambridge Road 
Milton
LKB/Wallac Instruments
Turku
Finland
Merck Ltd 
Lutterworth 
Leicestershire 
LE17 4XN
99
Monosan 
PO Box 540 
Netherlands
NIBSC 
PO Box 1193 
Hertfordshire 
United Kingdom
Olympus Instruments Ltd 
Hondurous Street 
London 
EC1Y0TX
Park Scientific Ltd
Northampton
England
Pharmacia Ltd 
Milton Keynes 
Buckinghamshire 
MK5 8 PH
Sanyo/Gallenkamp PLC
Leicester
LE3 2UZ
Sarstedt Ltd 
Beuamont Leys 
Leicester 
LE4 1AW
Sigma Diagnostics
Poole
Dorset
BH12 4QH
Sorvall/Hereaus Ltd
Brentwood
Essex
CM 15 9TB
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2.20 Equipment and Suppliers
Autolude model EV peristaltic pump
Biometra mini gel twin G42 tank
Cecil 1020 UV/Visible spectrophotometer
Cecil 5000 dual beam scanning spectrophotometer
Fast protein liquid chromatography system
General Glassware and equipment
Hera cell incubator
Hera safe hood
Hereaus transphor tank
Labysystems multiskan MS platereader
LKB 2117 multiphor electrophoresis tank
MSE Mistral 21 centrifuge
1261 Multigamma counter
Olympus light microscope
Paragon Electrophoresis tank
1212 Rackbeta liquid scintillation counter
Sorvall RC 5B Plus centrifuge
Sorvall super T21 centrifuge
Sorvall TC 6  centrifuge
Wallac Victor 1420 multilabel counter
Fahrenheit lab supplies 
Biometra Ltd 
Cecil instruments Ltd 
Cecil instruments Ltd 
Pharmacia Ltd 
Farhenheit lab supplies 
Sorvall/Hereaus Ltd 
Sorvall/Hereaus Ltd 
Sorvall/ Hereaus Ltd 
Life Sciences International 
LKB/Wallac instruments 
Sanyo/Gallenkamp PLC 
LKB/Wallac instruments 
Olympus instruments Ltd 
Beckmann Coulter Ltd 
LKB/Wallac instruments 
Sorvall/Hereaus Ltd 
Sorvall/Hereaus Ltd 
Sorvall/Hereaus Ltd 
LKB/ Wallac instrumemts Ltd
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Chapter Three 
The development of the purification 
protocol for PAPP-A
102
3.1. General Introduction
The purification of PAPP-A has been performed previously by other workers using a 
variety of different protocols, see table 3.1. There are a number of controversies 
surrounding these protocols, one being the wide use of a heparin sepharose column to 
which PAPP-A can bind specifically and reversibly, Sinosich et al. (1981). The 
development of a purification protocol that will produce the purest possible form of 
PAPP-A eliminating techniques that have been reported to either contaminate, or alter 
the structure of PAPP-A is of the utmost importance.
One of the purification protocols using the heparin sepharose column was a simple 
three step procedure involving gel filtration on Ac A 34 matrix, followed by heparin 
sepharose chromatography and negative affinity chromatography (Davey et al., 1983). 
However the use of heparin sepharose in these purifications may alter the properties of 
the purified PAPP-A produced. The interaction between heparin and PAPP-A has been 
shown to produce an alteration in the electrophoretic mobility of PAPP-A in crossed 
immunoelectrophoresis studies and a significant increase (22 to 64 % P<0.02) in levels 
of PAPP-A determined by electroimmunoassays (Westergaard et al., 1983b). Heparin 
may also contaminate the PAPP-A preparation, affecting its activities (Bischof et al,
1990).
Differing functions of PAPP-A may result from the purification protocols employed. It 
was suggested by Gore and Sutcliffe (1984) that a purification scheme involving 
ammonium salts may cause irreversible conformational changes to PAPP-A as it has 
been reported that ammonium salts can cause these changes in 0 C2m preventing the 
binding and inhibition of proteinases (Barrett et al., 1979), this however has yet to be 
confirmed by other workers. They proposed a purification scheme avoiding high salt 
concentrations which may disrupt the conformation of the molecule (Gore and 
Sutcliffe, 1984).
The efficiency of the removal of aim, an inhibitor of the four main classes of 
proteinase (Starkey and Barrett, 1977), from the sample is important since aim  
contamination may have influenced the reported activities of PAPP-A. aim  shares 
many similar physical and chemical properties with PAPP-A and therefore has a
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tendency to copurify with it (Sutcliffe et al., 1980).
PAPP-A and a 2m have been shown not to be resolved by affinity 
immunoelectrophoresis with any of the 13 lectins analysed in a study by Sinosich et al. 
(1987) indicating that the carbohydrate composition of the glycoproteins are 
qualitatively similar. Most plasma proteins bind to copper chelates but the binding of 
PAPP-A and ct2m to zinc chelate distinguishes them from the bulk of plasma proteins. 
Metal chelate chromatography however, has not generally been used in purification 
procedures reported, as following chromatography on zinc chelate sepharose minor 
immunoelectrophoretic changes were detected in PAPP-A. Further changes were 
detected for PAPP-A and 0 C2m by spectrophotometric scanning. Prior to 
chromatography, two absorption maxima at 280nm and 214 nm could be detected, 
however after chromatography on the zinc chelate sepharose the 214nm peak could not 
be detected.
Following zinc chelate chromatography ot2m loses it ability to inhibit plasmin and 
chymotrypsin. However both PAPP-A and a,2m retained their inhibitory activity against 
granulocyte elastase (Sinosich et al., 1982). In conclusion, a chelate chromatography 
step would not be a good step in the purification as it may lead to changes in the 
conformational structure of PAPP-A which may then lead to alterations in its activity 
(Sinosich et al., 1983).
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5
The different protocols used to purify PAPP-A have tended to give poor yields, impure 
PAPP-A, or both. Table 3.2 summarises the yield and purity achieved by some of these 
protocols.
The most efficient protocol for the purification is the one described by Oxvig et al. 
(1994), which was a six stage process and resulted in a 60% yield of pure PAPP-A. The 
purification did however involve a nickel chelate step which may have caused 
conformational changes in the structure of PAPP-A and lead to alterations in its activity 
(Sinosich et al., 1983). The more stages in a purification, the lower the yield of PAPP- 
A as it is inevitable that there will be slight losses at every stage. Oxvig et al. (1994) 
have produced a very good yield despite the number of stages in comparison to the five 
stage process described by Bischof et al. (1979) that only produced a 2.8% yield.
Table 3.2 Summary of the purification yields by other investigators
PURIFICATION FACTOR PERCENTAGE YIELD PURITY
Lin et al., 
1974
115 *n.s. Impure
Bischof et al., 
1979
*n.s 2 . 8 Pure
Sutcliffe et al., 
1980
*n.s 16 Impure
Sinosich et al., 
1982
700 2 2 Pure
Oxvig et al., 
1994
1 0 0 60 Pure
1 This protocol included a heparin sepharose step 
*n.s. None stated
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This study describes a protocol for PAPP-A purification that has been developed, 
avoiding the use of heparin Sepharose chromatography and chelate chromatography. 
The protocol was based on purification stages used by other workers and involved 
many developmental steps. The stages used in the final protocol proved to be the most 
successful in producing the purest PAPP-A with the highest yield from late term 
pregnancy plasma. The stages that were unsuccessful will not be discussed in any great 
detail.
3.2 The purification protocol for PAPP-A
A successful purification protocol was established using a number of techniques as 
described in the methods section, 2 .1 .
3.2.1 Ammonium sulphate precipitation
This was carried out as described in section 2.1.1.2
To 130ml of late term acid citrate dextrose treated plasma in a 500ml centrifuge bottle, 
21.58g of ammonium sulphate was added (30% saturation). The mixture was rotated 
end over end at 4°C for 18 hours and then centrifuged at 6000g for 30 minutes. The 
supernatant was then removed (1 1 0 ml) and this was poured into another 500ml 
centrifuge bottle and 25.02g of the ammonium sulphate added (60% saturation). The 
mixture was again rotated for 18 hours and then centrifuged as previously. The 
supernatant was kept and the pellet resuspended in column buffer (AcA 34) to a 
volume of 90ml.
The resuspension was then dialysed overnight in 3 changes 31 of column buffer. The 
volume obtained after dialysis was about 1 0 0 ml.
3.2.2 Gel filtration chromatography
This method was carried out as described in section 2.1.2.2.
An 80ml aliquot from the ammonium sulphate precipitation step was loaded onto the 
AcA 34 column at a flow rate of 40ml/hour, the remaining 20ml from the previous 
stage was stored at -20°C. The column was left to run until approximately 650ml had 
eluted from the column, 9ml fractions were then collected and monitored at 280nm,
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see figure 3.1 until the absorbance reached baseline indicating all the proteins had been 
eluted. The column was then washed with at least three column volumes before being 
used again, ideally the column should be left running at a slow flow rate constantly to 
prevent the column getting bacterial contamination and also to ensure that any “sticky” 
proteins have been eliminated from the column and it is free of all proteins. Initially the 
first 65 fractions containing protein eluted from the column were collected and the 
absorbance read at 280nm. This was later optimised to 40 fractions to cover the range 
before and after the elution of PAPP-A.
Figure 3.1 shows a typical profile for fractions 1-48 obtained from the AcA 34 column 
when monitoring the fractions eluting from the column at 280nm
3.5
i 25O00CN
®  2ooc
£  1.0 uo<n
< 1
0 .5
0 3 6  9  12 15  18 21 2 4  2 7  30  33  36  39  4 2  4 5  48
Fraction number (9ml)
Figure 3.1 AcA 34 column profile of the first 48 fractions containing protein eluted 
from the column.
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The profile indicated that a large amount of protein eluted from the column after 
fraction 2. PAPP-A eluted in the void volume (see section 2.1.2.1) along with many 
other proteins and was present in the first large protein peak as determined by rocket 
immunoelectrophoresis. Initially 65 fractions were tested for the presence of PAPP-A 
by rocket immunoelectrophoresis, as described in section 2.2.2. Later the testing was 
restricted to the first 40 fractions. PAPP-A was usually present in fractions 6-28, the 
highest concentration of PAPP-A being present in fraction 12 indicated by the highest 
rocket. Figure 3.2 show fractions 1-13 run on rocket immunoelectrophoresis.
Quantitation of PAPP-A using the height of the rockets was initially investigated by 
assigning pooled term plasma an arbitrary unit value. This proved unreliable as other 
components present in the plasma, in particular the haptoglobin and lipoproteins 
masked the rockets and produced a streaking effect, as seen in lane 1 (Bueler and 
Bersinger, 1989).
I4
jii
Fraction no. 1 2 3 4 5  6 7 8 9 1011 12 13
Figure 3.2 One of the plates from the rocket immunoelectrophoresis. Well 1 contains 
late pregnancy plasma and wells 7-19 contained fractions 1-13.
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More recently the development of the ELISA for PAPP-A has proven a much more 
reliable and simpler method for screening fractions for PAPP-A, see section 2.17.3.2.
Figure 3.3 shows a typical trace obtained with the fractions monitored at 280nm for 
protein and in the ELISA (see section 2.17.3.2) for PAPP-A at 492nm.
PAPP-A containing Fractions
3.5
3
2.5
280nm
2
1.5
492nm
1
0.5
0
1 4 8 12 16 20 24 28 32 36 40
Fraction num ber (9ml)
Figure 3.3 Atypical profile from the AcA 34 column, absorbance at 280nm 
monitoring proteins and absorbance at 492nm monitoring the PAPP-A by ELISA.
The fractions containing PAPP-A, determined using the ELISA method, were found to 
be similar to these containing PAPP-A as measured by rocket immunoelectrophoresis, 
the only difference being that the ELISA was much more sensitive resulting in a 
broading of the profile.
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The presence of lipoproteins in fractions 2-7, indicated by the appearance of a milky 
white precipitate in these fractions resulted in only the main peak of PAPP-A being 
pooled, fractions 8-26. Fractions containing very small amounts of PAPP-A were 
discarded.
3.2.3 Ion exchange chromatography (IEC)
The method was carried out as described in section 2.1.3.2.
The pooled fractions containing PAPP-A from the gel filtration stage, approximately 
180ml, were dialysed against 31 of 25mM Tris/HCl containing 50mM NaCl pH 7.6 
with three changes at 4°C. The dialysed sample pool was then loaded onto the DEAE 
Trisacryl IEC column, at a flow rate of 1ml per minute and the absorbance at 280nm 
monitored. After 15 minutes, protein started to elute from the column and these 
fractions were collected, to be analysed later for the presence of PAPP-A. After the 
sample had been loaded onto the column it was washed with 25mM Tris/HCl 
containing 50mM NaCl pH 7.6 until no more proteins could be detected. The collection 
of the fractions was stopped and the column washed for 30 minutes. The salt 
concentration of the buffer was then increased to 0.5M and after about 30 minutes a 
protein peak was eluted and this fraction collected. The salt concentration was then 
increased to 1 M to ensure that the column was completely stripped of any proteins still 
bound to it and the protein fraction collected. Figure 3.4 shows the elution profile.
The column was then put on a wash programme overnight with alternate high and low 
salt concentrations to clean it thoroughly. The samples collected from the high salt 
concentrations, 0.5M and 1M, varied in volume each time the protocol was carried out 
but they were always concentrated in Centripreps to a total pooled final volume of 5ml 
for the 0.5M and 1M salt concentrations. Fractions were collected from all the stages of 
the run, including run through sample load, to be tested on SDS PAGE.
There was no PAPP-A present in the sample load run through, as determined by SDS 
PAGE. PAPP-A was present in large amounts in the 0.5M salt elution as a very clear 
and distinct band could be seen at Mr 200,000 on SDS PAGE, under reducing 
conditions, corresponding to the PAPP-A subunit. A small amount of PAPP-A was also 
present in the 1M salt elution. At this stage several other bands could be detected on
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SDS PAGE, under reducing conditions, one of them being a 2m. Contaminating 
proteins present at this stage varied from batch to batch, 0 C2m however was the major 
contaminant, see figure 3.6, lane 2.
3.2.4 Negative affinity chromatography
The method was earned out as described in section 2.1.4.2.
Non pregnancy proteins will bind to the column and PAPP-A will not. Other pregnancy 
proteins would not bind to the column also, but these should have been removed in the 
early stages of the purification.
The 0.5M salt elution and the 1M salt elution from the IEC stage were pooled and 
loaded onto the column at a flow rate of 0.25ml per minute to ensure maximal binding. 
The column was then washed in column buffer at the same flow rate until 5ml of buffer 
had run through, the column flow was then stopped for 18 hours and it was incubated at 
4°C to ensure that the contaminating proteins in the loaded sample had the optimal 
conditions for binding to the antibodies immobilised onto the Sepharose column. The 
column was then run again at the same flow rate and the protein peaks were collected 
in sample tubes on ice. When all the proteins had been eluted from the column, 
determined by monitoring absorbance at 280nm, see figure 3.5, and 30ml of wash 
buffer had been eluted without a trace of protein, the column was washed with alternate 
high/low pH buffers as described in section 2.1.4.2 to elute all the bound proteins.
These protein samples were initially saved in the optimisation runs and tested on SDS 
PAGE to determine which proteins were binding to the column.
The elution profile, figure 3.5 indicated that two proteins were being eluted from the 
column, these two peaks are in fact both pure PAPP-A. A possible reason why there 
were two peaks could be that there may be slight differences in the glycosylation of the 
PAPP-A samples. Both peaks showed an identical band on SDS PAGE.
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The PAPP-A containing samples collected, as previously, varied in volume but they 
were always concentrated using the Centripreps to 1ml. The pooled sample load was 
run on SDS PAGE to confirm purity. As expected a single band was seen at Mr
200,000, under reducing conditions, figure 3.6. This band was confirmed to be PAPP- 
A by western blotting as described in section 2.2.4.3, see figure 3.7.
During the optimisation stages when all the samples were tested on SDS PAGE many 
bands were detected in the regeneration stages but no band at Mr 200,000 
corresponding to PAPP-A could be seen. Due to the nature of the column, over a period 
of time it lost its binding capacity for human serum proteins as the antibodies were 
leached from it in the wash stages or were degraded. As the column binding capacity 
was reduced it was found that not all of the contaminating proteins were eliminated and 
therefore the column had to be regenerated and the sample loaded for a second time. 
Reapplying the sample to the negative affinity column was not ideal because at every 
stage a small amount of PAPP-A was lost.
Lane: 1 2 3 4 5 6 7 8 9
Figure 3.6 A 4% SDS PAGE gel run under reducing conditions. Lanes 1 and 9, high 
Mr markers, lane 2, 0.5M salt IEC, lanes 3-7 samples from various negative affinity 
runs and lane 8  pure PAPP-A from the negative affinity step, a single band at Mr 
200,000, corresponding to the PAPP-A subunit.
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Lane: 1 2 3
Figure 3.7 A western blot using the polyclonal antibody (DAKO) confirming that the 
single band was PAPP-A. Lanes 1 and 3 contained high Mr markers and lane 2 
contained a PAPP-A sample.
The initial plasma pool used for the purification procedure was obtained from up to 100 
patients and therefore slight variations in the profile of the products from this stage was 
inevitable.
3.2.5 The efficiency of the PAPP-A purification
At all the stages in the purification procedure protein content and PAPP-A levels were 
measured by the BCA method and the ELISA as described in section 2.2.3.2. and 
2.17.3.2.
The purification of PAPP-A was a four stage process that yielded a pure sample of 
PAPP-A, see table 3.3. The yield was 48% which was higher than most yields 
previously obtained, table 3.1, with the exception of that produced by Oxvig et al. 
(1993) of 60%.
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Table 3.3 PAPP-A purification stages showing PAPP-A concentration and % yield 
purification at each stage.
PURIFICATION
STAGE
VOLUME OF
SAMPLE
(ML)
PAPP-A
CONCn
(UG/ML)
FOLD
ENRICHMENT
%
% YIELD
Term Plasma 130 50 1 0 0
Ammonium
Sulphate
suspension
1 0 0  ** 62.5 1.25 96
Ion Exchange 
(50mM salt)
5 800 16 76.8
Negative
Affinity
500ul 5,000 1 0 0 48
** Only used 80ml from this stage
The values obtained in the table were calculated using the ELISA method described in 
section 2.17.3.2.
3.2.6 Determination of the N terminal sequence of PAPP-A
The amino acid sequence of PAPP-A has been determined from partial protein 
sequencing and from sequencing of cloned cDNA. It has a single N-terminal sequence, 
Glu-Ala-Arg-Gly-Ala-Thr-Glu-Glu-Pro-Ser-Pro (Kristensen et al., 1994). The PAPP-A 
obtained from the purification procedure described above was analysed by Dr Arthur 
Moir at the University of Sheffield using the Applied Biosystems 467A protein 
sequencer. N-terminal sequence shown was found to be consistent with that published 
previously, see table 3.4 (Kristensen et al., 1994), giving further confirmation that the 
protein purified was PAPP-A.
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However there was a slight problem with salt contamination in the sample causing 
difficulties in identifying the first two residues though residue two appeared to be Ala 
(Moir; personal communication).
Table 3.4 A Table of the sequence results obtained from Dr Arthur Moir.
T he U n iversity  o f  Sh effie ld
KREB.
INSTITUTE
PflR mouni KfcjtAKlK
D epartm ent of Molecular 
Biology and Biotechnology 
University of Sheffield 
PO Box 594 
Sheffield S10 2UH, U.K. 
Tel: (0114)276  8555 
Fax: (0114) 272 8697
PROTEIN SEQUENCE ANALYSIS
RUN No SAMPLE QAVUL
RESIDUE AMINO ACID PICOMOLES RESIDUE AMINO ACID PICOMOLES
_1_______ X_________________ 26
J._______ X_________________ 27_3_______[R________ Vo*_____ 28
_4_______ £ ___________  29
_5_______A_________ i-n  30
_6_______ T _________  31
J _______§_________ lo-° 32
_8_______a,_______ i ‘43 33
_9________  L ± l _ _ 3 4
1 0_______S_______ »• 35
1 1__________________________ 36
3.2.7 Unsuitable Techniques
The techniques that were not suitable in the purification procedure were the gel 
filtration using the Trisacryl GF 2000, the anti-PAPP-A affinity column, a 2m affinity 
column and wheat germ lectin column. The anti-PAPP-A and anti a 2m columns were 
very efficient at removing the respective antigens from the samples but these could not 
be eluted from the columns, even using harsh conditions such as 0.1 M glycine pH 2.9. 
The PAPP-A would become inactive if harsh elution conditions were used and
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therefore would be useless for activity experiments. The wheat germ lectin column 
bound oc2m and PAPP-A with the same affinity and therefore they coeluted in the same 
fractions. The Trisacryl GF 2000 matrix was unsuitable as the fractions collected were 
very dilute and PAPP-A could not be detected using rocket immunoelectrophoresis.
3.3 Discussion
A purification procedure for PAPP-A has been optimised using a four stage process, 
ammonium sulphate precipitation, gel filtration chromatography with Ac A 34, ion 
exchange chromatography with DEAE Trisacryl and Negative Affinity 
chromatography with anti-total human serum. The protocol produced a 48% yield and 
the purity was confirmed by SDS PAGE and western blotting.
The purified PAPP-A did not produce a second band on SDS PAGE under reducing 
conditions, as reported by Oxvig et al. (1993). They observed a very large distinct band 
at Mr 215,000 corresponding to PAPP-A and a “smear” corresponding to a species of 
approximately Mr 50-90,000. This species was not detected under non reducing 
conditions and later investigations by western blot analysis led to the species being 
identified as proMBP. The band observed by Oxvig et al. (1993) was very faint 
indicating that proMBP may be present in smaller, undetectable (on SDS PAGE), 
quantities in the sample obtained in the purification process described in this thesis or 
that proMBP is not present in the sample. Zorin et al. (1995) purified PAPP-A using a 
three step process involving L-lysine Sepharose chromatography, heparin Sepharose 
chromatography and negative immunoaffinity chromatography and produced a pure 
sample of PAPP-A with an approximate yield of 32 %. The PAPP-A, when analysed 
using SDS PAGE, produced a single band under reducing conditions with an Mr
205,000. A second band corresponding to proMBP was not detected, as in the present 
study.
There appears to be a discrepancy as to whether proMBP is associated with purified 
PAPP-A or not. Oxvig et al. (1994) suggested it was an integral part of PAPP-A, 
however it does not appear to be present in the PAPP-A purified as part of this study. 
PAPP-A may exist in different forms and different purification protocols may favour 
different species of PAPP-A. Currently there are no commercially available antibodies
119
to proMBP which could be used to confirm or refute its presence in PAPP-A.
Despite the apparent lack of proMBP in the purified PAPP-A, its shows similar 
activities to that purified by Oxvig et al. (1994) as discussed later in the thesis.
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Chapter Four 
The effect of PAPP-A on the production 
and action of cytokines and PGE2.
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4.1 General Introduction
It was of relevanceto determine whether PAPP-A had any involvement in the remission 
of RA in terms of immunomodulatory and inflammomodulatory effects. The effects of 
PAPP-A on the production and action of cytokines, e.g. IL-1, TNFa and IL- 6  and 
PGE2 , all of which are known to be involved in RA (Firestein and Zvaifler, 1992), may 
provide evidence as to whether or not PAPP-A may be involved in the remission of RA 
commonly observed in pregnant women (Hench, 1938).
Initially its effects on cytokines and PGE2 production were investigated using two 
different cell lines, a human osteoblastic cell line (MG 63) and a human monocytic cell 
line (THP 1). Osteoblasts are present in the joint and monocytic cells infiltrate the joint 
during inflammation. The binding of PAPP-A to cytokines was also investigated to 
determine whether PAPP-A could act in the same manner as ct2m by binding to the 
cytokines and inhibiting their actions.
4.2 The effect of PAPP-A on IL-la stimulated PGE2 and cytokine production by 
the MG-63 human osteosarcoma cell line
4.2.1 Introduction
The MG-63 osteoblastic cell line is known to produce PGE2 and IL- 6  when stimulated 
with IL-la (Rosenquist et al.,1996; Koka et al.,1998) and was therefore chosen as an 
example of connective tissue cells to investigate the effects of PAPP-A on these 
parameters.
4.2.2 Method
The MG-63 cells were plated out into 24 well plates at 6  xlO4 cells/well (500ul) and 
left for 3 days at 37°C in a humidified atmosphere of 95% air/5% CO2 to reach 
confluence.
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On day three the media were removed from all of the wells, the cells washed three 
times in PBS and 500ul of test substances added to quadruplicate wells as follows :
1 . Control (DMEM)
2 . IL -la lOU/ml
3. IL-la lOU/ml + PAPP-A 0.5ug/ml (0.63nM)
4. IL-la lOU/ml + PAPP-A 5ug/ml (6.25nM)
5. IL-la lOU/ml + PAPP-A 25ug/ml (31.25nM)
6 . IL-la lOU/ml + PAPP-A 50ug/ml (62.50nM)
7. PAPP-A 0.5ug/ml (0.63nM)
8 . PAPP-A 5ug/ml (6.25nM)
9. PAPP-A 25ug/ml (31.25nM)
1 0 . PAPP-A 50ug/ml (62.50nM)
The plates were then incubated for 24 hours at 37°C in a humidified atmosphere of 95% 
air/5% CO2 . The supernatants were removed and stored at -70°C until they were 
assayed for PGE2 and cytokine production as described in sections 2.7.3 and 2 . 8  
respectively.
4.2.3 Results
IL-la stimulated the production of PGE2 , as expected, from previous reports, whereas 
PAPP-A alone, at all the concentrations tested had no significant effect on the 
production of PGE2 by the MG-63 cell line. IL -la with PAPP-A had no extra 
stimulatory effects other than those seen with IL-la alone, figure 4.1. IL -la stimulated 
the production of IL- 6  as expected, but PAPP-A alone had no effect on the production 
of IL-6 . PAPP-A with IL-la produced a slight increase in IL-6 , compared to IL -la 
alone, however this did not reach significance, figure 4.2.
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Figure 4.2. The effect of PAPP-A on IL-1 stimulated IL-6 production by MG-63 cells. 
The data is expressed as the mean concentration per 4 wells +/- the standard error.
4.2.4 Discussion
It would be expected that PAPP-A would either enhance or inhibit the production of the 
PGE2 and or IL- 6  because of its similarities with (X2m which is known to modulate 
cytokine mediated events (Borth, 1989; LaMarre et al., 1991; Crookston et al., 1994).
PGE2 is a potent inflammatory agent and IL- 6  stimulates B cell proliferation and 
differentiation. Both are present in the synovial fluid in RA (Taylor et al., 1986; Castor 
et al., 1997) therefore both may have a potential involvement in the pathogenesis of 
RA. The involvement of PAPP-A, if any, in the remission of the symptoms of RA 
during pregnancy may be due to its inhibitory activities on one or more of the factors 
involved in RA. The results however suggested that PAPP-A had no effect on PGE2 
and IL- 6  production, suggesting that it is neither anti-inflammatory nor 
immunosuppressive in this context.
4.3 The effect of PAPP-A on LPS stimulated PGE2  and cytokine production by 
the THP 1 human monocytic cell line.
4.3.1 Introduction
The THP 1 monocytic cell line can be differentiated on addition of agents such as 
dimethyl sulfoxide (DMSO) and phorbol 12-myristate 13-acetate (PMA), into 
macrophage-like cells which mimic native monocyte-derived macrophages (Auwerx,
1991). It therefore provides a valuable model for studying a wide variety of aspects of 
macrophage biology, ranging from the role of the macrophage in host defence and as a 
secretory cell, to involvement in the pathogenesis of atherosclerosis (Auwerx, 1991).
On addition of lipopolysaccharide (LPS) or any other phorbol ester the cell line will 
stop proliferating and differentiate into macrophage like cells which will then form 
secretory products. The most extensively documented of these is the secretion of IL-1 
(Krakauer, 1985; Matsushima et al., 1986; Fenton et al., 1987, Kovacs et al., 1987; 
Fenton et al., 1988, Schmidt and Abdulla, 1988, Turner et al., 1988; Kostura et al., 
1989, Molina et al., 1989). Stimulated THP 1 cells have also been reported to produce 
cathepsin B (Li et al., 1997).
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Similarly 1,25 -dihydroxyvitamin D3 will promote their differentiation to mature 
macrophages, increasing surface expression of CD 14, the LPS receptor, enhancing their 
responsiveness to LPS and dramatically increasing the secretion of TNFa , eicosanoids 
and other proinflammatory mediators (Mazzucco and Warr, 1996).
It was suggested (Tobias et al., 1993) that the receptor for LPS on monocytic cells is 
likely to be a multimeric receptor consisting of CD 14 and as yet unidentified proteins. 
Studies are presently in progress with the THP 1 cells to identify additional membrane 
proteins that act together with CD 14. Previous studies have documented LPS (1- 
lOug/ml) induced synthesis of cytokines including IL-1, TNFa and IL- 8  by THP 1 cells 
(Tobias etal., 1989, 1986).
In this study the effect of PAPP-A on LPS stimulated and unstimulated THP 1 cells 
was studied by investigating its effects on the production of cytokines, IL-1 p, IL- 6  and 
TNFa and on PGE2 production.
4.3.2 Method
THP 1 cells were plated out at 0.6 x 10 6 cells/ml (900ul) into 24 well plates and lOOul 
of interferon gamma (IFNy) was added to a final concentration of lOOU/ml. IFNy was 
added to the cells, as it has been reported that culturing macrophages in the presence of 
LPS (lug/ml) and IFNy (lOOU/ml), results in an increased production of PGE2 as 
opposed to incubating them with LPS alone (Hoffmann et al., 1988). The plates were 
then incubated for 3 hours at 37°C in a humidified atmosphere of 95% air/5 % C02.
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Test substances were then prepared and lOul added to give final concentrations as 
follows:
1. Control (RPMI)
2. LPS 5ug/ml
3. LPS 5ug/ml + PAPP-A lug/ml (1.25nM)
4. LPS 5ug/ml + PAPP-A 5ug/ml (6.25nM)
5. LPS 5ug/ml + PAPP-A lOug/ml (12.5nM)
6 . LPS 5ug/ml + PAPP-A 50ug/ml (62.5nM)
7. PAPP-A lug/ml (1.25nM)
8 . PAPP-A 5ug/ml (6.25nM)
9. PAPP-A lOug/ml (12.5nM)
10. PAPP-A 50ug/ml (62.5nM)
11. Heat treated LPS 5ug/ml
12. Heat treated PAPP-A 50ug/ml (62.5nM)
Heat treated LPS and PAPP-A were tested on the cells to eliminate the possibility that 
any effects of PAPP-A observed were due to bacterial contamination. Heat treatment 
consisted of heating samples at 90°C for 30 minutes. Treatments were set up in 
quadruplicate and plates were then incubated at 37°C in a humidified atmosphere of 
95% air/5% CO2 for 24 hours. The contents of the wells were then pipetted into 
Eppendorf tubes and spun at 6000g in the Sorvall super T21 centrifuge for 15 minutes. 
Cell supernatants were removed and stored at -70°C prior to being assayed for PGE2 , 
IL-1 p, IL- 6  and TNFa as described in section 2.7.3. and 2.8 respectively.
4.3.3 Results
LPS, as expected, stimulated the production of PGE2 . PAPP-A alone significantly 
stimulated the production of PGE2 at concentrations of 5.0ug/ml -50ug/ml, but was not 
as effective as LPS (5ug/ml) alone. PAPP-A, when incubated with LPS, produced a 
greater than additive effect on the production of PGE2 , see figure 4.3.
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Figure 4.3. The effect of PAPP-A and LPS on PGE production by the THP 1 cell line. The data is expressed as the mean concentration per 6 wells +/- the standard
error. Significant differences were determined by ANOVA, * p<0.05.
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LPS, as expected stimulated the production of IL-1 p, IL- 6  and TNFa. The effect of 
PAPP-A on cytokine production was slightly different in these cells compared to the 
MG-63 cells. PAPP-A alone also stimulated the production of all of these cytokines at 
concentrations between 5 -50 ug/ml (6.25-62.5nM), having a much greater effect at 
50ug/ml (62.5nM) than LPS. PAPP-A, incubated with LPS, would perhaps be 
expected therefore to have at least an additive effect. This was not the case, IL-1 p 
production did not increase significantly when LPS and PAPP-A between l-5ug/ml 
(1.25-6.25nM) were incubated together with the cells compared with the levels 
produced with LPS alone. Only at PAPP-A concentrations, 10 -50 ug/ml (12.5-62.5nM) 
was a significant increase in IL-1 p seen compared with that with LPS alone, even then 
it did not reach the level of IL-1 p produced with PAPP-A alone, figure 4.4.
The IL- 6  production did not significantly increase when PAPP-A was incubated with 
LPS even at the highest concentration, 50ug/ml (62.5nM) figure 4.5, and levels are 
approximately half of those obtained when PAPP-A alone was added to the cells.
PAPP-A alone stimulated TNFa production at levels between 1-50 ug/ml (1.25- 
62.5nM). PAPP-A incubated with LPS showed an increase in the production of TNFa 
at 50ug/ml (62.5nM) but this increase was not as great as with PAPP-A alone at 50 
ug/ml (62.5nM), figure 4.6. TNFa production showed a similar pattern to that of IL-1 p 
which was not surprising as they have been reported to regulate each other (Ridderstad 
et al., 1991) and TNFa shares many biological activities with IL-1 (Sherry et al., 1988).
The heat inactivated LPS stimulated the production of IL-1 p to give levels of 2,795 +/- 
697 pg/ml which were similar to the non heat treated LPS (5ug/ml). The levels obtained 
for the IL- 6  and TNFa also gave similar levels to those obtained for the non heat 
treated LPS. The heat inactivated PAPP-A at 50ug/ml (62.5nM) did not stimulate the 
production of IL-1 p, levels being undetectable by the ELISA. Similar results were seen 
for the other cytokines.
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Figure 4.4: The effect of PAPP-A and LPS on IL-1 production on THP 1 cells. Data expressed as the mean conc. per 6 wells +/- the SE. Significant differences
determined by ANOVA, * p< 0.05, compared with control; +p<0.05, compared with LPS stimulated.
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Figure 4.6. The effect of PAPP-A on LPS stimulated TNF production by THP-1 cells. Data expressed as mean conc.per 6 wells +/- the SE. Significant differences
determined by ANOVA, * p, 0.05, compared with control; +p<0.05,compared with LPS stimulated.
4.3.4 Discussion
From the results obtained, PAPP-A seems to be acting as a proinflammatory agent in 
this cell type by stimulating the production of cytokines and PGE2 which are known to 
have a role in RA. LPS, as previously documented significantly increased the 
production of PGE2 (Hoffman et al., 1988) and all the cytokines tested. PAPP-A had a 
significant effect on their production also, its effect being greater, at higher 
concentrations than that of LPS alone. It has been reported that incubation of cultured 
macrophages with (X2m- trypsin and IFN y results in an increase in PGE2 production at 
24 hours (Hoffman et al., 1988). It would be expected that PAPP-A plus LPS would 
have an additive effect on the production of the PGE2 and cytokines, however this was 
not seen, PAPP-A alone being a more effective stimulator at high concentrations than 
in combination with LPS. The results suggest that PAPP-A and LPS may be competing 
for a similar receptor site(s) on the cells which could be the CD 14 receptor. It is also 
possible that PAPP-A and LPS may bind together and the PAPP-A may become 
inactive. PAPP-A may be a more effective and less specific stimulator than LPS, acting 
via one or more receptors resulting in increased stimulation, which may explain why 
cells incubated with PAPP-A alone had a much higher release of cytokines than with 
LPS alone.
The results obtained from the heat treated samples confirmed that the effects observed 
were due to PAPP-A and not some bacterial contamination. There was no stimulation 
of cytokine production when the PAPP-A was heat treated suggesting the protein had 
been inactivated whereas the heat treated LPS was not, giving similar results as for the 
non heat treated LPS samples.
4.4 General Discussion
The results obtained were not consistent with the hypothesis that PAPP-A may have an 
involvement in the remission of RA. The effect of PAPP-A on IL-1 p stimulated 
production of PGE2 and IL- 6  by the MG-63 cells indicating that it was neither 
proinflammatory nor immunosuppressive. The effect of PAPP-A on LPS stimulated 
PGE2 , IL-1, IL- 6  and TNFa by the THP 1 cells indicated that PAPP-A was 
proinflammatory. Such effects would therefore preclude it from being involved in the 
remission of RA during pregnancy
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A possible explanation as to why PAPP-A stimulated the THP 1 cell line to produce 
PGE2 and the cytokines and not the MG-63 cell line is that PAPP-A may act by a 
specific cell surface receptor(s) that is not present on the MG-63 cell line. Future work 
would be to determine which cell lines PAPP-A has an effect on and possibly 
determine the nature of the common cell surface receptor. The cells could also be 
stripped of their surface receptors using trypsin, and PAPP-A incubated with them 
under the same conditions as previously and the levels of stimulation compared.
4.5 An investigation of binding of PAPP-A to IL-ip or TGF p
4.5.1 Introduction
It has been shown earlier in section 4.2 and 4.3 that PAPP-A does not inhibit the 
production of cytokines in two cell systems investigated. The aim of this work was to 
try to establish if PAPP-A has the ability to bind to cytokines and thereby inhibit their 
actions. It may also be that PAPP-A may bind cytokines and not inhibit their actions 
but return them to the systemic circulation where they can then be eliminated.
The reason for investigating the binding of cytokines to PAPP-A was that ct2m, which 
has similarities to PAPP-A, has been shown to be an important cytokine binding 
protein (Crookston et al., 1994). Several cytokines, including IL-1 p, TGFp and TNFa, 
bind non covalently to both native and proteinase-activated a 2m with varying affinity. 
Some covalent binding may also occur with slower kinetics (Crookson et al., 1994). It 
has been proposed that a 2m serves as a cytokine binding protein modulates cytokine- 
mediated events or, in the case of protease-activated a 2in, mediates cytokine clearance 
via the lipoprotein receptor related protein ( LRP) (these complexes are targeted to cells 
expressing LRP) (LaMarre et al., 1991). Cytokine binding is distinct from proteinase 
binding as it does not involve conformational changes of a 2m (Phillip and O’Conner- 
McCourt, 1991, Crookston et al., 1993). No peptide bonds are cleaved and there is no 
disruption of the thiol esters (Crookston et al., 1993).
The major binding protein of TGF p in serum or plasma is a 2m and the complex of 
TGF p with a 2in has been shown to be a latent form of TGF p (Huang et al., 1988). 
TGFp binds to a 2in with a much higher affinity than seen with other growth factors
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and is the only growth factor that binds with equivalent affinity to native (X2m and 
activated oc2m (Danielpour et al., 1990, Crookston et al., 1994).
The ability of PAPP-A to bind cytokines, IL-1 (3 and TGFp was studied using 125I 
labelled cytokines. Any complex formation was investigated using native PAGE and 
gel filtration chromatography after prior incubation of PAPP-A with 125I-IL-lp or 1 2 5 1- 
TGFp.
4.5.2 Native PAGE gels
4.5.2.1 Method
The native PAGE methods were carried out as described in section 2.15.2.3 
PAPP-A - cytokine complex formation was studied using a modification of the method 
described by Legres et al (1994).
PAPP-A (62.5ug/ml -lOOOug/ml) (0.078uM - 1.25uM) was incubated with various 
concentrations of the labelled cytokine, (1 2 5 IL-ip or 125I TGFP) (0.5nM -50nM). 50ul 
of the labelled cytokine was incubated with 50ul of the PAPP-A at 37°C for times 
ranging from 5 minutes to 24 hours. 30ul of each sample was then loaded onto the 
Native gels under reducing and non reducing conditions and run for three hours at 150 
volts. The gels were then dried on the gel dryer for about 1 hour and autoradiographed 
at -70°C for up to 14 days. Identical native PAGE gels were also run and stained with 
Coomassie R250 stain.
The above procedures were also carried out on crosslinked samples as described in 
section 2.15.2.3 to try to stabilise any complexes that may be produced.
4.5.2.2 Results
The incubated samples when run on the native PAGE gels and subjected to 
autoradiography, should produce one radioactive visible band at the top of the gel if the 
labelled cytokine has bound to the high Mr PAPP-A. No bands on autoradiography 
would indicate that the low Mr labelled cytokine has run off the bottom of the gel into 
the running buffer and the unlabelled PAPP-A could not be detected
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autoradiographically.
The autoradiographs from the native PAGE gels showed no bands were present, even 
after 2 weeks exposure at -70°C. Only the background was enhanced. Counting an
125 125aliquot of the running buffer in the gamma counter indicated that I TGFp and IIL- 
p had run off the bottom of the gel into the running buffer.
It was initially thought that under reducing conditions any complex formation may be 
broken down by the harsh treatments and therefore it was decided to run the samples 
under non reducing conditions. The non reduced samples also showed no bands on the 
autoradiographs indicating that under non reducing conditions the labelled cytokines 
and PAPP-A were not binding.
Crosslinking the samples and then applying them to native PAGE gels resulted in no 
bands being detected, indicating that not even weak binding between the PAPP-A and 
cytokine was occurring.
The native PAGE gels stained using Coomassie stain had very distinct PAPP-A bands 
present at the very top of the gel, for samples with the PAPP-A alone and PAPP-A 
incubated with the labelled cytokine. These results indicated that the PAPP-A had not 
been broken down or undergone any change on incubation with the cytokines.
Gels were also cut up into 5mm sections and then counted. However this gave 
inconclusive results as the gels expanded slightly on removing them from the plates and 
even a slight overlap from one lane to the other gave uninterpretable results.
4.5.3 Gel filtration chromatography
The method was carried out as described in section 2.15.1.2 and is a modification of the 
method described by O’Conner-McCourt and Wakefield, (1987).
4.5.3.X Method
An initial experiment was carried out loading 50ul of tracer + 50ul of buffer onto the 
column to determine the elution profile of the tracer. Subsequently buffer was replaced
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with PAPP-A. The experiments carried out initially contained either a fixed high 
concentration of PAPP-A (lOOOug/ml) (1.25uM) and variable concentrations of the 
labelled cytokine (0.5nM -50nM) or with a fixed high concentration of cytokine 
(50nM) and variable concentrations of PAPP-A (62.5ug/ml-1000ug/ml) (0.078uM - 
1.25uM). The aim of these experiments was to try to find an optimal binding ratio. 
Workers who have looked at the binding of a 2m to cytokines have determined that a 2m 
must be present in a large molar excess for binding to occur, for example Crookston et 
al. (1994) incubated 0.5nM of 125I TGFp with 2.8uM of ct2m . The PAPP-A containing 
fractions were determined using the BCA protein estimation method (section 2.2.3.2), 
and the fractions containing labelled cytokine by counting in a Wallac 1261 multi 
gamma counter.
Crosslinking of the samples was also carried out to try to stabilise any binding that was 
taking place and prevent any complexes formed from being dissociated when subjected 
to column chromatography. Crosslinking forms covalent bonds between the weakly 
formed non covalent bonds of the two components and allows them to remain in their 
complex form even after severe treatment processes such as gel filtration and PAGE.
4.5.3.2 Results
If PAPP-A binds to either of the two labelled cytokines, i.e. IL-1 or TGFp the complex 
formed would be detected in the early stages of the elution profile, as PAPP-A has a 
high Mr. Whereas if no binding was occurring between the two, the labelled cytokine 
would be eluted much later in the profile due to its much smaller Mr. If two peaks were 
seen then this would indicate that the cytokine has bound to PAPP-A and there was also 
unbound cytokine, suggesting either low affinity binding or the cytokine has saturated 
the PAPP-A present.
4.5.3.2.1 PAPP-A - I25I IL-1 p Binding
The results obtained, indicated that no binding was occurring between the PAPP-A and 
I2 5I- IL-1 p. When PAPP-A (lOOOug/ml) (1.25um) was incubated with 125I- IL-1 p 
(0.8nm) and loaded onto the column, PAPP-A alone was eluted from the column in 
either fraction 4 or 5 as determined by the BCA protein estimation method. 125I- IL-1 p 
was eluted from the column in the later fractions as determined by gamma counting,
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see figure 4.8. A large radioactive peak was eluted from the column at fraction 12 for 
all the samples loaded irrespective whether PAPP-A was present or absent suggesting 
that there was no complex formation between the PAPP-A and 125I- IL-1 (3.
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Figure 4.8 Elution of 125I- IL-lp and 125I- IL-ip + PAPP-A on Sephadex G200 
column. Results are expressed as cpm.
Results obtained from crosslinking the PAPP-A and 125I- IL-ip showed a major 
radioactive peak corresponding to 123I- IL-lp and a smaller radioactive peak in the 
earlier fractions. This peak however, was also detected when the 125I- IL-1 p alone was 
run down the column, figure 4.9, indicating that it was not due to any complex 
formation between the PAPP-A and l25I- IL-ip but most possibly due to complex 
formation between the 125I- IL-ip molecules.
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Figure 4.9 Elution of 12:T- IL-lp and 12:T- IL-ip + PAPP-A on Sephadex G2 0 0  column 
after being subjected to crosslinking procedures. Results are expressed as cpm.
4.5.3.2.2 PAPP-A and 125ITG F P Binding
The elution profile obtained with 123I TGFP alone was somewhat different from that 
obtained with the 125I IL-1 p. There were three peaks present in the profile, figure 4.10. 
The results also indicated these three peaks were present when PAPP-A and 125I TGFp 
were incubated together, figure 4.10. There was no difference in the number of peaks 
obtained from 125I TGFp alone and PAPP-A and 125I TGFp. The results therefore 
suggest that there is no binding occurring between PAPP-A and 123I TGFp.
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Figure 4.10 Elution of 125I TGFp and 1251 TGFP + PAPP-A on Sephadex G200 
column. Results are expressed as counts per minute.
The fractions containing the “free” 12T TGFp, that eluted in the later fractions (14-19), 
were then pooled and reloaded onto the column to determine if the smaller peak 
(fractions 2-6) was present or that this anomalous peak could only been seen on initial 
loading. As previously a peak was observed in the early fractions and it was concluded 
that this peak was possibly due to small amounts of the 125I TGFp forming a complex 
with itself.
4.5.4 Discussion
The results obtained from the native gels suggested that no binding was occurring 
between PAPP-A and the cytokines, despite varying both PAPP-A and cytokine 
concentrations to try to optimise the binding.
It was initially thought that subjecting the sample to denaturing conditions would break
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up any complex formation, particularly if binding was weak, therefore non denaturing, 
native PAGE was used which would not, break any links between the PAPP-A and 
labelled cytokine. However it has been shown by Crookston et al. (1994) that TGFp - 
oc2m complexes dissociate during non denaturing PAGE electrophoresis and after 
running a gel for 3 hours 30 minutes the binding was only 32 % and a band could not 
be detected on native PAGE. This could explain why a band was not detected for 
PAPP-A. It was also suggested by Crookston et al. (1994) that radioiodination may
•  • 19 Shave affected the structure of some cytokine molecules so that it is possible that the 
I -cytokines would be incapable of binding to PAPP-A but may possibly bind in their 
native state.
The results from the gel filtration experiments indicated that there was no 125I IL-1 p 
present in the early fractions that contained the PAPP-A also suggesting that PAPP-A 
does not bind to 125I IL-1 p under these conditions. 125I IL-lp and PAPP-A could bind in 
this system but when they are subjected to the column chromatography they may 
dissociate and elute from the column separately. However even when the PAPP-A and 
125I IL-1 were crosslinked the results obtained suggested that no binding was occurring 
between the two components.
The results for the125I TGFp initially indicated, that there was an 1 2 5 1- labelled peak 
present where the PAPP-A eluted from the column, which suggested that PAPP-A did 
bind to 125I TGFp forming a complex. However the results obtained when 125I TGFp 
alone was loaded onto the column refuted this as the early peak was still present 
suggesting that the effect was not due to complex formation with PAPP-A but to the 
125I TGFP itself.
O’Conner-McCourt and Wakefield (1987) published data indicating that a 2m bound to
19SI TGFp and one of the experiments confirming this, was gel filtration 
chromatography on Sephadex G200. They noted the presence of three peaks when ot2m
1 >y cand I TGFp were incubated and loaded onto the column. There is no indication in the 
paper that a control experiment was carried out and it is therefore questionable to 
whether binding was actually occurring or if it was the 125I TGFp itself forming the 
three peaks as seen in the data presented in this study.
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Studies have also revealed that many labelled cytokines, including IL-2 and TNFa bind 
much more effectively to the methylamine converted “fast form” of cc2m than to the 
native preparation, although some binding to the native form does occur (Cunningham 
et al., 1990). Similarly PAPP-A may need “activating” in the same way as a 2m in order 
to bind cytokines.
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Chapter Five 
The effect of PAPP-A on cartilage.
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5.1 General Introduction
A cartilage explant culture system was used to determine whether PAPP-A had any 
inhibitory effects on cartilage proteoglycan breakdown. The ability of PAPP-A to bind 
to human cartilage sections was also investigated to determine whether it may form a 
protective layer.
5.2 The binding of PAPP-A to human articular cartilage
5.2.1 Introduction
The possibility of PAPP-A binding to cartilage was investigated as this may facilitate 
any protective effects of PAPP-A on cartilage breakdown, such as proteinase inhibition.
5.2.2 Method
The method was carried out as described in section 2.9.3.
Normal cartilage sections were incubated with PAPP-A (500ug/ml) and sections 
incubated with PBS under the same conditions. After washing, the slides were then 
incubated, with lOOul of the following :
The PAPP-A incubated sections
1. Primary antibody (rabbit anti-human PAPP-A antibody)
2. Primary antibody (rabbit anti-human PAPP-A antibody)
3. Positive control (rabbit anti-human collagen type II antibody)
4. Negative control (rabbit immunoglobulin fraction)
PBS incubated sections
1. Primary antibody (rabbit anti-human PAPP-A antibody)
2. Positive control (rabbit anti-human type II collagen antibody)
The slides were left at room temperature for 1 hour in a moisture chamber, they were 
then washed in PBS as previously described. All sections were then incubated with 
lOOul of goat anti-rabbit IgG, peroxidase labelled antibody, for 1 hour at room
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temperature, with the exception of slide number two which was incubated with PBS. 
All of the sections were then incubated with peroxidase substrate, DAB, and then 
washed with PBS to remove any excess unbound substrate. The sections were then 
mounted in PBS : glycerol and examined under the light microscope and the results 
recorded photographically.
5.2.3 Results
Intense staining was seen with the PAPP-A and PBS incubated sections that had been 
incubated with the type II collagen antibody, particularly round the edges of the 
section, see figure 5.1 A.
Staining was observed when PAPP-A was incubated with the sections indicative of 
PAPP-A binding to cartilage. The staining seemed to be mostly around the edges of the 
cartilage and around the chondrocyte lacunae, see figure 5.IB
No staining was seen when the PAPP-A incubated section was incubated with the 
rabbit immunoglobulin fraction, instead of primary antibody, see figure 5.1C and no 
staining was detected in the section that had been incubated with PBS and then the 
PAPP-A antibody (results not shown)
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Figure 5.1 Immunohistochemical studies of PAPP-A binding to human articular 
cartilage
A) cryostat sections of human cartilage incubated with PAPP-A. PAPP-A 
binding is indicated by brown peroxidase staining
B) staining of human articular cartilage for type II collagen (positive control), 
type II collagen is indicated by brown peroxidase staining
C) cryostat sections of human cartilage incubated with PAPP-A and treated 
with rabbit immunoglobulin instead of PAPP-A primary antibody (negative 
control)
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5.2.4 Discussion
The results indicate that PAPP-A binds to cartilage. The staining seen was not due to 
the PAPP-A antibodies binding non specifically to the cartilage, as no staining was 
detected when the PAPP-A antibody was incubated with the section without PAPP-A. 
The exact mechanism for binding is not known. The binding of PAPP-A to cartilage 
may form a “protective” barrier to prevent attack from proteinases via proteinase 
inhibition or physically preventing them attacking the cartilage, due to the large Mr of 
PAPP-A causing steric hindrance. PAPP-A is also reported to bind to heparin (Davey et 
al., 1983). Heparin is an acidic glycosaminoglycan composed of sulphated glucosamine 
and uronic acid residues (Jacques, 1979; Casu, 1985) and has the ability to interact with 
basic plasma and cell surface components (Dziarski, 1989). PAPP-A may bind to 
cartilage proteoglycan by a similar interaction as for that with heparin.
5.3 The effect of PAPP-A on retinoic acid stimulated resorption of bovine nasal 
cartilage.
5.3.1 Introduction
As an experimental model of cartilage breakdown chondrocytes in explant culture can 
be induced to degrade their surrounding proteoglycan by application of compounds 
such as retinoic acid (Ret) (Meats et al.,1985) or proinflammatory cytokines IL-1 
(Saklatvala et al., 1984) and TNFa (Saklatvala 1986). The effect of PAPP-A on 
cartilage proteoglycan breakdown in culture was investigated by incubating PAPP-A 
alone with cartilage explants and also with Ret.
5.3.2 Method
The method employed was described in section 2.6.
Nasal septa were dissected from bovine noses and the cartilage cut into uniform 2mm 
diameter discs. The explants were incubated in a humidified atmosphere at 37°C and 
95% air/5% CO2 , for 24 hours. The following day the explants were plated out into 96 
well plates, 1 disc per well.
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The control and/or test substances were made up in DMEM as below and 200ul was 
added to each well.
1. Retinoic acid 10 ’6M
2. Solvent control (DMSO + DMEM)
3. Retinoic acid 10 '6M + PAPP-A 0.5ug/ml (0.62nM)
4. Retinoic acid 10 ' 6 M + PAPP-A 5.0ug/ml (6.25nM)
5. Retinoic acid 10 ^ M + PAPP-A 50.0ug/ml (62.5nM)
6 . PAPP-A 0.5ug/ml (0.62nM)
7. PAPP-A 5.0ug/ml (6.25nM)
8 . PAPP-A 50.0ug/ml (62.5nM)
9. DMEM control
The cartilage discs were incubated for a total of 7 days with a change of medium 
containing the test substances at day 3. Media from day 3 and day 7 were stored at 
-20°C prior to dimethylmethylene blue assay as described in section 2.6.3.
5.3.3 Results
Ret (10 ’6M) stimulated the release of proteoglycans from the cartilage, as expected. 
PAPP-A at 50ug/ml (62.5nM) also stimulated cartilage proteoglycan breakdown, but 
this effect was not as great as with Ret alone. PAPP-A incubated with Ret augmented 
Ret stimulated proteoglycan release. PAPP-A alone at 5ug/ml ( 6.25nM) had no 
significant effect on the release of proteoglycan from cartilage but when incubated with 
the cartilage explants in the presence of Ret there was a significant increase seen 
compared to Ret alone, see figure 5.2, suggestive of synergy.
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Figure 5.2: The effect of PAPP-A and Ret on % GAG release by bovine cartilage. Data expressed as the mean conc. per 6 wells +/- the SE. Significant differences 
determined by ANOVA, *p< 0.05, compared to control; +p< 0.05, compared to Ret alone.
5.3.4 Discussion
The results show that, as expected, Ret stimulated the resorption of cartilage. PAPP-A, 
however, also stimulated the resorption of cartilage at high concentrations, 50ug/ml, 
and augmented Ret-stimulated resorption. These results suggest that PAPP-A does not 
prevent cartilage breakdown in rheumatoid arthritis and therefore may not be involved 
in the remission of RA during pregnancy.
A possible explanation for this stimulation of proteoglycan release could be that PAPP- 
A as a proteoglycan (Oxvig et al., 1994) could be degraded by factor (s) released from 
the cartilage discs during the incubation period, releasing proteoglycan which was then 
detected in the DMB assay, thus giving anomalous results. PAPP-A itself, when 
incubated in the assay, in the absence of discs, does not release GAGs, detectable in the 
DMB assay.
Werb et al. (1989) discovered that fragments of other molecules, e.g. fibronectin are 
capable of binding to chondrocytes in a receptor mediated manner and stimulating 
matrix degradation. Degraded matrix molecules may therefore have a profound effect 
on cytokine and proteinase synthesis and release by cells. As described in section 5.2 
PAPP-A can bind to cartilage, as may PAPP-A fragments, and therefore could act in a 
similar way to fibronectin fragments and stimulate cartilage degradation. Furthermore 
GAGs such as heparin and heparan sulphate have been shown to stimulate plasminogen 
activation providing additional evidence for such a mechanism (Brunner et al., 1998). 
PAPP-A has been shown to contain a glycosaminoglycans that may be related to 
hyaluronic acid or heparan sulphate (Oxvig et al., 1994).
Buttle et al. (1993) investigated the mechanism of cartilage proteoglycan breakdown 
studying the effects of specific inhibitors of cathepsin B and MMPs on cartilage 
proteoglycan release. Their results demonstrated that a cathepsin B inhibitor was 
capable of inhibiting proteoglycan release from explants stimulated with IL-1 a  but not 
from explants stimulated with retinoic acid. The MMP inhibitor however was able to 
inhibit both IL-1 a  and retinoic acid stimulated release. This suggested two pathways of 
cartilage proteoglycan breakdown, one cytokine mediated and the other Ret mediated 
(Buttle et al., 1993). PAPP-A may activate the cytokine mediated pathway or augment
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Chapter Six 
The effect of PAPP-A on proteinases.
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6.1 General Introduction
It has been shown that o^m is able to inhibit proteinases from all four major classes and 
its mechanism of action has been described in detail by Starkey and Barrett (1977). In 
view of the similar properties of PAPP-A and a 2m (Sinosich, 1988) it was of great 
interest to investigate whether PAPP-A shared proteinase inhibitory activities.
Past reports of proteinase inhibitory activities of PAPP-A have been very 
controversial. Sinosich et al (1982, 1990) studying the inhibitory activity of PAPP-A, 
derived from serum, on elastase, using the synthetic substrate methoxysuccinyl-L-ala- 
L-ala-pro-L-val-pNA found it to be an uncompetitive inhibitor whereas Bischof et al. 
(1990) using the same substrate found no inhibition of elastase by plasma derived 
PAPP-A. It was initially thought that the source of PAPP-A, whether from serum, 
plasma and/or the type of anticoagulant used were reasons for the differing results 
(Bischof and Meisser, 1988).
Sinosich et al.(1982) presented evidence for a trapping mechanism for PAPP-A’s 
inhibition of elastase, as seen with c^m, but later studies (Sinosich et al.,1990) 
indicated this was not the case as covalent protease entrapment by 0 C2m is mediated by 
limited proteolysis of internal thioester groups which were not present in PAPP-A. 
Furthermore Oxvig et al. (1994) suggested that PAPP-A, derived from serum, was a 
competitive inhibitor of elastase at low ionic strengths, and that the inhibition was not 
due to the “trapping mechanism”, as proposed for 0 C2m, but to the electrostatic 
interactions between the negatively charged PAPP-A and elastase, which is a basic 
protein.
Subsequently other workers have presented evidence that proteinase inhibition by 
PAPP-A is via a trapping mechanism. Zorin et al. (1995) reported the inhibition of 
trypsin and plasmin by PAPP-A, derived from plasma, using the large Mr substrate 
remazol brilliant blue hide powder. Inhibition was seen to a much lesser extent using 
smaller Mr substrates, Bz-DL-Arg-pNA-HCl (DL-BAPNA) for trypsin and D-val-leu- 
lys-pNA for plasmin. It was suggested that the mechanism of interaction was similar to 
that of oi2m and the access of the substrates to the active site of the enzymes 
“encapsulated” within the PAPP-A molecule becomes sterically hindered, causing
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inhibition that is more marked for large Mr substrate molecules. The enzymes were also 
found to be protected from inhibition by soya bean trypsin inhibitor and pancreatic 
trypsin inhibitor, due to their large size but both enzymes could be inactivated by 
PMSF. Zorin et al. (1995) also demonstrated PAPP-A trypsin complexes on native 
PAGE. In addition when the mixtures were subjected to reducing SDS PAGE, PAPP-A 
was specifically cleaved by trypsin and plasmin to produce a major fragment of Mr 
85,000 and many minor fragments in the range Mr 45,000-200,000. The major 85,000 
fragment generated was similar to that produced on cleavage of a 2m at the bait region. 
(Zorin et al., 1995).
It has been suggested that PAPP-A may undergo slight modifications due to the 
purification procedure used and the action of endogenous proteinases present during the 
purification. This could partially explain the conflicting reports of the activities of 
PAPP-A. Gore and Sutcliffe (1984) developed a purification protocol for PAPP-A 
under mild conditions, to minimise any conformational changes, as previously 
mentioned in section 1.1 and then studied the effects of the PAPP-A obtained, on 
trypsin, plasmin and complement activities. In contrast to other studies, there was no 
evidence that PAPP-A had any inhibitory activities and it was suggested that the 
proteinase-inhibitory activity of PAPP-A, observed by some workers, was due to 
contaminating a 2m (Gore and Sutcliffe, 1984). Leached heparin, from the heparin 
sepharose column during the purification has also been reported to be responsible for 
the inhibition of elastase, previously attributed to PAPP-A (Bischof et al., 1990).
The aim of this study was to determine the proteinase inhibitory activities of the pure 
PAPP-A preparation obtained using the purification procedure described in section 3.1.
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6.2 Plasmin inhibition
6.2.1 Introduction
Plasmin is a broad spectrum serine proteinase consisting of two polypeptide chains held 
together by disulphide bonds. The light chain contains the active site and has amino 
acid sequence homologies with other serine proteases such as trypsin, chymotrypsin 
and elastase (Robbins et al., 1978). Plasmin is generated from its zymogen 
plasminogen, by the catalytic action of plasminogen activators, urokinase type 
plasminogen activator (u-PA) and tissue type plasminogen activator (t-PA). Plasmin 
preferentially cleaves lysyl bonds and seems to have evolved for the function of 
breaking down fibrin clots. Not only is plasmin itself very active in degrading fibrin, 
but plasminogen has a high affinity for fibrin so when a clot forms it has a built in 
mechanism for its own dissolution. Plasmin has been shown to degrade proteoglycan 
aggregates and monomers isolated from cartilage (Mochan et al., 1984), but has little 
action on collagen although it does activate latent collagenase and stromelysin (Werb, 
1977). Plasmin has been shown to activate MMP-2 indirectly via other plasmin- 
activated MMPs (Nagase et al., 1997). A more recent report suggests that plasmin 
degrades MMP-2 (Mazzieri et al., 1997) but when bound to cells MMP-2 is protected 
from degradation by plasmin. The major plasma inhibitors of plasmin are the 0 C2  
plasmin inhibitor and 012 m (Harpel, 1977).
6.2.2 Method
Plasmin was assayed using a colorimetric substrate H-D -Ile-Phe-Lys-pNA as 
described in section 2.11.3
6.2.3 Results
The results were obtained as scanning traces and the rate of reaction was calculated in 
absorbance change per minute, see table 6.1. The rate of formation of p-nitroaniline 
was calculated using the extinction coefficient at 405nm of 10,400 mol/L/cm, see table 
6 . 1.
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Table 6.1 The effect of PAPP-A (62.5nM) on plasmin activity (0.4uM) at varying 
substrate concentrations expressed as the amount of p- nitroaniline produced in pmole/ 
minute +/- SE
Substrate 
Cone (mM)
Rate of Reaction
AA4 05 (10 "2) / minute +/- SE
Rate of
p - nitroaniline production 
pmole / minute +/- SE
- PAPP-A + PAPP-A -PAPP-A +PAPP-A
1 . 0 1 0 .0 + / - 0 9.8 +/- 0.03 961.5+/-0 942.3 +/- 5.5
0 . 8 9.8 +/- 0.02 1 0 .0 + / - 0 942.3 +/- 3.9 961.5 +/-0
0 . 6 1 0 .0 + / - 0 1 1 .0 + / - 0 961.5+/-0 1057.7+/-0
0.4 1 0 .0 +/-0 . 0 1 1 0 . 0  + / - 0 959.1 +/- 2.4 961.5+/-0
0 . 2 9.4 +/- 0.07 1 0 .0 + / - 0 906.3 +/- 12.6 961.5+/-0
0 . 1 1 0 .0 + / - 0 1 0 .0 + /-0 . 0 1 961.5+/-0 959.1 +/-2.4
0.08 8 . 8  +/- 0.07 8 . 6  +/- 0 . 0 1 843.8+/- 13.8 834.1 +/- 27.3
0.04 6.5 +/- 0.01 6.7+/- 0.13 620.2 +/- 2 . 8 639.4 +/- 25.0
0 . 0 2 2.7+/- 0.01 2 . 6  +/- 0 262.0 +/- 2.4 250.0 +/- 0
0 . 0 1 2 . 0  +/- 0 . 0 2 1.9+/-0.04 192.3+/-3.9 185.1 +/- 8.2
There was no significant difference in either the rate of reaction or amount of p- 
nitroaniline produced in the presence or absence of PAPP-A.
The results suggest therefore, that PAPP-A, at 62.5nM had no effect on the inhibition 
of plasmin at varying substrate concentrations
6.3 Trypsin inhibition
6.3.1 Introduction
Trypsin is a monomeric digestive enzyme that is produced by the pancreas. 
Trypsinogen is converted to trypsin by the action of enteropeptidase, or trypsin itself, in 
the intestine to produce the active trypsin. Trypsin is found in increasing amounts in 
plasma in certain diseases of the pancreas, particularly acute pancreatitis (Colowick and
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Kaplan, 1981) and in the context of these experiments it was used as a representative 
serine proteinase.
6.3.2 Method
Trypsin was assayed using a colorimetric substrate, DL-BAPNA, as described in 
section 2.12.3.
6.3.3 Results
The results were expressed as the rate of reaction in absorbance change per minute and 
the rate of formation of p-nitroaniline calculated as for plasmin in section 5.2.3, see 
table 6 .2 .
Table 6.2 The effect of PAPP-A (62.5nM) on trypsin activity (0.45uM) at varying 
substrate concentrations expressed as the amount of p- nitroaniline produced in pmole/ 
minute +/- SE
Substrate 
Cone (mM)
Rate of Reaction 
A A 405 (10 *2) / minute +/- SE
Rate of
p -  nitroaniline production 
pmole / minute +/- SE
- PAPP-A + PAPP-A -PAPP-A +PAPP-A
2.5 1.85+/-0.10 1.80+/-0.04 177.9+/- 18.6 173.1 +/- 8 . 8
2 . 0 1.85+/-0.09 1.95+/-0.01 177.9+/- 17.8 187.5+/-2.8
1 . 0 1.30+/-0 1.35+/-0.01 125.0 +/- 0 129.8+/-2.8
0 . 8 1.05+/-0.01 1.13+/-0.01 1 0 1 .0 +/-2 . 8 108.2+/-2.4
0 . 6 0.90 +/- 0 0 . 8 6  +/- 0 . 0 2 87.0+/-1.6 82.5 +/- 3.2
0.4 0.67 +/- 0.01 0.69 +/- 0 63.9+/-1.9 66.3+/-1.0
0.3 0.56 +/- 0 0.56 +/- 0 53.3+/- 1.6 5 4 .I +/. 1 . 4
0 . 2 0.4 +/- 0 0.39 +/- 0 38.5 +/- 0 37.5+/- 1.0
There was no significant difference in either the rate of reaction or amount of p- 
nitroaniline produced in the presence or absence of PAPP-A.
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The results suggest therefore, that PAPP-A, at 62.5nM had no effect on the inhibition 
of trypsin at varying substrate concentrations
6.4 Cathepsin B inhibition
6.4.1 Introduction
Cathepsin B is a lysosomal cysteine proteinase that has been purified from various 
mammalian tissues e.g. muscle and the liver (Okitani et al., 1988). It is a protein of 
about Mr 25,000 that has a pH optimum on synthetic substrates of 6.0, but maximal 
activity against proteins occurs at a pH as low as 3. Cathepsin B loses activity 
irreversibly above pH 7.0 and is best-assayed fluorometrically (Barrett et al., 1982). 
Cathepsin B cleaves the hyaluronic acid-binding region from cartilage-proteoglycan 
and degrades the glycosaminoglycan-attachment region to small fragments (Morrison 
et al., 1973). Cathepsin B can also cleave the N terminal peptides of collagen that 
contain the crosslinks within and between molecules (Kirschke et al., 1982).
There is evidence that cathepsin B may play an important role in the proteolytic 
cascade involved in cartilage breakdown by activation of prometalloproteinases and pro 
urokinase plasminogen activator (uPA), leading to the breakdown of extracellular 
matrix components aggrecan and type II collagen (Mort and Buttle, 1997). It has also 
been shown that the breakdown of cartilage in tissue culture systems can be inhibited 
by cathepsin B inhibitors, the lipophilic inhibitors being more effective than the 
hydrophilic inhibitors which suggests that cathepsin B is more important in the 
breakdown of cartilage components intracellulary than extracellularly. It has been 
concluded from this work that cathepsin B may act as an intracellular activator of other 
proteinases that can then degrade the extracellular matrix components (Buttle, 1994).
6.4.2 Method
Cathepsin B was assayed using a fluorogenic substrate, Z-Arg-Arg-fNA, as described 
in section 2.13.3.
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6.4.3 Results
The results were expressed as the change in fluorescence per second, see table 6.3 .
Table 6.3 The effect of PAPP-A (62.5nM) on Cathepsin B activity (9.8nM) using 
various substrate concentrations
Substrate Cone (mM) Rate of Reaction 
AF 3 55-4 6O / second +/- SE
- PAPP-A + PAPP-A
2.5 184.2+/-5.1 179.5+/-1.2
2 159.0+/-5.8 169.0+/-5.3
1.5 170.7+/-4.0 168.0+/- 6.5
1 175.1 +/-1.4 147.8+/-4.1
0.8 140.4 +/- 2.0 146.4+/- 1.4
0.6 103.0+/-1.2 120.3+/- 1.0
0.3 91 +/-1.3 80.2 +/- 0.85
0.15 51.1+/-0.35 46.0 +/- 0.25
There was no significant difference in the rate of reactions in the presence or absence of 
PAPP-A (62.5nM) indicating that PAPP-A has no inhibitory effect on Cathepsin B in 
the assay system.
6.5 Elastase inhibition
6.5.1 Introduction
Elastase is a neutral serine proteinase stored within the primary granules of 
polymorphonuclear granulocytes. It is released in large quantities at inflammatory sites 
and is able to cause tissue damage. The active site of human leukocyte elastase is a 
channel on the protein surface that has extended substrate binding sites and it is in this
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channel that the catalytic triad of Ser195, His 57 and Asp102 catalyse amide bond 
hydrolysis of various proteins including elastin, collagen types III and IV and 
fibronectin (Janoff, 1985). Elastase also acts on cartilage proteoglycan to remove the 
hyaluronic acid-binding region and then to fragment the glycosaminoglycan attachment 
region (Roughley,1977). Circulating elastase is normally found associated with 
endogenous inhibitors, the major one being ai proteinase inhibitor, the remainder being 
bound to 0 C2m (Ohlsson et al., 1974). These circulating inhibitors occur in excess even 
in chronic inflammation and therefore free elastase activity has been found only in the 
synovial fluid of patients with extremely high granulocyte counts (Kleesiek et al., 
1986). Elastase mediated tissue damage in rheumatoid arthritis may result from 
interference with elastase-ai proteinase inhibitor (PI) complex formation at the 
cartilage surface (Burkhardt et al., 1987, Schalkwijk et al., 1987).
6.5.2 Method
Elastase was assayed using a colorimetric substrate, MeO-Suc-Ala-Ala-Pro- Val-pNA, 
as described in section 2.10. Elastase activity was measured with differing PAPP-A 
concentrations at 62.5uM, 6.25uM and 0.625uM, and differing substrate concentrations 
(0.05-1.0 mM).
6.5.3 Results
The results were determined as the rate of reaction in absorbance change per minute 
and the rate of formation of p-nitroaniline, calculated as for plasmin in section 6 .2 .3 , 
see table 6.4.
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Table 6.4. The effect of PAPP-A (62.5nM) expressed as the amount of p- nitroaniline 
produced in pmole/minute +/- SE on elastase activity (12.5nM) using different 
substrate concentrations (0.05 -l.OmM). Significant inhibition as determined by the t- 
test, *p< 0.05, ** p< 0.01, *** pO.001.
Substrate 
Cone (mM)
Rate of Reaction
A A 405 (10 '2) / minute +/- SE
Rate of
p - nitroaniline production 
pmole / minute +/- SE
- PAPP-A + PAPP-A -PAPP-A +PAPP-A
1 . 0 2.25 +/- 0.05 0.83 +/- 0.01 432.6 +/- 14.2 159.6+/-2.9**
0.5 1.76+/-0.05 0.43 +/- 0.01 338.4+/- 15.4 83.4+/- 2.4**
0.25 1.57+/-0.01 0.31+/-0.01 303.2 +/- 2.4 59.6+/-1.6***
0 . 1 1.14+/-0.02 0 . 1 0  + / - 0 218.6+/-5.3 19.8+/-0.6***
0.05 0.83 +/- 0.01 0.08 +/- 0 160.2+/-2.9 16.6+/-0.6 ***
PAPP-A at 62.5nM significantly inhibited elastase activity at all the substrate 
concentrations investigated. It was seen that the substrate concentration did affect the % 
inhibition of the PAPP-A, see table 6.5.
Table 6.5. The effect of varying substrate concentrations (0.05 -1.0 mM) on the 
inhibition of PAPP-A (62.5nM) at a fixed enzyme concentration (12.5nM)
Substrate Cone (mM) % Inhibition
1 . 0 63.1
0.5 75.4
0.25 80.3
0 . 1 90.9
0.05 90.0
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The results suggest that PAPP-A has greater inhibitory action on the elastase when the 
substrate concentration is very low, which is characteristic of competitive inhibition.
The results obtained from the varying substrate concentrations were also graphically 
expressed on a Lineweaver Burke plot, see figure 6 .1 . The results again suggest 
competitive inhibiton since a competitive inhibitor is able to compete with the substrate 
for the available active site of the enzyme and therefore increases the apparent Km 
value and the velocity of the reaction is decreased, as seen here.
Figure 6.1 The activity of elastase (12.5nM) in the presence and absence of fixed 
PAPP-A concentration (62.5nM) at varying substrate concentrations (0.05 -1.0 mM)
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PAPP-A incubated at different concentrations (0.625 -62.5nM) with elastase (12.5nM) 
and fixed substrate concentration (0.5mM) resulted in different rates of production of p 
nitroaniline dependent on the concentration of PAPP-A, the higher the concentration of 
PAPP-A the greater the inhibition, see table 6 .6 .
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Table 6 .6 . The effect of differing concentrations of PAPP-A ( 0.625 -62.5nM) on the % 
inhibition of elastase (12.5nM) at a fixed substrate concentration ( 0.5mM)
Concentration 
of PAPP-A 
(nM)
Rate of Reaction 
AA405 ( 1 0  2) / 
minute +/- SE
Rate of p - nitroaniline 
production 
pmole / minute +/- SE
% Inhibition
0 . 0 1.76+/-0.05 338.4+/- 10.2 0
0.625 1.89+/-0.02 363.4 +/- 8.0 0
6.25 1.33+/-0.04 255.8 +/- 12.2 24.4
62.5 0.43 +/- 0.01 82.6+/-3.3 75.6
The Ki was calculated as described in section 2.14 and found to be 6.25 x 10 '9 M 
which compares favourably with the Ki determined by Oxvig et al (1994) of 
5-10 x 10 ~9 M. Overall, the results suggest that the inhibition of elastase by PAPP-A is 
competitive, as the degree of inhibition is dependent on the relative concentrations of 
the substrate and inhibitor and by suitably increasing the substrate concentration the 
inhibition can be reduced. Whereas non competitive inhibition depends only on the 
inhibitor concentration and is unaffected by the variation in substrate concentration
6.5.4 Discussion
The results indicate that PAPP-A only seems to have an inhibitory effect on elastase 
and not on the other proteinases studied. The results obtained from this study agree 
with those of Oxvig et al. (1994) that PAPP-A is a competitive inhibitor of elastase. 
Oxvig stated that a four fold molar excess of PAPP-A greatly reduced the activity of 
elastase. The results obtained in this study indicate that with an approximate five fold 
molar excess of PAPP-A to elastase, 13nM of elastase and 62.5nM of PAPP-A, PAPP- 
A has a profound effect on the activity of elastase producing 75.6 % inhibition (table 
6 .6 ). A smaller inhibition can also be detected when the molar ratio of PAPP-A to 
elastase is much smaller.
This study used only small peptide substrates and if PAPP-A were acting via a 
trapping mechanism (Zorin et al., 1995) it may not be expected to inhibit the
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activity was observed with small substrates by Zorin et al, (1995) which was not seen 
in this study.
The effect of PAPP-A on elastase even with a small peptide substrate may indicate that 
the mechanism for inhibition by PAPP-A is not by trapping, as the smaller substrates 
should still be able to gain access to the proteinase and therefore little, if any inhibition 
should be detected. There are however other explanations that may explain the 
inhibitory effects of PAPP- A on elastase. PAPP-A is known to contain approximately 
19% carbohydrate including GAGs. Travis et al. (1983) reported that GAGs prevent the 
release and action of HLE. Chondroitin sulphate (CS) and dermatan sulphate (Ds) were 
chemically oversulphated to give many preparations with varying degrees of sulphation 
to enable their inhibitory effect on HLE to be investigated. HLE is a basic protein 
containing a number of arginine residues. The results showed that increased sulphation 
and oversulphation generally increased the inhibitory effects of GAGs on elastase. The 
interactions between GAGs and proteins are both specific and non specific and are 
thought to occur mainly between cationic residues of the side chains of the proteins and 
anionic residues of the GAGs. The binding ability of GAGs of similar Mr was ; heparin 
> Ds > CS and this is due to the higher charge density in heparin. PAPP-A, with its 
high GAG content, could therefore inhibit elastase in the same manner.
Oxvig et al. (1994) also reported that the inhibition of HLE was likely to be due to the 
electrostatic interactions between the negatively charged GAG on the pro MBP and a 
set of Arg- residues located close to the active site of elastase.
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Chapter Seven 
The production of a monoclonal antibody
for PAPP-A
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7.1 Quantitation of PAPP-A
A variety of techniques have been used to measure PAPP-A. Measurement was initially 
carried out using immunodiffusion and immunoelectrophoretic techniques because only 
an antiserum was required, however these techniques were very insensitive (detection 
limit 10mg/l) and PAPP-A could only be measured in the later stages of pregnancy.
The first ELISA to be established for PAPP-A was a sandwich assay using polyclonal 
antibodies. The sensitivity was very poor and levels of PAPP-A could only be detected 
in second and third trimester samples (Macdonald et al., 1984). An ELISA was then 
developed to detect levels of PAPP-A in the first trimester using plates coated with the 
commercial polyclonal antibody (DAKO) that had been adsorbed, by negative affinity 
chromatography, with an immobilised < 300kDa fraction of pregnancy serum obtained 
by pressure ultrafiltration. The secondary antibody used was the polyclonal rabbit anti- 
PAPP-A peroxidase conjugate. The sensitivity of the assay was good, detecting PAPP- 
A levels as low as 0.04mIU/ml (40mIU/l) (0.02 ug/ml) and could detect PAPP-A in 
normal pregnancy as early as 5-7 weeks (Bersinger et al., 1995).
More recently four double-monoclonal time-resolved immunofluorometric assays 
(TrIFMAs) were developed for PAPP-A/proMBP complex determination and a 
TrIFMA was also described using the commercially available polyclonal antibody 
(DAKO) (Qin et al., 1997). The polyclonal TrIFMA had a working range of 4- 
1000mIU/l (2-500 ug/1). The monoclonal TrIFMAs have a similar or better sensitivity 
compared to the polyclonal TrIFMA. In this assay some of the monoclonal assay 
combinations used have given much higher concentrations of PAPP-A than in the 
polyclonal assay. This may be attributable to variations in the detection of isoforms of 
PAPP-A/proMBP or that other complexes containing either or both of the two proteins 
PAPP-A and proMBP may exist in different stages of pregnancy.
Unfortunately polyclonal antibodies tend not to be absolutely specific for PAPP-A.
The polyclonal anti-PAPP-A antibodies raised to date often recognise anti-PAPP- 
A/proMBP, because PAPP-A isolated from serum and used in antibody production is in 
the form of PAPP-A/proMBP complex. The commercially available polyclonal 
antiserum (DAKO) has also been shown to react with haptoglobin (Bueler et al., 1989)
167
and SP 1 (Bersinger et al., 1995). Therefore the levels of PAPP-A determined using 
these antibodies may be severely biased by cross reactivity.
More recently it has been reported that a monoclonal antibody to PAPP-A has been 
successfully produced (Qin et al., 1997). Under both native and denaturing and 
reducing conditions, western blots have demonstrated that this antibody reacts with the 
PAPP-A part of the PAPP-A/proMBP complex and not the proMBP part (Qin et al., 
1996). It is of the utmost importance that the monoclonal antibodies produced do not 
recognise the proMBP part of the PAPP-A molecule as at least two other proMBP 
complexes are present in term pregnant serum, complexes with angiotensinogen and 
complexes with complement 3dg. (Oxvig et al., 1995). Nothing is currently known 
about the function of these complexes or their serum concentrations in DS pregnancies.
Bersinger et al. (1999) have produced four monoclonal antibodies that specifically 
recognize the pure PAPP-A and not the pro MBP with the purpose of using them in an 
automated DS screening test for testing large numbers of serum specimens. The 
monoclonal antibodies were tested in an ELISA system and had a reported detection 
range of 0.06-2.04 mlU/ml. It was reported that in the future, large scale prospective 
clinical DS screening will be required, with such a project being either present or being 
launched in many countries. It is believed that the use of highly specific antibodies will 
significantly contribute to the elucidation of the biological role of PAPP-A and its 
clinical usefulness in large screening programmes for the detection of abnormal human 
pregnancies (Bersinger et al., 1999).
The importance of producing a monoclonal antibody to PAPP-A has been described 
and for the reasons stated an in house monoclonal antibody was produced. The 
monoclonal antibody was thought to be a valuable asset for the determination of PAPP- 
A levels in the research undertaken in this work and could also be used in an ELISA 
system to detect abnormal levels of PAPP-A in first trimester pregnancy blood samples.
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7.2 The Preparation of a monoclonal antibody for PAPP-A
7.2.1 Introduction
Most monoclonal antibodies are made in mouse cells and are suitable for diagnostic 
and many other purposes. In this study mice were used for monoclonal antibody 
production.
Monoclonal antibodies are produced by a single clone of B cells and thus consist of a 
single population of identical antibody molecules that are highly specific for a single 
epitope of an antigen. This is in contrast to polyclonal antibodies which are directed 
against several epitopes of an antigen and produced by several B cell clones. They thus 
have more potential for cross reactivity and therefore less specificity. Monoclonal 
antibodies have three very useful characteristics, their specificity of binding, their 
homogeneity and their ability to be produced in unlimited quantities.
The immortalisation of monoclonal antibody producing hybridoma cells was first 
described by Kohler and Millstein in 1975. They used a technique that took advantage 
of immortal malignant plasma cells (myeloma cells) which can be maintained in culture 
indefinitely and selected out those unable to secrete immunoglobulin and also deficient 
in the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT). Myeloma 
cells and spleen cells were fused using PEG and hybrid cells selected using HAT 
medium. The only cells that survive are hybrids with the myeloma’s ability to continue 
to divide and the B cells ability to produce antibody and provide HGPRT to ensure 
survival.
The hybridoma cells producing the specific antibody can be screened by a variety of 
different methods and the positive ones cloned and then grown up in tissue culture. The 
monoclonal antibody is secreted into the cell culture supernatant and is relatively dilute 
(0.01-0.5 mg/ml culture fluid), this supernatant can then be purified to obtain a pure 
monoclonal antibody.
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7.2.2. Primary stages in the preparation of the monoclonal antibody
7.2.2.1 Immunization of the mice
The method was as described in section 2.16.1
12.22  Fusion of the cells
The method employed was as described in section 2.16.2
122.3 Results
During the cloning procedure hundreds of supernatants had to be tested to identify any 
wells that contained cells secreting the antibody for PAPP-A. The screening procedure 
employed was described in section 2.16.3. The supernatants must be screened on the 
same day to enable the positive clones, i.e. those clones secreting the most antibody to 
be further subcultured. Clones producing an absorbance value of 0.8 or above in the 
screening assay were kept, the others rejected. RPMI alone gave an absorbance of 
approximately 0.2 in the screening assay (negative control). The mice tail bleed was 
used as a positive control and this gave an absorbance reading of between 1.4 and 1.9. 
The positive clones were recloned and tested several times to ensure they were still 
secreting the antibody. Many of the clones throughout the recloning lost their ability to 
secrete the antibody and were unstable.
The screening procedure picked up 10 positive clones, see table 7.1, after subcloning 
and these were further subcloned. The results, indicate that only five of those subclones 
continued to secrete the antibody, table 7.1. The antibody secreting subclones had all 
originated from the DF11 clone and the non antibody secreting subclones had all 
originated from the FC11 clone indicating that these clones had lost their ability to 
secrete the antibody over time.
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Table 7.1 Results obtained from the screening procedure
Subclones Absorbance 405nm Source o f Clone
Negative Control 0.067
Positive Control 1.798
1 1.713 DF11/E1/C5
2 1.615 DF11/E1/D3
3 1.232 DF11
4 1.586 DF11/D1/B6
5 1.550 DF11/D1/D5
6 0.074 FC11/D2/C5
7 0.141 FC11/A5/D5
8 0.151 FC11/A5/A5
9 0.098 FC11/D2/D2
1 0 0.091 FC11
Two positive single clones were chosen, numbers 1 and 2 and these were then grown 
up in cell culture to enable a sufficient amount of cell culture supernatant to be 
produced containing the antibody to carry out the next stage, which was the 
purification procedure.
7.2.3 Purification of the monoclonal antibody
7.2.3.1 Method
The method employed was described in section 2.16.4
6.3.3.2 Results
Two single clones were grown up to confluency in large scale culture and the 
supernatants (800ml) taken from each to be purified. The clones were identified as 
DF11/E1/C5 and DF11/E1/D3.
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The majority of the protein was eliminated in the wash through procedure on the Hitrap 
column and the antibody was then eluted using the elution buffer. The total volume of 
antibody obtained was approximately 5 ml from each clone and were at concentrations 
of 1 mg/ml and 1.4mg/ml for DF11/E1/C5 and DF11/El/ D3 respectively.
A Beckmann Electrophoresis gel was performed to determine the purity of the 
antibody, figure 7.1. The results indicated that the monoclonal antibody produced one 
band which was present in the immunoglobulin migration region of the gel.
. BECKMAN Paragon® SPE Gel ®
1 2 3 4 5 6 7 8  10 *
Figure 7.1 An SPE gel, lane 1 is monoclonal DF11/E1/C5, lane 2 is monoclonal 
DF11/E1/D3, lane 4 is serum albumin and lanes 6 , 7 and 10 are identical repeat of the 
lanes 1, 2 and 4 respectively.
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7.3 Comparison of ELISAs for PAPP-A.
Currently available ELISAs were compared with the ELISA developed ‘in house’ using 
the ‘in house’ monoclonal.
7.3.1 Commercial polyclonal assay (DAKO)
7.3.1.1 Method
As described in section 2.16.1.3
7.3.1.2 Results
The results obtained from the commercial assay suggested that it was detecting PAPP- 
A in the samples. A typical calibration curve was provided with the protocol and this 
was poor as the background absorbance reading was quite high, 0.26, and the highest 
absorbance reading obtained for the standards was 0.7 at a concentration of PAPP-A of 
1.5mg/l. The detection range for the assay was between 0.2 -2  mg/1 (0.2-2.0ug/ml). 
PAPP-A levels in serum samples at weeks 11/12 are approximately 1.5ug/ml 
(3mIU/ml) and in fetal disorders, 0.75ug/ml (1.5mIU/ml) (Bersinger et al., 1999), 
which would probably be within the detection range of the assay. However levels may 
be lower earlier in pregnancy as Bersinger also reported values as low as 0.025ug/ml 
(0.05mIU/ml) in samples obtained at week 7, and therefore these levels would not be 
easily detected. There is an absorbance difference between 300 and 1500 ug/1 of only 
0.3 (0.4-0.7) therefore a significant and possibly critical difference in PAPP-A levels 
even in the early detectable region would not result in a significantly different 
absorbance reading and therefore may go undetected. The standard curve obtained 
using late term pregnancy plasma and assuming a concentration of 50mg/l gave a 
slightly better calibration curve, than the one provided with the protocol, see figure 7 .2 .
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Figure 7.2 A typical standard curve obtained from the ELISA in the range 0 - 2500ug/l
0 . 9
0.8
0 . 7
E
<N 0.6o>
( § )  0 . 5
0)o
n  0 . 4  jak.o52 0 . 3■Q<
0.2
0.1
1000 1 5 0 0 2000 2 5 0 05 0 00
PAPP-A C o n cen tra tio n  ug/l
The results obtained suggest that this assay could not be used to determine PAPP-A 
levels in the early stages of pregnancy as it is not sensitive enough. The detection limits 
are approximately 200-2000 ug/l, assuming a PAPP-A concentration of 50ug/ml at 
term. Therefore it could not detect levels of 0.025ug/ml observed by Bersinger et 
al.(1999) in early pregnancy.
7.3.2 Dr Christiansen’s monoclonal assay
7.3.2.1 Method
As described in section 2.16.2.3.
7.3.2.2 Results
The results obtained suggested that the assay was detecting PAPP-A in the samples and 
a reasonable standard curve was produced using the PAPP-A standard provided by Dr 
Christiansen. The standard curve absorbance readings were not as high as would have
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been expected, compared to the standard curve produced using late term pregnancy 
plasma and diluted to the same concentrations. This suggested the provided standard 
PAPP-A had degraded or was not at the concentration given. A standard curve was 
constructed using term plasma, assuming a concentration of 50mg/l, see figure 7.3, and 
this was used to determine PAPP-A levels in samples from different stages of the 
purification. The lower detection limit was set at the concentration of PAPP-A giving 
an absorbance value twice that of the blank. Any lower absorbance reading cannot be 
assumed to be a true value compared to zero. The detection limits for PAPP-A in this 
assay were within the range 100-5000ug/l.
Figure 7.3 A typical standard curve obtained for PAPP-A in the range 0- 5000ug/l
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7.3.3 The “In House” ELISA
7.3.3.1 Method
As described in section 2.16.3.2.
7.3.3.2 Results
Experiments that were carried out using the ‘in house’ monoclonal antibody and 
substituting this into the protocol of Dr Christiansens assay gave a very good standard 
curve, see figure 7.4. The assay was performed using late term pregnancy plasma for 
the standard and the samples obtained from the stages in the purification process. The 
standard curve was linear in the range 0  -1600ug/l with the detection limits 1 0 0 - 
1600ug/l.
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Figure 7.4 A typical standard curve for PAPP-A in the range 0-1600ug/ml.
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7.3.4 Comparison of the ‘in house’ monoclonal ELISA with Dr Christiansens 
monoclonal ELISA
7.3.4.1 Method
The methods were carried out for both assays as described in sections 2.16.2.3 and
2.16.3.2 respectively. The protocols were identical with the substitution of Dr 
Christiansens monoclonal with the ‘in house’ monoclonal into the protocol provided by 
Dr Christiansen. The fractions obtained from the gel filtration stage of the purification 
were tested to compare Dr Christiansen’s assay with the assay using the monoclonal 
antibody produced ‘in house’.
7.3.4.2 Results
Both of the assays detected PAPP-A in the fractions. Dr Christiansen’s assay however 
indicated a much broader PAPP-A containing peak than the assay using the in house 
monoclonal, see figure 7.5.
The results from Dr Christiansens assay suggest that PAPP-A is present in fractions 6 - 
38 (an absorbance of less than 0.5 being rejected) and the results from the ‘in house’ 
assay suggest that PAPP-A is present in fractions 2-26. There is one major PAPP-A 
peak, as expected with the ‘in house assay’, whereas Dr Christiansen’s assay contains 
many PAPP-A peaks. The elution profile is very poor for this assay and it does not 
seem to reflect the elution of PAPP-A from the column compared to the rocket 
immunoelectrophoresis results which showed distinct rockets only for fractions 8-26, 
see figure 3.3.
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Figure 7.5. Absorbance traces obtained from the ELISA methods at 492nm and from protein analysis at 280nm.
7.4 Discussion
Two monoclonal antibodies were obtained from the preparation procedure and the 
purity was confirmed on a paragon electrophoresis gel. The antibodies were aliquoted 
and stored at -20°C and these antibodies were used in the ‘in house’ assay.
The DAKO ELISA using the two polyclonal antibodies gave poor results. The 
sensitivity was very poor, with levels below 2 0 0 ug/ml being undetected and the 
absorbance reading for the blank was high (0.26) suggesting there was non specific 
binding. Two polyclonal antibodies, one a derivative of the other, were used in the 
ELISA possibly enabling polyspecific binding to occur. Therefore the readings 
obtained may not be a true reflection of PAPP-A alone, other factors present in the 
standards or samples contributing. The ELISA would be suitable to determine the 
concentration of PAPP-A in pure samples but would not be suitable for the 
determination of PAPP-A in crude samples due to potential interference from 
contaminants present.
The ELISA protocol and reagents, very kindly donated by Dr Christiansen gave a 
reasonable standard curve, however the values were low, even after long incubation 
periods with the substrate. On repeating this assay with substitution of the ‘in house’ 
monoclonal for that donated by Dr Christiansen, higher absorbance values were 
obtained. The time of colour development was also much quicker and the absorbance 
values were much higher, for example the maximum absorbance obtained for the 
standard at 500ug/ml was 0.4 as opposed to 0.28 for Dr Christiansens ELISA.
Detection levels for the ELISAs were very similar, both assays detecting levels as low 
as 100ug/l (200 mIU/1 assuming 100IU/1 at term).
The results from the standard curves indicate that the ‘in house’ assay and Dr 
Christiansen’s assay may be used as a potential screening assay for samples obtained 
from week 8  onwards in pregnancy. Samples obtained before week 8 , should not be 
screened using the assays described as they would not be sensitive enough to detect any 
differences between normal and abnormal levels of PAPP-A in serum.
The results obtained from the elution profiles from Dr Christiansen’s assay suggest that 
the monoclonal antibody may not be specific for PAPP-A and may be detecting other 
proteins in the fractions. At present it cannot be confirmed that the monoclonal
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8.1 Discussion
The aim of this study was to determine PAPP-A’s involvement, if any, in the remission 
of RA in terms of immunomodulatory and inflammomodulatory effects. There have 
been many studies of the purification and characterisation of PAPP-A, mostly 
controversial. The effect of PAPP-A on proteinases has been studied previously and the 
results obtained in this study confirmed the finding of some of the most recent work 
carried out on PAPP-A. There has been no published data however, on the effect of 
PAPP-A on cytokine and PGE2 production by cell lines and the ability of PAPP-A to 
bind to cytokines and also to cartilage, which makes the data presented here unique, see 
table 8 .1 .
A major part of this work was the development of a purification protocol for PAPP-A. 
A 4 stage process was developed which produced pure PAPP-A as determined by SDS 
PAGE and western blotting. The PAPP-A isolated, did not have the pro MBP attached, 
as there was no band corresponding to this detected on SDS PAGE, as detected by 
other workers (Oxvig et al., 1995a). Whether proMBP was ever attached to the PAPP- 
A purified and has become detached on purification is uncertain and could not be 
clarified as at present there are no commercial monoclonal antibodies available to 
proMBP. PAPP-A therefore may not be in its normal physiological, circulating form 
and therefore the actions seen for the pure PAPP-A may not truly reflect its actions in 
vivo. This however, is true for all the work on PAPP-A to date as purification 
procedures may have structurally slightly altered the PAPP-A molecule. Alternatively 
there may be different isoforms of the PAPP-A/proMBP complex or other complexes 
containing either or both of the two proteins PAPP-A and proMBP that may exist in 
different stages of pregnancy (Qin et al., 1997). The PAPP-A species purified may 
depend on the protocol used. The protocol described in this thesis may favour 
purification of uncomplexed PAPP-A. It has also been reported that other proMBP 
complexes are present in term serum, complexes with angiotensinogen and complement 
3dg (Oxvig et al., 1995b) and as yet nothing is currently known about the function of 
these complexes and their serum concentration in DS pregnancies.
This project was totally dependent on an available source of PAPP-A and on occasion 
was slowed due to lack of availability of pregnancy plasma. Continuation of this work 
in the future would include the investigation of a possible alternative source(s) of
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PAPP-A. One potential source of PAPP-A would be from secreting endometrial cells, 
Bersinger et al.(1997) observed small amounts of PAPP-A production in endometrial 
explant cultures obtained in the secretory phase of the normal menstrual cycle. The 
supernatant obtained from these cultures would still have to undergo purification to to 
obtain pure PAPP-A. Another source of PAPP-A would possibly be from cell lines as it 
has been reported that fibroblasts, obtained from human foreskin produce PAPP-A 
(Lawrence et al., 1999). Short term cultures of trophoblastic and decidual explants have 
also been reported to produce PAPP-A (719 +/- 172 ng/ml) in vitro (Barnea et al.,
1986).
The results indicate that PAPP-A does stimulate the production of PGE2 and also IL-1, 
IL- 6  and TNFa in THP 1 cells. These cytokines have been reported to have an 
involvement in the pathogenesis of RA (Harris, 1990, Ridderstad et al., 1991). PAPP-A 
however had no effect on the stimulation or inhibition of PGE2 and IL- 6  production by 
the MG-63 cell line. Further work needs to be carried out to determine the actual 
mechanism of stimulation of the cytokine production in the THP 1 cells by PAPP-A. 
One possibility, as discussed earlier (section 4.3), is the involvement of the CD 14, LPS 
receptor. This could be tested by incubating the cells with an anti CD 14 antibody which 
blocks the CD 14 receptor sites on the cell surface to see whether the effects of PAPP-A 
would then be inhibited.
Studies of cellular binding of labelled PAPP-A to cell lines may also help in 
determining whether there are specific receptors for PAPP-A and their distribution. 
Responsiveness of cell lines to PAPP-A in terms of their cytokine production may also 
indicate the presence of PAPP-A receptors and their distribution.
PAPP-A does not appear to inhibit the actions of cytokines by binding to IL-1 p or 
TGFp. PAPP-A therefore does not act in the same way as a 2in by inactivating them by 
complex formation.
The large numbers of neutrophils entering the synovial joint in RA should bring in 
large amounts of proteinases. However on direct assay of active proteinases in 
rheumatoid synovial fluid, little activity has been found probably due to inactivation of
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proteinases by inhibitors in the synovial fluid (Harris et al., 1969). However neutrophil 
proteinases may still be involved in cartilage breakdown in two ways, one being that 
the proteinases escape inhibitors in the synovial fluid that would render them inactivate 
by adhering to the cartilage surface and acting locally. Another theory is that of 
‘frustrated phagocytosis’ which is direct release of enzymes onto the cartilage surface 
by the cells adhering to it. Microscopic evidence has shown that neutrophils adhere to 
the cartilage surface and then release enzymes, directly leading to the erosion of tissue 
(Henson, 1973; Cochrane, 1977; Mohr et al., 1980). A molecule that may coat the 
surface of the cartilage perhaps preventing binding of neurophils or their enzymes 
could protect cartilage. PAPP-A is known to bind to cartilage and may form such a 
protective layer on the cartilage. Alternatively its elastase inhibitory activity may 
prevent cartilage damage.
The observed stimulation of resorption by PAPP-A in explant cultures could result 
from degradation of PAPP-A in the presence of enzymes released from chondrocytes, 
releasing proteoglycan that may be detected in the DMB assay and augment the 
apparent proteoglycan release. It may also be produced by the breakdown products of 
PAPP-A stimulating cartilage breakdown in a similar way to fibronectin fragments, as 
discussed in section 5.2.
Further work would be to look at the effect of PAPP-A on IL-1 stimulated cartilage 
resorption, since the EL-1 stimulatory pathway is different from that of the Ret pathway 
(Buttle et al. 1993). In addition effects of PAPP-A fragments on resorption could be 
studied, in particular those produced by aggrecanase digestion.
The proteinase inhibitory activities of PAPP-A have been studied by a number of 
workers over the years but still remain controversial. In this study inhibition of elastase 
has been demonstrated but no inhibition seen for plasmin, trypsin or cathepsin B using 
peptide substrates. This agrees with the work carried out by Oxvig et al. (1994). 
Elastase, though involved in the pathogenesis of RA, is not solely responsible for 
connective tissue breakdown. Thus the role of PAPP-A in reducing cartilage 
breakdown in RA during pregnancy by proteinase inhibition may be limited.
Further work in this area would be to try and establish if PAPP-As effects on any of the 
proteinases studied would be different using substrates with varying Mr values. This
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investigation would either confirm or refute the proposed theory that PAPP-A may be 
acting via a trapping mechanism (Zorin et al., 1995).
Overall the results obtained indicated that PAPP-A does not have have a key role in the 
remission of RA which occurs in pregnancy.
Generally the functions of PAPP-A are not clear even in pregnancy and further 
investigations may uncover possible roles. One possibility may be in the maintenance 
of a successful pregnancy until term. PAPP-A has been reported to be present in 
seminal plasma and present at ovulation, it may be immunosuppressive in vivo and 
serve to blunt the maternal immune response to sperm antigens and following 
fertilisation to the fertilised ovum. This hypothetical immunoregulatory role would 
continue throughout pregnancy to protect the developing fetus by the continued 
presence of PAPP-A in the maternal circulation. However as discussed in this thesis, its 
immune functions are by no means clear-cut.
In view of recent publications, PAPP-A shows most promise in its use in the detection 
of first trimester fetal abnormalities (Wald et al., 1996; Bersinger et al 1999). 
Development of the ‘in house’ monoclonal antibody for potential use in a screening 
assay for fetal abnormalities in first trimester serum samples from pregnant women 
will continue.
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Table 8.1 A summary of the activities o f PAPP-A.
Parameter Effect
THP 1 cell line PGE production Significant IT
IL-1 p production Significant IT
IL- 6  production Significant IT
TNF a  production Significant IT
MG-63 cell line PGE production None
IL- 6  production None
Cytokine Binding IL-1 p No binding
TGFP No binding
Proteinase activity Cathepsin B None
Elastase Significant -U
Plasmin None
Trypsin None
Cartilage Resorption % GAG release Significant 1T
(Ret stimulated)
Cartilage Binding Human cartilage sections Binding
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Abbreviated Terms
a  PAG 
a2m
AAPV-pNA
AC
ADAM
AFP
Ag
ANOVA
APS
ATCC
BAN
BCA
Boc-L-glu-L-lys-L-lys
BSA
BTN
BTS
C3
CD 14 
Ci
CN-Br-act.sep.4B
cpm
CS
Cu
CVS
DAB
DL-BAPNA
DMB
D M E M
Pregnancy associated globulin 
ot2  macroglobulin
Methoxysuccinyl-L-alanine-L-alanine-L-proline-L-
valine-p-nitroaniline
Amniocentesis
A disintegrin and a metalloproteinase
a-fetoprotein
Antigen
Analysis of variance 
Ammonium persulphate 
American type culture collection 
N-tert-butoxy-carbonyl-L-alanine- p-nitroaniline 
Bichinchoninic acid solution 
•MCA N-tert-butoxy-carbonyl-L-glutamic acid-L-lysine-L- 
lysine-4-methyl coumaryl-7-amide 
Bovine serum albumin 
N-butoxy-L-tyrosine-p-nitroaniline 
Blood transfusion service 
Complement component 3 
Cluster of differentiation antigen 14 
Curie
Cyanogen bromide activated sepharose 4B 
Counts per minute 
Chondroitin sulphate 
Copper
Chorionic villus sampling 
Diaminobenzidine
Na- Benzoyl-DL-arginine-p-nitroaniline 
1,9-dimethylmethylene blue 
Dulbecco’s Modified Eagles Medium
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DMSO Dimethyl sulphoxide
Ds Dermatan sulphate
DS Downs syndrome
DTT Dithiothreitol
ECACC European collection of animal cell cultures
EDTA Ethylenediaminetetra acetic acid
ELISA Enzyme-linked-immunosorbant-assay
FCS Foetal calf serum
FDA Federal drug agency
FPLC Fast protein liquid chromatography
GAG Glycosaminoglycan
GM-CSF Granulocyte/macrophage colony stimulating factor
H20 2 Hydrogen peroxide
HB-EGF Heparin binding epidermal growth factor
hCG Human chorionic gonadotrophin
HC1 Hydrochloric acid
HGRT Hypoxanthine-guanine phosporibosyl transferase
HLE Human leukocyte elastase
hPL Human placental lactogen
HRP Horse radish peroxidase
IEC Ion exchange chromatography
IGF Insulin like growth factor
IgG Immunoglobulin G
IL 1 Interleukin 1
IL 6 Interleukin 6
IL Interleukin
ISF I Immunosupressive factor I
ISF II Immunosupressive factor II
Ki Inhibitor constant
LDL Low density lipoprotein
LDLRP Low density lipoprotein receptor related protein
LIF Leukaemia inhibitory factor
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LPS Lipopolysaccharide
LRP Lipoprotein receptor related protein
MBP Major basic protein
MHC Major histocompatibility complex
MMP Matrix metalloproteinases
Mr Relative molecular mass
NaCl Sodium chloride
NSAIDS Non steroidal anti-inflammatory drugs
NSB Non specific binding
OPD o-Phenylenediamine dihydrochloride
PA Plasminogen activator
PAF Platelet activating factor
PAGE Polyacrylamide gel electrophoresis
PAPP Pregnancy associated protein
PAPP-A Pregnancy associated protein A
PBS Phosphate buffered saline
PG Proteoglycans
p g e2 Prostaglandin E2
PHA Phytohaemagglutinin
PI Proteinase inhibitor
PMA Phorbol 12-myristate 13-acetate
PP Placental proteins
PRL Prolactin
Pro MBP proform major basic protein
PTI Pancreatic trypsin inhibitor
PVDF Polyvinyl difluoride
PZP Pregnancy zone protein
Ret all-trans-retinoic acid
RA Rheumatoid arthritis
RIA Radioimmunoassay
RPMI Roswell Park Memorial Institute
SAAVN N-Succinyl-L-anlanyl-L-alanyl-L-valine-p-nitroaniline
212
SDS Sodium dodecyl sulphate
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel
electrophoresis 
SE Standard error
SP 1 Pregnancy specific glycoprotein
TBS Tris buffered saline
TBST Tris buffered saline with tween
TC Total counts
TEMED N,N,N,N’- tetramethylethylenediamine
TGFp Transforming growth factor p
TIMP Tissue inhibitor of matrix metalloproteinase
TNFa Tumour necrosis factor a
TrIFMA Time resolved immunofluorometric assays
Tris Tris [hydroxymethyl] aminomethane
UE3 Unconjugated estriol
uPA Urokinase plasminogen activator
w/v weight per volume
WHO World health organisation
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